,source,target,value,type,source layer,target layer,normalized value
0,KVD20,Initial triggering of complement,0.008470961906202612,0,0,1,0.00960486100019581
1,KVD20,Initial triggering of complement,0.00884521076647789,1,0,1,0.010029205758468624
2,KVD20,Regulation of Complement cascade,0.008470961906202612,0,0,1,0.00960486100019581
3,KVD20,Regulation of Complement cascade,0.00884521076647789,1,0,1,0.010029205758468624
4,KVD20,FCGR activation,0.008470961906202612,0,0,1,0.00960486100019581
5,KVD20,FCGR activation,0.00884521076647789,1,0,1,0.010029205758468624
6,KVD20,Regulation of actin dynamics for phagocytic cup formation,0.008470961906202612,0,0,1,0.00960486100019581
7,KVD20,Regulation of actin dynamics for phagocytic cup formation,0.00884521076647789,1,0,1,0.010029205758468624
8,KVD20,Role of phospholipids in phagocytosis,0.008470961906202612,0,0,1,0.00960486100019581
9,KVD20,Role of phospholipids in phagocytosis,0.00884521076647789,1,0,1,0.010029205758468624
10,KVD20,Role of LAT2/NTAL/LAB on calcium mobilization,0.008470961906202612,0,0,1,0.00960486100019581
11,KVD20,Role of LAT2/NTAL/LAB on calcium mobilization,0.00884521076647789,1,0,1,0.010029205758468624
12,KVD20,FCERI mediated MAPK activation,0.008470961906202612,0,0,1,0.00960486100019581
13,KVD20,FCERI mediated MAPK activation,0.00884521076647789,1,0,1,0.010029205758468624
14,KVD20,FCERI mediated Ca+2 mobilization,0.008470961906202612,0,0,1,0.00960486100019581
15,KVD20,FCERI mediated Ca+2 mobilization,0.00884521076647789,1,0,1,0.010029205758468624
16,KVD20,FCERI mediated NF-kB activation,0.008470961906202612,0,0,1,0.00960486100019581
17,KVD20,FCERI mediated NF-kB activation,0.00884521076647789,1,0,1,0.010029205758468624
18,KVD20,Parasite infection,0.008470961906202612,0,0,1,0.00960486100019581
19,KVD20,Parasite infection,0.00884521076647789,1,0,1,0.010029205758468624
20,KVD20,Leishmania parasite growth and survival,0.008470961906202612,0,0,1,0.00960486100019581
21,KVD20,Leishmania parasite growth and survival,0.00884521076647789,1,0,1,0.010029205758468624
22,KVD20,Potential therapeutics for SARS,0.008470961906202612,0,0,1,0.00960486100019581
23,KVD20,Potential therapeutics for SARS,0.00884521076647789,1,0,1,0.010029205758468624
24,KVD20,CD22 mediated BCR regulation,0.008470961906202612,0,0,1,0.00960486100019581
25,KVD20,CD22 mediated BCR regulation,0.00884521076647789,1,0,1,0.010029205758468624
26,KVD20,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.008470961906202612,0,0,1,0.00960486100019581
27,KVD20,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00884521076647789,1,0,1,0.010029205758468624
28,KVD20,Cell surface interactions at the vascular wall,0.008470961906202612,0,0,1,0.00960486100019581
29,KVD20,Cell surface interactions at the vascular wall,0.00884521076647789,1,0,1,0.010029205758468624
30,KVD20,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.008470961906202612,0,0,1,0.00960486100019581
31,KVD20,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00884521076647789,1,0,1,0.010029205758468624
32,KVD20,Scavenging of heme from plasma,0.008470961906202612,0,0,1,0.00960486100019581
33,KVD20,Scavenging of heme from plasma,0.00884521076647789,1,0,1,0.010029205758468624
34,IGLC7,Initial triggering of complement,0.0065805834241489235,0,0,1,0.0074614417806391714
35,IGLC7,Initial triggering of complement,0.006771037279753359,1,0,1,0.0076773892527547665
36,IGLC7,Regulation of Complement cascade,0.0065805834241489235,0,0,1,0.0074614417806391714
37,IGLC7,Regulation of Complement cascade,0.006771037279753359,1,0,1,0.0076773892527547665
38,IGLC7,FCGR activation,0.0065805834241489235,0,0,1,0.0074614417806391714
39,IGLC7,FCGR activation,0.006771037279753359,1,0,1,0.0076773892527547665
40,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.0065805834241489235,0,0,1,0.0074614417806391714
41,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.006771037279753359,1,0,1,0.0076773892527547665
42,IGLC7,Role of phospholipids in phagocytosis,0.0065805834241489235,0,0,1,0.0074614417806391714
43,IGLC7,Role of phospholipids in phagocytosis,0.006771037279753359,1,0,1,0.0076773892527547665
44,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.0065805834241489235,0,0,1,0.0074614417806391714
45,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.006771037279753359,1,0,1,0.0076773892527547665
46,IGLC7,FCERI mediated MAPK activation,0.0065805834241489235,0,0,1,0.0074614417806391714
47,IGLC7,FCERI mediated MAPK activation,0.006771037279753359,1,0,1,0.0076773892527547665
48,IGLC7,FCERI mediated Ca+2 mobilization,0.0065805834241489235,0,0,1,0.0074614417806391714
49,IGLC7,FCERI mediated Ca+2 mobilization,0.006771037279753359,1,0,1,0.0076773892527547665
50,IGLC7,FCERI mediated NF-kB activation,0.0065805834241489235,0,0,1,0.0074614417806391714
51,IGLC7,FCERI mediated NF-kB activation,0.006771037279753359,1,0,1,0.0076773892527547665
52,IGLC7,Parasite infection,0.0065805834241489235,0,0,1,0.0074614417806391714
53,IGLC7,Parasite infection,0.006771037279753359,1,0,1,0.0076773892527547665
54,IGLC7,Leishmania parasite growth and survival,0.0065805834241489235,0,0,1,0.0074614417806391714
55,IGLC7,Leishmania parasite growth and survival,0.006771037279753359,1,0,1,0.0076773892527547665
56,IGLC7,Potential therapeutics for SARS,0.0065805834241489235,0,0,1,0.0074614417806391714
57,IGLC7,Potential therapeutics for SARS,0.006771037279753359,1,0,1,0.0076773892527547665
58,IGLC7,CD22 mediated BCR regulation,0.0065805834241489235,0,0,1,0.0074614417806391714
59,IGLC7,CD22 mediated BCR regulation,0.006771037279753359,1,0,1,0.0076773892527547665
60,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0065805834241489235,0,0,1,0.0074614417806391714
61,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006771037279753359,1,0,1,0.0076773892527547665
62,IGLC7,Cell surface interactions at the vascular wall,0.0065805834241489235,0,0,1,0.0074614417806391714
63,IGLC7,Cell surface interactions at the vascular wall,0.006771037279753359,1,0,1,0.0076773892527547665
64,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0065805834241489235,0,0,1,0.0074614417806391714
65,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006771037279753359,1,0,1,0.0076773892527547665
66,IGLC7,Scavenging of heme from plasma,0.0065805834241489235,0,0,1,0.0074614417806391714
67,IGLC7,Scavenging of heme from plasma,0.006771037279753359,1,0,1,0.0076773892527547665
68,FCN3,Initial triggering of complement,0.0013221568431359275,0,0,1,0.001499137033006808
69,FCN3,Initial triggering of complement,0.0011861197769763058,1,0,1,0.0013448904284528583
70,CERU,Metal ion SLC transporters,0.00511393880280257,0,0,1,0.005798476242522206
71,CERU,Metal ion SLC transporters,0.006140782367844266,1,0,1,0.006962770194068529
72,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.00511393880280257,0,0,1,0.005798476242522206
73,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.006140782367844266,1,0,1,0.006962770194068529
74,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.00511393880280257,0,0,1,0.005798476242522206
75,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.006140782367844266,1,0,1,0.006962770194068529
76,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00511393880280257,0,0,1,0.005798476242522206
77,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006140782367844266,1,0,1,0.006962770194068529
78,CERU,Post-translational protein phosphorylation,0.00511393880280257,0,0,1,0.005798476242522206
79,CERU,Post-translational protein phosphorylation,0.006140782367844266,1,0,1,0.006962770194068529
80,F13A,Interleukin-4 and Interleukin-13 signaling,0.008995563422584897,0,0,1,0.010199684197506418
81,F13A,Interleukin-4 and Interleukin-13 signaling,0.008733645400112632,1,0,1,0.00990270656649497
82,F13A,Platelet degranulation ,0.008995563422584897,0,0,1,0.010199684197506418
83,F13A,Platelet degranulation ,0.008733645400112632,1,0,1,0.00990270656649497
84,F13A,Common Pathway of Fibrin Clot Formation,0.008995563422584897,0,0,1,0.010199684197506418
85,F13A,Common Pathway of Fibrin Clot Formation,0.008733645400112632,1,0,1,0.00990270656649497
86,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.02018940165806726,0,0,1,0.02289189808076805
87,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.018729637144564368,1,0,1,0.021236733602345903
88,THRB,Regulation of Complement cascade,0.02018940165806726,0,0,1,0.02289189808076805
89,THRB,Regulation of Complement cascade,0.018729637144564368,1,0,1,0.021236733602345903
90,THRB,Class A/1 (Rhodopsin-like receptors),0.02018940165806726,0,0,1,0.02289189808076805
91,THRB,Class A/1 (Rhodopsin-like receptors),0.018729637144564368,1,0,1,0.021236733602345903
92,THRB,G alpha (q) signalling events,0.02018940165806726,0,0,1,0.02289189808076805
93,THRB,G alpha (q) signalling events,0.018729637144564368,1,0,1,0.021236733602345903
94,THRB,Defective factor XII causes hereditary angioedema,0.02018940165806726,0,0,1,0.02289189808076805
95,THRB,Defective factor XII causes hereditary angioedema,0.018729637144564368,1,0,1,0.021236733602345903
96,THRB,Defective factor VIII causes hemophilia A,0.02018940165806726,0,0,1,0.02289189808076805
97,THRB,Defective factor VIII causes hemophilia A,0.018729637144564368,1,0,1,0.021236733602345903
98,THRB,Cell surface interactions at the vascular wall,0.02018940165806726,0,0,1,0.02289189808076805
99,THRB,Cell surface interactions at the vascular wall,0.018729637144564368,1,0,1,0.021236733602345903
100,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.02018940165806726,0,0,1,0.02289189808076805
101,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.018729637144564368,1,0,1,0.021236733602345903
102,THRB,Common Pathway of Fibrin Clot Formation,0.02018940165806726,0,0,1,0.02289189808076805
103,THRB,Common Pathway of Fibrin Clot Formation,0.018729637144564368,1,0,1,0.021236733602345903
104,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.02018940165806726,0,0,1,0.02289189808076805
105,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.018729637144564368,1,0,1,0.021236733602345903
106,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.02018940165806726,0,0,1,0.02289189808076805
107,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.018729637144564368,1,0,1,0.021236733602345903
108,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.01330550235381248,0,0,1,0.015086539410898669
109,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.014301789723825743,1,0,1,0.016216187001241545
110,FA9,Defective factor VIII causes hemophilia A,0.01330550235381248,0,0,1,0.015086539410898669
111,FA9,Defective factor VIII causes hemophilia A,0.014301789723825743,1,0,1,0.016216187001241545
112,FA9,Defective factor IX causes hemophilia B,0.01330550235381248,0,0,1,0.015086539410898669
113,FA9,Defective factor IX causes hemophilia B,0.014301789723825743,1,0,1,0.016216187001241545
114,FA9,Defective factor IX causes thrombophilia,0.01330550235381248,0,0,1,0.015086539410898669
115,FA9,Defective factor IX causes thrombophilia,0.014301789723825743,1,0,1,0.016216187001241545
116,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.01330550235381248,0,0,1,0.015086539410898669
117,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.014301789723825743,1,0,1,0.016216187001241545
118,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.01330550235381248,0,0,1,0.015086539410898669
119,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.014301789723825743,1,0,1,0.016216187001241545
120,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.007379063695933608,0,0,1,0.008366804371902254
121,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.009407351910537622,1,0,1,0.010666593532250405
122,FA10,Defective factor VIII causes hemophilia A,0.007379063695933608,0,0,1,0.008366804371902254
123,FA10,Defective factor VIII causes hemophilia A,0.009407351910537622,1,0,1,0.010666593532250405
124,FA10,Defective factor IX causes hemophilia B,0.007379063695933608,0,0,1,0.008366804371902254
125,FA10,Defective factor IX causes hemophilia B,0.009407351910537622,1,0,1,0.010666593532250405
126,FA10,Defective factor IX causes thrombophilia,0.007379063695933608,0,0,1,0.008366804371902254
127,FA10,Defective factor IX causes thrombophilia,0.009407351910537622,1,0,1,0.010666593532250405
128,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.007379063695933608,0,0,1,0.008366804371902254
129,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.009407351910537622,1,0,1,0.010666593532250405
130,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.007379063695933608,0,0,1,0.008366804371902254
131,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.009407351910537622,1,0,1,0.010666593532250405
132,FA10,Common Pathway of Fibrin Clot Formation,0.007379063695933608,0,0,1,0.008366804371902254
133,FA10,Common Pathway of Fibrin Clot Formation,0.009407351910537622,1,0,1,0.010666593532250405
134,PLMN,Platelet degranulation ,0.005489304820352785,0,0,1,0.006224087697595209
135,PLMN,Platelet degranulation ,0.009878998016344417,1,0,1,0.01120137285692673
136,PLMN,Dissolution of Fibrin Clot,0.005489304820352785,0,0,1,0.006224087697595209
137,PLMN,Dissolution of Fibrin Clot,0.009878998016344417,1,0,1,0.01120137285692673
138,PLMN,Activation of Matrix Metalloproteinases,0.005489304820352785,0,0,1,0.006224087697595209
139,PLMN,Activation of Matrix Metalloproteinases,0.009878998016344417,1,0,1,0.01120137285692673
140,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005489304820352785,0,0,1,0.006224087697595209
141,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.009878998016344417,1,0,1,0.01120137285692673
142,PLMN,Signaling by PDGF,0.005489304820352785,0,0,1,0.006224087697595209
143,PLMN,Signaling by PDGF,0.009878998016344417,1,0,1,0.01120137285692673
144,FA12,Defective factor XII causes hereditary angioedema,0.004806613667457712,0,0,1,0.0054500134304427
145,FA12,Defective factor XII causes hereditary angioedema,0.004204884524816815,1,0,1,0.0047677385201280965
146,FA12,Defective SERPING1 causes hereditary angioedema,0.004806613667457712,0,0,1,0.0054500134304427
147,FA12,Defective SERPING1 causes hereditary angioedema,0.004204884524816815,1,0,1,0.0047677385201280965
148,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.004806613667457712,0,0,1,0.0054500134304427
149,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.004204884524816815,1,0,1,0.0047677385201280965
150,CAH2,Reversible hydration of carbon dioxide,0.010676113408386947,0,0,1,0.012105187869490898
151,CAH2,Reversible hydration of carbon dioxide,0.009053848341535749,1,0,1,0.0102657709714914
152,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.010676113408386947,0,0,1,0.012105187869490898
153,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.009053848341535749,1,0,1,0.0102657709714914
154,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.010676113408386947,0,0,1,0.012105187869490898
155,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.009053848341535749,1,0,1,0.0102657709714914
156,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.001439985183352322,0,0,1,0.001632737542865503
157,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.0013387092065014236,1,0,1,0.0015179050490964465
158,ANT3,Common Pathway of Fibrin Clot Formation,0.001439985183352322,0,0,1,0.001632737542865503
159,ANT3,Common Pathway of Fibrin Clot Formation,0.0013387092065014236,1,0,1,0.0015179050490964465
160,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001439985183352322,0,0,1,0.001632737542865503
161,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0013387092065014236,1,0,1,0.0015179050490964465
162,ANT3,Post-translational protein phosphorylation,0.001439985183352322,0,0,1,0.001632737542865503
163,ANT3,Post-translational protein phosphorylation,0.0013387092065014236,1,0,1,0.0015179050490964465
164,ANGT,Class A/1 (Rhodopsin-like receptors),0.01594861745940286,0,0,1,0.01808345445759777
165,ANGT,Class A/1 (Rhodopsin-like receptors),0.0159278829100006,1,0,1,0.01805994443983171
166,ANGT,G alpha (q) signalling events,0.01594861745940286,0,0,1,0.01808345445759777
167,ANGT,G alpha (q) signalling events,0.0159278829100006,1,0,1,0.01805994443983171
168,ANGT,G alpha (i) signalling events,0.01594861745940286,0,0,1,0.01808345445759777
169,ANGT,G alpha (i) signalling events,0.0159278829100006,1,0,1,0.01805994443983171
170,ANGT,PPARA activates gene expression,0.01594861745940286,0,0,1,0.01808345445759777
171,ANGT,PPARA activates gene expression,0.0159278829100006,1,0,1,0.01805994443983171
172,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.01594861745940286,0,0,1,0.01808345445759777
173,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.0159278829100006,1,0,1,0.01805994443983171
174,A2MG,Platelet degranulation ,0.007083935384443221,0,0,1,0.008032171016154064
175,A2MG,Platelet degranulation ,0.006694633081201143,1,0,1,0.0075907578034517
176,A2MG,HDL assembly,0.007083935384443221,0,0,1,0.008032171016154064
177,A2MG,HDL assembly,0.006694633081201143,1,0,1,0.0075907578034517
178,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.007083935384443221,0,0,1,0.008032171016154064
179,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.006694633081201143,1,0,1,0.0075907578034517
180,CO3,Initial triggering of complement,0.023437914310416832,0,0,1,0.026575247484139662
181,CO3,Initial triggering of complement,0.025659569704917246,1,0,1,0.029094287410276864
182,CO3,Activation of C3 and C5,0.023437914310416832,0,0,1,0.026575247484139662
183,CO3,Activation of C3 and C5,0.025659569704917246,1,0,1,0.029094287410276864
184,CO3,Regulation of Complement cascade,0.023437914310416832,0,0,1,0.026575247484139662
185,CO3,Regulation of Complement cascade,0.025659569704917246,1,0,1,0.029094287410276864
186,CO3,Class A/1 (Rhodopsin-like receptors),0.023437914310416832,0,0,1,0.026575247484139662
187,CO3,Class A/1 (Rhodopsin-like receptors),0.025659569704917246,1,0,1,0.029094287410276864
188,CO3,G alpha (i) signalling events,0.023437914310416832,0,0,1,0.026575247484139662
189,CO3,G alpha (i) signalling events,0.025659569704917246,1,0,1,0.029094287410276864
190,CO3,Cell recruitment (pro-inflammatory response),0.023437914310416832,0,0,1,0.026575247484139662
191,CO3,Cell recruitment (pro-inflammatory response),0.025659569704917246,1,0,1,0.029094287410276864
192,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.023437914310416832,0,0,1,0.026575247484139662
193,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.025659569704917246,1,0,1,0.029094287410276864
194,CO3,Neutrophil degranulation,0.023437914310416832,0,0,1,0.026575247484139662
195,CO3,Neutrophil degranulation,0.025659569704917246,1,0,1,0.029094287410276864
196,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.023437914310416832,0,0,1,0.026575247484139662
197,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.025659569704917246,1,0,1,0.029094287410276864
198,CO3,Post-translational protein phosphorylation,0.023437914310416832,0,0,1,0.026575247484139662
199,CO3,Post-translational protein phosphorylation,0.025659569704917246,1,0,1,0.029094287410276864
200,CO5,Terminal pathway of complement,0.007298118788950948,0,0,1,0.008275024407731603
201,CO5,Terminal pathway of complement,0.012128115410644659,1,0,1,0.01375155076878331
202,CO5,Activation of C3 and C5,0.007298118788950948,0,0,1,0.008275024407731603
203,CO5,Activation of C3 and C5,0.012128115410644659,1,0,1,0.01375155076878331
204,CO5,Regulation of Complement cascade,0.007298118788950948,0,0,1,0.008275024407731603
205,CO5,Regulation of Complement cascade,0.012128115410644659,1,0,1,0.01375155076878331
206,CO5,Class A/1 (Rhodopsin-like receptors),0.007298118788950948,0,0,1,0.008275024407731603
207,CO5,Class A/1 (Rhodopsin-like receptors),0.012128115410644659,1,0,1,0.01375155076878331
208,CO5,G alpha (i) signalling events,0.007298118788950948,0,0,1,0.008275024407731603
209,CO5,G alpha (i) signalling events,0.012128115410644659,1,0,1,0.01375155076878331
210,CYTC,Neutrophil degranulation,0.010931731782794675,0,0,1,0.012395022599297026
211,CYTC,Neutrophil degranulation,0.009091152501225708,1,0,1,0.01030806856089371
212,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.010931731782794675,0,0,1,0.012395022599297026
213,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.009091152501225708,1,0,1,0.01030806856089371
214,CYTC,Amyloid fiber formation,0.010931731782794675,0,0,1,0.012395022599297026
215,CYTC,Amyloid fiber formation,0.009091152501225708,1,0,1,0.01030806856089371
216,CYTC,Post-translational protein phosphorylation,0.010931731782794675,0,0,1,0.012395022599297026
217,CYTC,Post-translational protein phosphorylation,0.009091152501225708,1,0,1,0.01030806856089371
218,KNG1,Class A/1 (Rhodopsin-like receptors),0.007700756124594944,0,0,1,0.008731557642702009
219,KNG1,Class A/1 (Rhodopsin-like receptors),0.006336743496880315,1,0,1,0.007184962127720657
220,KNG1,G alpha (q) signalling events,0.007700756124594944,0,0,1,0.008731557642702009
221,KNG1,G alpha (q) signalling events,0.006336743496880315,1,0,1,0.007184962127720657
222,KNG1,G alpha (i) signalling events,0.007700756124594944,0,0,1,0.008731557642702009
223,KNG1,G alpha (i) signalling events,0.006336743496880315,1,0,1,0.007184962127720657
224,KNG1,Platelet degranulation ,0.007700756124594944,0,0,1,0.008731557642702009
225,KNG1,Platelet degranulation ,0.006336743496880315,1,0,1,0.007184962127720657
226,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.007700756124594944,0,0,1,0.008731557642702009
227,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.006336743496880315,1,0,1,0.007184962127720657
228,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007700756124594944,0,0,1,0.008731557642702009
229,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006336743496880315,1,0,1,0.007184962127720657
230,KNG1,Post-translational protein phosphorylation,0.007700756124594944,0,0,1,0.008731557642702009
231,KNG1,Post-translational protein phosphorylation,0.006336743496880315,1,0,1,0.007184962127720657
232,IGJ,Cell surface interactions at the vascular wall,0.0007332014070518928,0,0,1,0.0008313456816190973
233,IGJ,Cell surface interactions at the vascular wall,0.0007160186406487464,1,0,1,0.0008118628785173373
234,IGJ,Scavenging of heme from plasma,0.0007332014070518928,0,0,1,0.0008313456816190973
235,IGJ,Scavenging of heme from plasma,0.0007160186406487464,1,0,1,0.0008118628785173373
236,KV117,Initial triggering of complement,0.005973001307152984,0,0,1,0.006772530433313
237,KV117,Initial triggering of complement,0.005404675225179538,1,0,1,0.006128129823254315
238,KV117,Regulation of Complement cascade,0.005973001307152984,0,0,1,0.006772530433313
239,KV117,Regulation of Complement cascade,0.005404675225179538,1,0,1,0.006128129823254315
240,KV117,FCGR activation,0.005973001307152984,0,0,1,0.006772530433313
241,KV117,FCGR activation,0.005404675225179538,1,0,1,0.006128129823254315
242,KV117,Regulation of actin dynamics for phagocytic cup formation,0.005973001307152984,0,0,1,0.006772530433313
243,KV117,Regulation of actin dynamics for phagocytic cup formation,0.005404675225179538,1,0,1,0.006128129823254315
244,KV117,Role of phospholipids in phagocytosis,0.005973001307152984,0,0,1,0.006772530433313
245,KV117,Role of phospholipids in phagocytosis,0.005404675225179538,1,0,1,0.006128129823254315
246,KV117,Role of LAT2/NTAL/LAB on calcium mobilization,0.005973001307152984,0,0,1,0.006772530433313
247,KV117,Role of LAT2/NTAL/LAB on calcium mobilization,0.005404675225179538,1,0,1,0.006128129823254315
248,KV117,FCERI mediated MAPK activation,0.005973001307152984,0,0,1,0.006772530433313
249,KV117,FCERI mediated MAPK activation,0.005404675225179538,1,0,1,0.006128129823254315
250,KV117,FCERI mediated Ca+2 mobilization,0.005973001307152984,0,0,1,0.006772530433313
251,KV117,FCERI mediated Ca+2 mobilization,0.005404675225179538,1,0,1,0.006128129823254315
252,KV117,FCERI mediated NF-kB activation,0.005973001307152984,0,0,1,0.006772530433313
253,KV117,FCERI mediated NF-kB activation,0.005404675225179538,1,0,1,0.006128129823254315
254,KV117,Parasite infection,0.005973001307152984,0,0,1,0.006772530433313
255,KV117,Parasite infection,0.005404675225179538,1,0,1,0.006128129823254315
256,KV117,Leishmania parasite growth and survival,0.005973001307152984,0,0,1,0.006772530433313
257,KV117,Leishmania parasite growth and survival,0.005404675225179538,1,0,1,0.006128129823254315
258,KV117,Potential therapeutics for SARS,0.005973001307152984,0,0,1,0.006772530433313
259,KV117,Potential therapeutics for SARS,0.005404675225179538,1,0,1,0.006128129823254315
260,KV117,CD22 mediated BCR regulation,0.005973001307152984,0,0,1,0.006772530433313
261,KV117,CD22 mediated BCR regulation,0.005404675225179538,1,0,1,0.006128129823254315
262,KV117,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005973001307152984,0,0,1,0.006772530433313
263,KV117,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005404675225179538,1,0,1,0.006128129823254315
264,KV117,Cell surface interactions at the vascular wall,0.005973001307152984,0,0,1,0.006772530433313
265,KV117,Cell surface interactions at the vascular wall,0.005404675225179538,1,0,1,0.006128129823254315
266,KV117,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005973001307152984,0,0,1,0.006772530433313
267,KV117,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005404675225179538,1,0,1,0.006128129823254315
268,KV117,Scavenging of heme from plasma,0.005973001307152984,0,0,1,0.006772530433313
269,KV117,Scavenging of heme from plasma,0.005404675225179538,1,0,1,0.006128129823254315
270,KVD16,Initial triggering of complement,0.004142427106124919,0,0,1,0.004696920727342671
271,KVD16,Initial triggering of complement,0.004241408887143034,1,0,1,0.004809151930688619
272,KVD16,Regulation of Complement cascade,0.004142427106124919,0,0,1,0.004696920727342671
273,KVD16,Regulation of Complement cascade,0.004241408887143034,1,0,1,0.004809151930688619
274,KVD16,FCGR activation,0.004142427106124919,0,0,1,0.004696920727342671
275,KVD16,FCGR activation,0.004241408887143034,1,0,1,0.004809151930688619
276,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.004142427106124919,0,0,1,0.004696920727342671
277,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.004241408887143034,1,0,1,0.004809151930688619
278,KVD16,Role of phospholipids in phagocytosis,0.004142427106124919,0,0,1,0.004696920727342671
279,KVD16,Role of phospholipids in phagocytosis,0.004241408887143034,1,0,1,0.004809151930688619
280,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.004142427106124919,0,0,1,0.004696920727342671
281,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.004241408887143034,1,0,1,0.004809151930688619
282,KVD16,FCERI mediated MAPK activation,0.004142427106124919,0,0,1,0.004696920727342671
283,KVD16,FCERI mediated MAPK activation,0.004241408887143034,1,0,1,0.004809151930688619
284,KVD16,FCERI mediated Ca+2 mobilization,0.004142427106124919,0,0,1,0.004696920727342671
285,KVD16,FCERI mediated Ca+2 mobilization,0.004241408887143034,1,0,1,0.004809151930688619
286,KVD16,FCERI mediated NF-kB activation,0.004142427106124919,0,0,1,0.004696920727342671
287,KVD16,FCERI mediated NF-kB activation,0.004241408887143034,1,0,1,0.004809151930688619
288,KVD16,Parasite infection,0.004142427106124919,0,0,1,0.004696920727342671
289,KVD16,Parasite infection,0.004241408887143034,1,0,1,0.004809151930688619
290,KVD16,Leishmania parasite growth and survival,0.004142427106124919,0,0,1,0.004696920727342671
291,KVD16,Leishmania parasite growth and survival,0.004241408887143034,1,0,1,0.004809151930688619
292,KVD16,Potential therapeutics for SARS,0.004142427106124919,0,0,1,0.004696920727342671
293,KVD16,Potential therapeutics for SARS,0.004241408887143034,1,0,1,0.004809151930688619
294,KVD16,CD22 mediated BCR regulation,0.004142427106124919,0,0,1,0.004696920727342671
295,KVD16,CD22 mediated BCR regulation,0.004241408887143034,1,0,1,0.004809151930688619
296,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004142427106124919,0,0,1,0.004696920727342671
297,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004241408887143034,1,0,1,0.004809151930688619
298,KVD16,Cell surface interactions at the vascular wall,0.004142427106124919,0,0,1,0.004696920727342671
299,KVD16,Cell surface interactions at the vascular wall,0.004241408887143034,1,0,1,0.004809151930688619
300,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004142427106124919,0,0,1,0.004696920727342671
301,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004241408887143034,1,0,1,0.004809151930688619
302,KVD16,Scavenging of heme from plasma,0.004142427106124919,0,0,1,0.004696920727342671
303,KVD16,Scavenging of heme from plasma,0.004241408887143034,1,0,1,0.004809151930688619
304,KV105,Initial triggering of complement,0.00645998386945424,0,0,1,0.0073246991093399655
305,KV105,Initial triggering of complement,0.00606786948308878,1,0,1,0.006880097395990313
306,KV105,Regulation of Complement cascade,0.00645998386945424,0,0,1,0.0073246991093399655
307,KV105,Regulation of Complement cascade,0.00606786948308878,1,0,1,0.006880097395990313
308,KV105,FCGR activation,0.00645998386945424,0,0,1,0.0073246991093399655
309,KV105,FCGR activation,0.00606786948308878,1,0,1,0.006880097395990313
310,KV105,Regulation of actin dynamics for phagocytic cup formation,0.00645998386945424,0,0,1,0.0073246991093399655
311,KV105,Regulation of actin dynamics for phagocytic cup formation,0.00606786948308878,1,0,1,0.006880097395990313
312,KV105,Role of phospholipids in phagocytosis,0.00645998386945424,0,0,1,0.0073246991093399655
313,KV105,Role of phospholipids in phagocytosis,0.00606786948308878,1,0,1,0.006880097395990313
314,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.00645998386945424,0,0,1,0.0073246991093399655
315,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.00606786948308878,1,0,1,0.006880097395990313
316,KV105,FCERI mediated MAPK activation,0.00645998386945424,0,0,1,0.0073246991093399655
317,KV105,FCERI mediated MAPK activation,0.00606786948308878,1,0,1,0.006880097395990313
318,KV105,FCERI mediated Ca+2 mobilization,0.00645998386945424,0,0,1,0.0073246991093399655
319,KV105,FCERI mediated Ca+2 mobilization,0.00606786948308878,1,0,1,0.006880097395990313
320,KV105,FCERI mediated NF-kB activation,0.00645998386945424,0,0,1,0.0073246991093399655
321,KV105,FCERI mediated NF-kB activation,0.00606786948308878,1,0,1,0.006880097395990313
322,KV105,Parasite infection,0.00645998386945424,0,0,1,0.0073246991093399655
323,KV105,Parasite infection,0.00606786948308878,1,0,1,0.006880097395990313
324,KV105,Leishmania parasite growth and survival,0.00645998386945424,0,0,1,0.0073246991093399655
325,KV105,Leishmania parasite growth and survival,0.00606786948308878,1,0,1,0.006880097395990313
326,KV105,Potential therapeutics for SARS,0.00645998386945424,0,0,1,0.0073246991093399655
327,KV105,Potential therapeutics for SARS,0.00606786948308878,1,0,1,0.006880097395990313
328,KV105,CD22 mediated BCR regulation,0.00645998386945424,0,0,1,0.0073246991093399655
329,KV105,CD22 mediated BCR regulation,0.00606786948308878,1,0,1,0.006880097395990313
330,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00645998386945424,0,0,1,0.0073246991093399655
331,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00606786948308878,1,0,1,0.006880097395990313
332,KV105,Cell surface interactions at the vascular wall,0.00645998386945424,0,0,1,0.0073246991093399655
333,KV105,Cell surface interactions at the vascular wall,0.00606786948308878,1,0,1,0.006880097395990313
334,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00645998386945424,0,0,1,0.0073246991093399655
335,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00606786948308878,1,0,1,0.006880097395990313
336,KV105,Scavenging of heme from plasma,0.00645998386945424,0,0,1,0.0073246991093399655
337,KV105,Scavenging of heme from plasma,0.00606786948308878,1,0,1,0.006880097395990313
338,KV320,Initial triggering of complement,0.006432285188525271,0,0,1,0.007293292761022342
339,KV320,Initial triggering of complement,0.006279100365253854,1,0,1,0.007119603048903086
340,KV320,Regulation of Complement cascade,0.006432285188525271,0,0,1,0.007293292761022342
341,KV320,Regulation of Complement cascade,0.006279100365253854,1,0,1,0.007119603048903086
342,KV320,FCGR activation,0.006432285188525271,0,0,1,0.007293292761022342
343,KV320,FCGR activation,0.006279100365253854,1,0,1,0.007119603048903086
344,KV320,Regulation of actin dynamics for phagocytic cup formation,0.006432285188525271,0,0,1,0.007293292761022342
345,KV320,Regulation of actin dynamics for phagocytic cup formation,0.006279100365253854,1,0,1,0.007119603048903086
346,KV320,Role of phospholipids in phagocytosis,0.006432285188525271,0,0,1,0.007293292761022342
347,KV320,Role of phospholipids in phagocytosis,0.006279100365253854,1,0,1,0.007119603048903086
348,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.006432285188525271,0,0,1,0.007293292761022342
349,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.006279100365253854,1,0,1,0.007119603048903086
350,KV320,FCERI mediated MAPK activation,0.006432285188525271,0,0,1,0.007293292761022342
351,KV320,FCERI mediated MAPK activation,0.006279100365253854,1,0,1,0.007119603048903086
352,KV320,FCERI mediated Ca+2 mobilization,0.006432285188525271,0,0,1,0.007293292761022342
353,KV320,FCERI mediated Ca+2 mobilization,0.006279100365253854,1,0,1,0.007119603048903086
354,KV320,FCERI mediated NF-kB activation,0.006432285188525271,0,0,1,0.007293292761022342
355,KV320,FCERI mediated NF-kB activation,0.006279100365253854,1,0,1,0.007119603048903086
356,KV320,Parasite infection,0.006432285188525271,0,0,1,0.007293292761022342
357,KV320,Parasite infection,0.006279100365253854,1,0,1,0.007119603048903086
358,KV320,Leishmania parasite growth and survival,0.006432285188525271,0,0,1,0.007293292761022342
359,KV320,Leishmania parasite growth and survival,0.006279100365253854,1,0,1,0.007119603048903086
360,KV320,Potential therapeutics for SARS,0.006432285188525271,0,0,1,0.007293292761022342
361,KV320,Potential therapeutics for SARS,0.006279100365253854,1,0,1,0.007119603048903086
362,KV320,CD22 mediated BCR regulation,0.006432285188525271,0,0,1,0.007293292761022342
363,KV320,CD22 mediated BCR regulation,0.006279100365253854,1,0,1,0.007119603048903086
364,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006432285188525271,0,0,1,0.007293292761022342
365,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006279100365253854,1,0,1,0.007119603048903086
366,KV320,Cell surface interactions at the vascular wall,0.006432285188525271,0,0,1,0.007293292761022342
367,KV320,Cell surface interactions at the vascular wall,0.006279100365253854,1,0,1,0.007119603048903086
368,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006432285188525271,0,0,1,0.007293292761022342
369,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006279100365253854,1,0,1,0.007119603048903086
370,KV320,Scavenging of heme from plasma,0.006432285188525271,0,0,1,0.007293292761022342
371,KV320,Scavenging of heme from plasma,0.006279100365253854,1,0,1,0.007119603048903086
372,LV151,Initial triggering of complement,0.0030263715779495306,0,0,1,0.003431473150630556
373,LV151,Initial triggering of complement,0.0031929438298534127,1,0,1,0.003620342294860199
374,LV151,Regulation of Complement cascade,0.0030263715779495306,0,0,1,0.003431473150630556
375,LV151,Regulation of Complement cascade,0.0031929438298534127,1,0,1,0.003620342294860199
376,LV151,FCGR activation,0.0030263715779495306,0,0,1,0.003431473150630556
377,LV151,FCGR activation,0.0031929438298534127,1,0,1,0.003620342294860199
378,LV151,Regulation of actin dynamics for phagocytic cup formation,0.0030263715779495306,0,0,1,0.003431473150630556
379,LV151,Regulation of actin dynamics for phagocytic cup formation,0.0031929438298534127,1,0,1,0.003620342294860199
380,LV151,Role of phospholipids in phagocytosis,0.0030263715779495306,0,0,1,0.003431473150630556
381,LV151,Role of phospholipids in phagocytosis,0.0031929438298534127,1,0,1,0.003620342294860199
382,LV151,Role of LAT2/NTAL/LAB on calcium mobilization,0.0030263715779495306,0,0,1,0.003431473150630556
383,LV151,Role of LAT2/NTAL/LAB on calcium mobilization,0.0031929438298534127,1,0,1,0.003620342294860199
384,LV151,FCERI mediated MAPK activation,0.0030263715779495306,0,0,1,0.003431473150630556
385,LV151,FCERI mediated MAPK activation,0.0031929438298534127,1,0,1,0.003620342294860199
386,LV151,FCERI mediated Ca+2 mobilization,0.0030263715779495306,0,0,1,0.003431473150630556
387,LV151,FCERI mediated Ca+2 mobilization,0.0031929438298534127,1,0,1,0.003620342294860199
388,LV151,FCERI mediated NF-kB activation,0.0030263715779495306,0,0,1,0.003431473150630556
389,LV151,FCERI mediated NF-kB activation,0.0031929438298534127,1,0,1,0.003620342294860199
390,LV151,Parasite infection,0.0030263715779495306,0,0,1,0.003431473150630556
391,LV151,Parasite infection,0.0031929438298534127,1,0,1,0.003620342294860199
392,LV151,Leishmania parasite growth and survival,0.0030263715779495306,0,0,1,0.003431473150630556
393,LV151,Leishmania parasite growth and survival,0.0031929438298534127,1,0,1,0.003620342294860199
394,LV151,Potential therapeutics for SARS,0.0030263715779495306,0,0,1,0.003431473150630556
395,LV151,Potential therapeutics for SARS,0.0031929438298534127,1,0,1,0.003620342294860199
396,LV151,CD22 mediated BCR regulation,0.0030263715779495306,0,0,1,0.003431473150630556
397,LV151,CD22 mediated BCR regulation,0.0031929438298534127,1,0,1,0.003620342294860199
398,LV151,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0030263715779495306,0,0,1,0.003431473150630556
399,LV151,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0031929438298534127,1,0,1,0.003620342294860199
400,LV151,Cell surface interactions at the vascular wall,0.0030263715779495306,0,0,1,0.003431473150630556
401,LV151,Cell surface interactions at the vascular wall,0.0031929438298534127,1,0,1,0.003620342294860199
402,LV151,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0030263715779495306,0,0,1,0.003431473150630556
403,LV151,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0031929438298534127,1,0,1,0.003620342294860199
404,LV151,Scavenging of heme from plasma,0.0030263715779495306,0,0,1,0.003431473150630556
405,LV151,Scavenging of heme from plasma,0.0031929438298534127,1,0,1,0.003620342294860199
406,LV140,Initial triggering of complement,0.0031027732242565665,0,0,1,0.0035181017060520936
407,LV140,Initial triggering of complement,0.003883778904205435,1,0,1,0.004403650605850543
408,LV140,Regulation of Complement cascade,0.0031027732242565665,0,0,1,0.0035181017060520936
409,LV140,Regulation of Complement cascade,0.003883778904205435,1,0,1,0.004403650605850543
410,LV140,FCGR activation,0.0031027732242565665,0,0,1,0.0035181017060520936
411,LV140,FCGR activation,0.003883778904205435,1,0,1,0.004403650605850543
412,LV140,Regulation of actin dynamics for phagocytic cup formation,0.0031027732242565665,0,0,1,0.0035181017060520936
413,LV140,Regulation of actin dynamics for phagocytic cup formation,0.003883778904205435,1,0,1,0.004403650605850543
414,LV140,Role of phospholipids in phagocytosis,0.0031027732242565665,0,0,1,0.0035181017060520936
415,LV140,Role of phospholipids in phagocytosis,0.003883778904205435,1,0,1,0.004403650605850543
416,LV140,Role of LAT2/NTAL/LAB on calcium mobilization,0.0031027732242565665,0,0,1,0.0035181017060520936
417,LV140,Role of LAT2/NTAL/LAB on calcium mobilization,0.003883778904205435,1,0,1,0.004403650605850543
418,LV140,FCERI mediated MAPK activation,0.0031027732242565665,0,0,1,0.0035181017060520936
419,LV140,FCERI mediated MAPK activation,0.003883778904205435,1,0,1,0.004403650605850543
420,LV140,FCERI mediated Ca+2 mobilization,0.0031027732242565665,0,0,1,0.0035181017060520936
421,LV140,FCERI mediated Ca+2 mobilization,0.003883778904205435,1,0,1,0.004403650605850543
422,LV140,FCERI mediated NF-kB activation,0.0031027732242565665,0,0,1,0.0035181017060520936
423,LV140,FCERI mediated NF-kB activation,0.003883778904205435,1,0,1,0.004403650605850543
424,LV140,Parasite infection,0.0031027732242565665,0,0,1,0.0035181017060520936
425,LV140,Parasite infection,0.003883778904205435,1,0,1,0.004403650605850543
426,LV140,Leishmania parasite growth and survival,0.0031027732242565665,0,0,1,0.0035181017060520936
427,LV140,Leishmania parasite growth and survival,0.003883778904205435,1,0,1,0.004403650605850543
428,LV140,Potential therapeutics for SARS,0.0031027732242565665,0,0,1,0.0035181017060520936
429,LV140,Potential therapeutics for SARS,0.003883778904205435,1,0,1,0.004403650605850543
430,LV140,CD22 mediated BCR regulation,0.0031027732242565665,0,0,1,0.0035181017060520936
431,LV140,CD22 mediated BCR regulation,0.003883778904205435,1,0,1,0.004403650605850543
432,LV140,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0031027732242565665,0,0,1,0.0035181017060520936
433,LV140,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003883778904205435,1,0,1,0.004403650605850543
434,LV140,Cell surface interactions at the vascular wall,0.0031027732242565665,0,0,1,0.0035181017060520936
435,LV140,Cell surface interactions at the vascular wall,0.003883778904205435,1,0,1,0.004403650605850543
436,LV140,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0031027732242565665,0,0,1,0.0035181017060520936
437,LV140,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003883778904205435,1,0,1,0.004403650605850543
438,LV140,Scavenging of heme from plasma,0.0031027732242565665,0,0,1,0.0035181017060520936
439,LV140,Scavenging of heme from plasma,0.003883778904205435,1,0,1,0.004403650605850543
440,LV214,Initial triggering of complement,0.005695542451428057,0,0,1,0.006457931716895685
441,LV214,Initial triggering of complement,0.0055256300884416925,1,0,1,0.006265275363724758
442,LV214,Regulation of Complement cascade,0.005695542451428057,0,0,1,0.006457931716895685
443,LV214,Regulation of Complement cascade,0.0055256300884416925,1,0,1,0.006265275363724758
444,LV214,FCGR activation,0.005695542451428057,0,0,1,0.006457931716895685
445,LV214,FCGR activation,0.0055256300884416925,1,0,1,0.006265275363724758
446,LV214,Regulation of actin dynamics for phagocytic cup formation,0.005695542451428057,0,0,1,0.006457931716895685
447,LV214,Regulation of actin dynamics for phagocytic cup formation,0.0055256300884416925,1,0,1,0.006265275363724758
448,LV214,Role of phospholipids in phagocytosis,0.005695542451428057,0,0,1,0.006457931716895685
449,LV214,Role of phospholipids in phagocytosis,0.0055256300884416925,1,0,1,0.006265275363724758
450,LV214,Role of LAT2/NTAL/LAB on calcium mobilization,0.005695542451428057,0,0,1,0.006457931716895685
451,LV214,Role of LAT2/NTAL/LAB on calcium mobilization,0.0055256300884416925,1,0,1,0.006265275363724758
452,LV214,FCERI mediated MAPK activation,0.005695542451428057,0,0,1,0.006457931716895685
453,LV214,FCERI mediated MAPK activation,0.0055256300884416925,1,0,1,0.006265275363724758
454,LV214,FCERI mediated Ca+2 mobilization,0.005695542451428057,0,0,1,0.006457931716895685
455,LV214,FCERI mediated Ca+2 mobilization,0.0055256300884416925,1,0,1,0.006265275363724758
456,LV214,FCERI mediated NF-kB activation,0.005695542451428057,0,0,1,0.006457931716895685
457,LV214,FCERI mediated NF-kB activation,0.0055256300884416925,1,0,1,0.006265275363724758
458,LV214,Parasite infection,0.005695542451428057,0,0,1,0.006457931716895685
459,LV214,Parasite infection,0.0055256300884416925,1,0,1,0.006265275363724758
460,LV214,Leishmania parasite growth and survival,0.005695542451428057,0,0,1,0.006457931716895685
461,LV214,Leishmania parasite growth and survival,0.0055256300884416925,1,0,1,0.006265275363724758
462,LV214,Potential therapeutics for SARS,0.005695542451428057,0,0,1,0.006457931716895685
463,LV214,Potential therapeutics for SARS,0.0055256300884416925,1,0,1,0.006265275363724758
464,LV214,CD22 mediated BCR regulation,0.005695542451428057,0,0,1,0.006457931716895685
465,LV214,CD22 mediated BCR regulation,0.0055256300884416925,1,0,1,0.006265275363724758
466,LV214,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005695542451428057,0,0,1,0.006457931716895685
467,LV214,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0055256300884416925,1,0,1,0.006265275363724758
468,LV214,Cell surface interactions at the vascular wall,0.005695542451428057,0,0,1,0.006457931716895685
469,LV214,Cell surface interactions at the vascular wall,0.0055256300884416925,1,0,1,0.006265275363724758
470,LV214,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005695542451428057,0,0,1,0.006457931716895685
471,LV214,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0055256300884416925,1,0,1,0.006265275363724758
472,LV214,Scavenging of heme from plasma,0.005695542451428057,0,0,1,0.006457931716895685
473,LV214,Scavenging of heme from plasma,0.0055256300884416925,1,0,1,0.006265275363724758
474,LV211,Initial triggering of complement,0.0013580312408449932,0,0,1,0.0015398134765177887
475,LV211,Initial triggering of complement,0.0015066397439734535,1,0,1,0.0017083142951734459
476,LV211,Regulation of Complement cascade,0.0013580312408449932,0,0,1,0.0015398134765177887
477,LV211,Regulation of Complement cascade,0.0015066397439734535,1,0,1,0.0017083142951734459
478,LV211,FCGR activation,0.0013580312408449932,0,0,1,0.0015398134765177887
479,LV211,FCGR activation,0.0015066397439734535,1,0,1,0.0017083142951734459
480,LV211,Regulation of actin dynamics for phagocytic cup formation,0.0013580312408449932,0,0,1,0.0015398134765177887
481,LV211,Regulation of actin dynamics for phagocytic cup formation,0.0015066397439734535,1,0,1,0.0017083142951734459
482,LV211,Role of phospholipids in phagocytosis,0.0013580312408449932,0,0,1,0.0015398134765177887
483,LV211,Role of phospholipids in phagocytosis,0.0015066397439734535,1,0,1,0.0017083142951734459
484,LV211,Role of LAT2/NTAL/LAB on calcium mobilization,0.0013580312408449932,0,0,1,0.0015398134765177887
485,LV211,Role of LAT2/NTAL/LAB on calcium mobilization,0.0015066397439734535,1,0,1,0.0017083142951734459
486,LV211,FCERI mediated MAPK activation,0.0013580312408449932,0,0,1,0.0015398134765177887
487,LV211,FCERI mediated MAPK activation,0.0015066397439734535,1,0,1,0.0017083142951734459
488,LV211,FCERI mediated Ca+2 mobilization,0.0013580312408449932,0,0,1,0.0015398134765177887
489,LV211,FCERI mediated Ca+2 mobilization,0.0015066397439734535,1,0,1,0.0017083142951734459
490,LV211,FCERI mediated NF-kB activation,0.0013580312408449932,0,0,1,0.0015398134765177887
491,LV211,FCERI mediated NF-kB activation,0.0015066397439734535,1,0,1,0.0017083142951734459
492,LV211,Parasite infection,0.0013580312408449932,0,0,1,0.0015398134765177887
493,LV211,Parasite infection,0.0015066397439734535,1,0,1,0.0017083142951734459
494,LV211,Leishmania parasite growth and survival,0.0013580312408449932,0,0,1,0.0015398134765177887
495,LV211,Leishmania parasite growth and survival,0.0015066397439734535,1,0,1,0.0017083142951734459
496,LV211,Potential therapeutics for SARS,0.0013580312408449932,0,0,1,0.0015398134765177887
497,LV211,Potential therapeutics for SARS,0.0015066397439734535,1,0,1,0.0017083142951734459
498,LV211,CD22 mediated BCR regulation,0.0013580312408449932,0,0,1,0.0015398134765177887
499,LV211,CD22 mediated BCR regulation,0.0015066397439734535,1,0,1,0.0017083142951734459
500,LV211,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0013580312408449932,0,0,1,0.0015398134765177887
501,LV211,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0015066397439734535,1,0,1,0.0017083142951734459
502,LV211,Cell surface interactions at the vascular wall,0.0013580312408449932,0,0,1,0.0015398134765177887
503,LV211,Cell surface interactions at the vascular wall,0.0015066397439734535,1,0,1,0.0017083142951734459
504,LV211,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0013580312408449932,0,0,1,0.0015398134765177887
505,LV211,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0015066397439734535,1,0,1,0.0017083142951734459
506,LV211,Scavenging of heme from plasma,0.0013580312408449932,0,0,1,0.0015398134765177887
507,LV211,Scavenging of heme from plasma,0.0015066397439734535,1,0,1,0.0017083142951734459
508,LV208,Initial triggering of complement,0.002446801230559839,0,0,1,0.002774323149467508
509,LV208,Initial triggering of complement,0.0025251401951389826,1,0,1,0.0028631483471267
510,LV208,Regulation of Complement cascade,0.002446801230559839,0,0,1,0.002774323149467508
511,LV208,Regulation of Complement cascade,0.0025251401951389826,1,0,1,0.0028631483471267
512,LV208,FCGR activation,0.002446801230559839,0,0,1,0.002774323149467508
513,LV208,FCGR activation,0.0025251401951389826,1,0,1,0.0028631483471267
514,LV208,Regulation of actin dynamics for phagocytic cup formation,0.002446801230559839,0,0,1,0.002774323149467508
515,LV208,Regulation of actin dynamics for phagocytic cup formation,0.0025251401951389826,1,0,1,0.0028631483471267
516,LV208,Role of phospholipids in phagocytosis,0.002446801230559839,0,0,1,0.002774323149467508
517,LV208,Role of phospholipids in phagocytosis,0.0025251401951389826,1,0,1,0.0028631483471267
518,LV208,Role of LAT2/NTAL/LAB on calcium mobilization,0.002446801230559839,0,0,1,0.002774323149467508
519,LV208,Role of LAT2/NTAL/LAB on calcium mobilization,0.0025251401951389826,1,0,1,0.0028631483471267
520,LV208,FCERI mediated MAPK activation,0.002446801230559839,0,0,1,0.002774323149467508
521,LV208,FCERI mediated MAPK activation,0.0025251401951389826,1,0,1,0.0028631483471267
522,LV208,FCERI mediated Ca+2 mobilization,0.002446801230559839,0,0,1,0.002774323149467508
523,LV208,FCERI mediated Ca+2 mobilization,0.0025251401951389826,1,0,1,0.0028631483471267
524,LV208,FCERI mediated NF-kB activation,0.002446801230559839,0,0,1,0.002774323149467508
525,LV208,FCERI mediated NF-kB activation,0.0025251401951389826,1,0,1,0.0028631483471267
526,LV208,Parasite infection,0.002446801230559839,0,0,1,0.002774323149467508
527,LV208,Parasite infection,0.0025251401951389826,1,0,1,0.0028631483471267
528,LV208,Leishmania parasite growth and survival,0.002446801230559839,0,0,1,0.002774323149467508
529,LV208,Leishmania parasite growth and survival,0.0025251401951389826,1,0,1,0.0028631483471267
530,LV208,Potential therapeutics for SARS,0.002446801230559839,0,0,1,0.002774323149467508
531,LV208,Potential therapeutics for SARS,0.0025251401951389826,1,0,1,0.0028631483471267
532,LV208,CD22 mediated BCR regulation,0.002446801230559839,0,0,1,0.002774323149467508
533,LV208,CD22 mediated BCR regulation,0.0025251401951389826,1,0,1,0.0028631483471267
534,LV208,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002446801230559839,0,0,1,0.002774323149467508
535,LV208,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0025251401951389826,1,0,1,0.0028631483471267
536,LV208,Cell surface interactions at the vascular wall,0.002446801230559839,0,0,1,0.002774323149467508
537,LV208,Cell surface interactions at the vascular wall,0.0025251401951389826,1,0,1,0.0028631483471267
538,LV208,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002446801230559839,0,0,1,0.002774323149467508
539,LV208,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0025251401951389826,1,0,1,0.0028631483471267
540,LV208,Scavenging of heme from plasma,0.002446801230559839,0,0,1,0.002774323149467508
541,LV208,Scavenging of heme from plasma,0.0025251401951389826,1,0,1,0.0028631483471267
542,LV319,Initial triggering of complement,0.006494110521242737,0,0,1,0.007363393858585691
543,LV319,Initial triggering of complement,0.006661236913378413,1,0,1,0.007552891318697276
544,LV319,Regulation of Complement cascade,0.006494110521242737,0,0,1,0.007363393858585691
545,LV319,Regulation of Complement cascade,0.006661236913378413,1,0,1,0.007552891318697276
546,LV319,FCGR activation,0.006494110521242737,0,0,1,0.007363393858585691
547,LV319,FCGR activation,0.006661236913378413,1,0,1,0.007552891318697276
548,LV319,Regulation of actin dynamics for phagocytic cup formation,0.006494110521242737,0,0,1,0.007363393858585691
549,LV319,Regulation of actin dynamics for phagocytic cup formation,0.006661236913378413,1,0,1,0.007552891318697276
550,LV319,Role of phospholipids in phagocytosis,0.006494110521242737,0,0,1,0.007363393858585691
551,LV319,Role of phospholipids in phagocytosis,0.006661236913378413,1,0,1,0.007552891318697276
552,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.006494110521242737,0,0,1,0.007363393858585691
553,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.006661236913378413,1,0,1,0.007552891318697276
554,LV319,FCERI mediated MAPK activation,0.006494110521242737,0,0,1,0.007363393858585691
555,LV319,FCERI mediated MAPK activation,0.006661236913378413,1,0,1,0.007552891318697276
556,LV319,FCERI mediated Ca+2 mobilization,0.006494110521242737,0,0,1,0.007363393858585691
557,LV319,FCERI mediated Ca+2 mobilization,0.006661236913378413,1,0,1,0.007552891318697276
558,LV319,FCERI mediated NF-kB activation,0.006494110521242737,0,0,1,0.007363393858585691
559,LV319,FCERI mediated NF-kB activation,0.006661236913378413,1,0,1,0.007552891318697276
560,LV319,Parasite infection,0.006494110521242737,0,0,1,0.007363393858585691
561,LV319,Parasite infection,0.006661236913378413,1,0,1,0.007552891318697276
562,LV319,Leishmania parasite growth and survival,0.006494110521242737,0,0,1,0.007363393858585691
563,LV319,Leishmania parasite growth and survival,0.006661236913378413,1,0,1,0.007552891318697276
564,LV319,Potential therapeutics for SARS,0.006494110521242737,0,0,1,0.007363393858585691
565,LV319,Potential therapeutics for SARS,0.006661236913378413,1,0,1,0.007552891318697276
566,LV319,CD22 mediated BCR regulation,0.006494110521242737,0,0,1,0.007363393858585691
567,LV319,CD22 mediated BCR regulation,0.006661236913378413,1,0,1,0.007552891318697276
568,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006494110521242737,0,0,1,0.007363393858585691
569,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006661236913378413,1,0,1,0.007552891318697276
570,LV319,Cell surface interactions at the vascular wall,0.006494110521242737,0,0,1,0.007363393858585691
571,LV319,Cell surface interactions at the vascular wall,0.006661236913378413,1,0,1,0.007552891318697276
572,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006494110521242737,0,0,1,0.007363393858585691
573,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006661236913378413,1,0,1,0.007552891318697276
574,LV319,Scavenging of heme from plasma,0.006494110521242737,0,0,1,0.007363393858585691
575,LV319,Scavenging of heme from plasma,0.006661236913378413,1,0,1,0.007552891318697276
576,LV301,Initial triggering of complement,0.00030104899619674797,0,0,1,0.0003413465666279294
577,LV301,Initial triggering of complement,0.00013902429094433773,1,0,1,0.00015763369083190003
578,LV301,Regulation of Complement cascade,0.00030104899619674797,0,0,1,0.0003413465666279294
579,LV301,Regulation of Complement cascade,0.00013902429094433773,1,0,1,0.00015763369083190003
580,LV301,FCGR activation,0.00030104899619674797,0,0,1,0.0003413465666279294
581,LV301,FCGR activation,0.00013902429094433773,1,0,1,0.00015763369083190003
582,LV301,Regulation of actin dynamics for phagocytic cup formation,0.00030104899619674797,0,0,1,0.0003413465666279294
583,LV301,Regulation of actin dynamics for phagocytic cup formation,0.00013902429094433773,1,0,1,0.00015763369083190003
584,LV301,Role of phospholipids in phagocytosis,0.00030104899619674797,0,0,1,0.0003413465666279294
585,LV301,Role of phospholipids in phagocytosis,0.00013902429094433773,1,0,1,0.00015763369083190003
586,LV301,Role of LAT2/NTAL/LAB on calcium mobilization,0.00030104899619674797,0,0,1,0.0003413465666279294
587,LV301,Role of LAT2/NTAL/LAB on calcium mobilization,0.00013902429094433773,1,0,1,0.00015763369083190003
588,LV301,FCERI mediated MAPK activation,0.00030104899619674797,0,0,1,0.0003413465666279294
589,LV301,FCERI mediated MAPK activation,0.00013902429094433773,1,0,1,0.00015763369083190003
590,LV301,FCERI mediated Ca+2 mobilization,0.00030104899619674797,0,0,1,0.0003413465666279294
591,LV301,FCERI mediated Ca+2 mobilization,0.00013902429094433773,1,0,1,0.00015763369083190003
592,LV301,FCERI mediated NF-kB activation,0.00030104899619674797,0,0,1,0.0003413465666279294
593,LV301,FCERI mediated NF-kB activation,0.00013902429094433773,1,0,1,0.00015763369083190003
594,LV301,Parasite infection,0.00030104899619674797,0,0,1,0.0003413465666279294
595,LV301,Parasite infection,0.00013902429094433773,1,0,1,0.00015763369083190003
596,LV301,Leishmania parasite growth and survival,0.00030104899619674797,0,0,1,0.0003413465666279294
597,LV301,Leishmania parasite growth and survival,0.00013902429094433773,1,0,1,0.00015763369083190003
598,LV301,Potential therapeutics for SARS,0.00030104899619674797,0,0,1,0.0003413465666279294
599,LV301,Potential therapeutics for SARS,0.00013902429094433773,1,0,1,0.00015763369083190003
600,LV301,CD22 mediated BCR regulation,0.00030104899619674797,0,0,1,0.0003413465666279294
601,LV301,CD22 mediated BCR regulation,0.00013902429094433773,1,0,1,0.00015763369083190003
602,LV301,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00030104899619674797,0,0,1,0.0003413465666279294
603,LV301,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00013902429094433773,1,0,1,0.00015763369083190003
604,LV301,Cell surface interactions at the vascular wall,0.00030104899619674797,0,0,1,0.0003413465666279294
605,LV301,Cell surface interactions at the vascular wall,0.00013902429094433773,1,0,1,0.00015763369083190003
606,LV301,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00030104899619674797,0,0,1,0.0003413465666279294
607,LV301,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00013902429094433773,1,0,1,0.00015763369083190003
608,LV301,Scavenging of heme from plasma,0.00030104899619674797,0,0,1,0.0003413465666279294
609,LV301,Scavenging of heme from plasma,0.00013902429094433773,1,0,1,0.00015763369083190003
610,LV325,Initial triggering of complement,0.015762531142005713,0,0,1,0.017872459150048436
611,LV325,Initial triggering of complement,0.015195522067869784,1,0,1,0.017229551838785752
612,LV325,Regulation of Complement cascade,0.015762531142005713,0,0,1,0.017872459150048436
613,LV325,Regulation of Complement cascade,0.015195522067869784,1,0,1,0.017229551838785752
614,LV325,FCGR activation,0.015762531142005713,0,0,1,0.017872459150048436
615,LV325,FCGR activation,0.015195522067869784,1,0,1,0.017229551838785752
616,LV325,Regulation of actin dynamics for phagocytic cup formation,0.015762531142005713,0,0,1,0.017872459150048436
617,LV325,Regulation of actin dynamics for phagocytic cup formation,0.015195522067869784,1,0,1,0.017229551838785752
618,LV325,Role of phospholipids in phagocytosis,0.015762531142005713,0,0,1,0.017872459150048436
619,LV325,Role of phospholipids in phagocytosis,0.015195522067869784,1,0,1,0.017229551838785752
620,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.015762531142005713,0,0,1,0.017872459150048436
621,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.015195522067869784,1,0,1,0.017229551838785752
622,LV325,FCERI mediated MAPK activation,0.015762531142005713,0,0,1,0.017872459150048436
623,LV325,FCERI mediated MAPK activation,0.015195522067869784,1,0,1,0.017229551838785752
624,LV325,FCERI mediated Ca+2 mobilization,0.015762531142005713,0,0,1,0.017872459150048436
625,LV325,FCERI mediated Ca+2 mobilization,0.015195522067869784,1,0,1,0.017229551838785752
626,LV325,FCERI mediated NF-kB activation,0.015762531142005713,0,0,1,0.017872459150048436
627,LV325,FCERI mediated NF-kB activation,0.015195522067869784,1,0,1,0.017229551838785752
628,LV325,Parasite infection,0.015762531142005713,0,0,1,0.017872459150048436
629,LV325,Parasite infection,0.015195522067869784,1,0,1,0.017229551838785752
630,LV325,Leishmania parasite growth and survival,0.015762531142005713,0,0,1,0.017872459150048436
631,LV325,Leishmania parasite growth and survival,0.015195522067869784,1,0,1,0.017229551838785752
632,LV325,Potential therapeutics for SARS,0.015762531142005713,0,0,1,0.017872459150048436
633,LV325,Potential therapeutics for SARS,0.015195522067869784,1,0,1,0.017229551838785752
634,LV325,CD22 mediated BCR regulation,0.015762531142005713,0,0,1,0.017872459150048436
635,LV325,CD22 mediated BCR regulation,0.015195522067869784,1,0,1,0.017229551838785752
636,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.015762531142005713,0,0,1,0.017872459150048436
637,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.015195522067869784,1,0,1,0.017229551838785752
638,LV325,Cell surface interactions at the vascular wall,0.015762531142005713,0,0,1,0.017872459150048436
639,LV325,Cell surface interactions at the vascular wall,0.015195522067869784,1,0,1,0.017229551838785752
640,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.015762531142005713,0,0,1,0.017872459150048436
641,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.015195522067869784,1,0,1,0.017229551838785752
642,LV325,Scavenging of heme from plasma,0.015762531142005713,0,0,1,0.017872459150048436
643,LV325,Scavenging of heme from plasma,0.015195522067869784,1,0,1,0.017229551838785752
644,LV327,Initial triggering of complement,0.002086708966931623,0,0,1,0.0023660299499829963
645,LV327,Initial triggering of complement,0.001498064213335613,1,0,1,0.0016985908681658153
646,LV327,Regulation of Complement cascade,0.002086708966931623,0,0,1,0.0023660299499829963
647,LV327,Regulation of Complement cascade,0.001498064213335613,1,0,1,0.0016985908681658153
648,LV327,FCGR activation,0.002086708966931623,0,0,1,0.0023660299499829963
649,LV327,FCGR activation,0.001498064213335613,1,0,1,0.0016985908681658153
650,LV327,Regulation of actin dynamics for phagocytic cup formation,0.002086708966931623,0,0,1,0.0023660299499829963
651,LV327,Regulation of actin dynamics for phagocytic cup formation,0.001498064213335613,1,0,1,0.0016985908681658153
652,LV327,Role of phospholipids in phagocytosis,0.002086708966931623,0,0,1,0.0023660299499829963
653,LV327,Role of phospholipids in phagocytosis,0.001498064213335613,1,0,1,0.0016985908681658153
654,LV327,Role of LAT2/NTAL/LAB on calcium mobilization,0.002086708966931623,0,0,1,0.0023660299499829963
655,LV327,Role of LAT2/NTAL/LAB on calcium mobilization,0.001498064213335613,1,0,1,0.0016985908681658153
656,LV327,FCERI mediated MAPK activation,0.002086708966931623,0,0,1,0.0023660299499829963
657,LV327,FCERI mediated MAPK activation,0.001498064213335613,1,0,1,0.0016985908681658153
658,LV327,FCERI mediated Ca+2 mobilization,0.002086708966931623,0,0,1,0.0023660299499829963
659,LV327,FCERI mediated Ca+2 mobilization,0.001498064213335613,1,0,1,0.0016985908681658153
660,LV327,FCERI mediated NF-kB activation,0.002086708966931623,0,0,1,0.0023660299499829963
661,LV327,FCERI mediated NF-kB activation,0.001498064213335613,1,0,1,0.0016985908681658153
662,LV327,Parasite infection,0.002086708966931623,0,0,1,0.0023660299499829963
663,LV327,Parasite infection,0.001498064213335613,1,0,1,0.0016985908681658153
664,LV327,Leishmania parasite growth and survival,0.002086708966931623,0,0,1,0.0023660299499829963
665,LV327,Leishmania parasite growth and survival,0.001498064213335613,1,0,1,0.0016985908681658153
666,LV327,Potential therapeutics for SARS,0.002086708966931623,0,0,1,0.0023660299499829963
667,LV327,Potential therapeutics for SARS,0.001498064213335613,1,0,1,0.0016985908681658153
668,LV327,CD22 mediated BCR regulation,0.002086708966931623,0,0,1,0.0023660299499829963
669,LV327,CD22 mediated BCR regulation,0.001498064213335613,1,0,1,0.0016985908681658153
670,LV327,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002086708966931623,0,0,1,0.0023660299499829963
671,LV327,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001498064213335613,1,0,1,0.0016985908681658153
672,LV327,Cell surface interactions at the vascular wall,0.002086708966931623,0,0,1,0.0023660299499829963
673,LV327,Cell surface interactions at the vascular wall,0.001498064213335613,1,0,1,0.0016985908681658153
674,LV327,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002086708966931623,0,0,1,0.0023660299499829963
675,LV327,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001498064213335613,1,0,1,0.0016985908681658153
676,LV327,Scavenging of heme from plasma,0.002086708966931623,0,0,1,0.0023660299499829963
677,LV327,Scavenging of heme from plasma,0.001498064213335613,1,0,1,0.0016985908681658153
678,LV657,Initial triggering of complement,0.011493347260526218,0,0,1,0.013031814342536984
679,LV657,Initial triggering of complement,0.012213577688542863,1,0,1,0.013848452786412658
680,LV657,Regulation of Complement cascade,0.011493347260526218,0,0,1,0.013031814342536984
681,LV657,Regulation of Complement cascade,0.012213577688542863,1,0,1,0.013848452786412658
682,LV657,FCGR activation,0.011493347260526218,0,0,1,0.013031814342536984
683,LV657,FCGR activation,0.012213577688542863,1,0,1,0.013848452786412658
684,LV657,Regulation of actin dynamics for phagocytic cup formation,0.011493347260526218,0,0,1,0.013031814342536984
685,LV657,Regulation of actin dynamics for phagocytic cup formation,0.012213577688542863,1,0,1,0.013848452786412658
686,LV657,Role of phospholipids in phagocytosis,0.011493347260526218,0,0,1,0.013031814342536984
687,LV657,Role of phospholipids in phagocytosis,0.012213577688542863,1,0,1,0.013848452786412658
688,LV657,Role of LAT2/NTAL/LAB on calcium mobilization,0.011493347260526218,0,0,1,0.013031814342536984
689,LV657,Role of LAT2/NTAL/LAB on calcium mobilization,0.012213577688542863,1,0,1,0.013848452786412658
690,LV657,FCERI mediated MAPK activation,0.011493347260526218,0,0,1,0.013031814342536984
691,LV657,FCERI mediated MAPK activation,0.012213577688542863,1,0,1,0.013848452786412658
692,LV657,FCERI mediated Ca+2 mobilization,0.011493347260526218,0,0,1,0.013031814342536984
693,LV657,FCERI mediated Ca+2 mobilization,0.012213577688542863,1,0,1,0.013848452786412658
694,LV657,FCERI mediated NF-kB activation,0.011493347260526218,0,0,1,0.013031814342536984
695,LV657,FCERI mediated NF-kB activation,0.012213577688542863,1,0,1,0.013848452786412658
696,LV657,Parasite infection,0.011493347260526218,0,0,1,0.013031814342536984
697,LV657,Parasite infection,0.012213577688542863,1,0,1,0.013848452786412658
698,LV657,Leishmania parasite growth and survival,0.011493347260526218,0,0,1,0.013031814342536984
699,LV657,Leishmania parasite growth and survival,0.012213577688542863,1,0,1,0.013848452786412658
700,LV657,Potential therapeutics for SARS,0.011493347260526218,0,0,1,0.013031814342536984
701,LV657,Potential therapeutics for SARS,0.012213577688542863,1,0,1,0.013848452786412658
702,LV657,CD22 mediated BCR regulation,0.011493347260526218,0,0,1,0.013031814342536984
703,LV657,CD22 mediated BCR regulation,0.012213577688542863,1,0,1,0.013848452786412658
704,LV657,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.011493347260526218,0,0,1,0.013031814342536984
705,LV657,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012213577688542863,1,0,1,0.013848452786412658
706,LV657,Cell surface interactions at the vascular wall,0.011493347260526218,0,0,1,0.013031814342536984
707,LV657,Cell surface interactions at the vascular wall,0.012213577688542863,1,0,1,0.013848452786412658
708,LV657,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.011493347260526218,0,0,1,0.013031814342536984
709,LV657,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012213577688542863,1,0,1,0.013848452786412658
710,LV657,Scavenging of heme from plasma,0.011493347260526218,0,0,1,0.013031814342536984
711,LV657,Scavenging of heme from plasma,0.012213577688542863,1,0,1,0.013848452786412658
712,HV169,Initial triggering of complement,0.0008038925730887845,0,0,1,0.0009114993679706963
713,HV169,Initial triggering of complement,0.0006428273074855132,1,0,1,0.0007288743597120371
714,HV169,Regulation of Complement cascade,0.0008038925730887845,0,0,1,0.0009114993679706963
715,HV169,Regulation of Complement cascade,0.0006428273074855132,1,0,1,0.0007288743597120371
716,HV169,FCGR activation,0.0008038925730887845,0,0,1,0.0009114993679706963
717,HV169,FCGR activation,0.0006428273074855132,1,0,1,0.0007288743597120371
718,HV169,Regulation of actin dynamics for phagocytic cup formation,0.0008038925730887845,0,0,1,0.0009114993679706963
719,HV169,Regulation of actin dynamics for phagocytic cup formation,0.0006428273074855132,1,0,1,0.0007288743597120371
720,HV169,Role of phospholipids in phagocytosis,0.0008038925730887845,0,0,1,0.0009114993679706963
721,HV169,Role of phospholipids in phagocytosis,0.0006428273074855132,1,0,1,0.0007288743597120371
722,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.0008038925730887845,0,0,1,0.0009114993679706963
723,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.0006428273074855132,1,0,1,0.0007288743597120371
724,HV169,FCERI mediated MAPK activation,0.0008038925730887845,0,0,1,0.0009114993679706963
725,HV169,FCERI mediated MAPK activation,0.0006428273074855132,1,0,1,0.0007288743597120371
726,HV169,FCERI mediated Ca+2 mobilization,0.0008038925730887845,0,0,1,0.0009114993679706963
727,HV169,FCERI mediated Ca+2 mobilization,0.0006428273074855132,1,0,1,0.0007288743597120371
728,HV169,FCERI mediated NF-kB activation,0.0008038925730887845,0,0,1,0.0009114993679706963
729,HV169,FCERI mediated NF-kB activation,0.0006428273074855132,1,0,1,0.0007288743597120371
730,HV169,Parasite infection,0.0008038925730887845,0,0,1,0.0009114993679706963
731,HV169,Parasite infection,0.0006428273074855132,1,0,1,0.0007288743597120371
732,HV169,Leishmania parasite growth and survival,0.0008038925730887845,0,0,1,0.0009114993679706963
733,HV169,Leishmania parasite growth and survival,0.0006428273074855132,1,0,1,0.0007288743597120371
734,HV169,Potential therapeutics for SARS,0.0008038925730887845,0,0,1,0.0009114993679706963
735,HV169,Potential therapeutics for SARS,0.0006428273074855132,1,0,1,0.0007288743597120371
736,HV169,CD22 mediated BCR regulation,0.0008038925730887845,0,0,1,0.0009114993679706963
737,HV169,CD22 mediated BCR regulation,0.0006428273074855132,1,0,1,0.0007288743597120371
738,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0008038925730887845,0,0,1,0.0009114993679706963
739,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0006428273074855132,1,0,1,0.0007288743597120371
740,HV169,Cell surface interactions at the vascular wall,0.0008038925730887845,0,0,1,0.0009114993679706963
741,HV169,Cell surface interactions at the vascular wall,0.0006428273074855132,1,0,1,0.0007288743597120371
742,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0008038925730887845,0,0,1,0.0009114993679706963
743,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0006428273074855132,1,0,1,0.0007288743597120371
744,HV169,Scavenging of heme from plasma,0.0008038925730887845,0,0,1,0.0009114993679706963
745,HV169,Scavenging of heme from plasma,0.0006428273074855132,1,0,1,0.0007288743597120371
746,HV146,Initial triggering of complement,0.008366088333982979,0,0,1,0.009485949347078115
747,HV146,Initial triggering of complement,0.008072015320967522,1,0,1,0.009152512549085426
748,HV146,Regulation of Complement cascade,0.008366088333982979,0,0,1,0.009485949347078115
749,HV146,Regulation of Complement cascade,0.008072015320967522,1,0,1,0.009152512549085426
750,HV146,FCGR activation,0.008366088333982979,0,0,1,0.009485949347078115
751,HV146,FCGR activation,0.008072015320967522,1,0,1,0.009152512549085426
752,HV146,Regulation of actin dynamics for phagocytic cup formation,0.008366088333982979,0,0,1,0.009485949347078115
753,HV146,Regulation of actin dynamics for phagocytic cup formation,0.008072015320967522,1,0,1,0.009152512549085426
754,HV146,Role of phospholipids in phagocytosis,0.008366088333982979,0,0,1,0.009485949347078115
755,HV146,Role of phospholipids in phagocytosis,0.008072015320967522,1,0,1,0.009152512549085426
756,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.008366088333982979,0,0,1,0.009485949347078115
757,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.008072015320967522,1,0,1,0.009152512549085426
758,HV146,FCERI mediated MAPK activation,0.008366088333982979,0,0,1,0.009485949347078115
759,HV146,FCERI mediated MAPK activation,0.008072015320967522,1,0,1,0.009152512549085426
760,HV146,FCERI mediated Ca+2 mobilization,0.008366088333982979,0,0,1,0.009485949347078115
761,HV146,FCERI mediated Ca+2 mobilization,0.008072015320967522,1,0,1,0.009152512549085426
762,HV146,FCERI mediated NF-kB activation,0.008366088333982979,0,0,1,0.009485949347078115
763,HV146,FCERI mediated NF-kB activation,0.008072015320967522,1,0,1,0.009152512549085426
764,HV146,Parasite infection,0.008366088333982979,0,0,1,0.009485949347078115
765,HV146,Parasite infection,0.008072015320967522,1,0,1,0.009152512549085426
766,HV146,Leishmania parasite growth and survival,0.008366088333982979,0,0,1,0.009485949347078115
767,HV146,Leishmania parasite growth and survival,0.008072015320967522,1,0,1,0.009152512549085426
768,HV146,Potential therapeutics for SARS,0.008366088333982979,0,0,1,0.009485949347078115
769,HV146,Potential therapeutics for SARS,0.008072015320967522,1,0,1,0.009152512549085426
770,HV146,CD22 mediated BCR regulation,0.008366088333982979,0,0,1,0.009485949347078115
771,HV146,CD22 mediated BCR regulation,0.008072015320967522,1,0,1,0.009152512549085426
772,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.008366088333982979,0,0,1,0.009485949347078115
773,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.008072015320967522,1,0,1,0.009152512549085426
774,HV146,Cell surface interactions at the vascular wall,0.008366088333982979,0,0,1,0.009485949347078115
775,HV146,Cell surface interactions at the vascular wall,0.008072015320967522,1,0,1,0.009152512549085426
776,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.008366088333982979,0,0,1,0.009485949347078115
777,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.008072015320967522,1,0,1,0.009152512549085426
778,HV146,Scavenging of heme from plasma,0.008366088333982979,0,0,1,0.009485949347078115
779,HV146,Scavenging of heme from plasma,0.008072015320967522,1,0,1,0.009152512549085426
780,HV348,Initial triggering of complement,0.0004970123626195502,0,0,1,0.0005635410371570989
781,HV348,Initial triggering of complement,0.00036243979295694847,1,0,1,0.0004109549624750696
782,HV348,Regulation of Complement cascade,0.0004970123626195502,0,0,1,0.0005635410371570989
783,HV348,Regulation of Complement cascade,0.00036243979295694847,1,0,1,0.0004109549624750696
784,HV348,FCGR activation,0.0004970123626195502,0,0,1,0.0005635410371570989
785,HV348,FCGR activation,0.00036243979295694847,1,0,1,0.0004109549624750696
786,HV348,Regulation of actin dynamics for phagocytic cup formation,0.0004970123626195502,0,0,1,0.0005635410371570989
787,HV348,Regulation of actin dynamics for phagocytic cup formation,0.00036243979295694847,1,0,1,0.0004109549624750696
788,HV348,Role of phospholipids in phagocytosis,0.0004970123626195502,0,0,1,0.0005635410371570989
789,HV348,Role of phospholipids in phagocytosis,0.00036243979295694847,1,0,1,0.0004109549624750696
790,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.0004970123626195502,0,0,1,0.0005635410371570989
791,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.00036243979295694847,1,0,1,0.0004109549624750696
792,HV348,FCERI mediated MAPK activation,0.0004970123626195502,0,0,1,0.0005635410371570989
793,HV348,FCERI mediated MAPK activation,0.00036243979295694847,1,0,1,0.0004109549624750696
794,HV348,FCERI mediated Ca+2 mobilization,0.0004970123626195502,0,0,1,0.0005635410371570989
795,HV348,FCERI mediated Ca+2 mobilization,0.00036243979295694847,1,0,1,0.0004109549624750696
796,HV348,FCERI mediated NF-kB activation,0.0004970123626195502,0,0,1,0.0005635410371570989
797,HV348,FCERI mediated NF-kB activation,0.00036243979295694847,1,0,1,0.0004109549624750696
798,HV348,Parasite infection,0.0004970123626195502,0,0,1,0.0005635410371570989
799,HV348,Parasite infection,0.00036243979295694847,1,0,1,0.0004109549624750696
800,HV348,Leishmania parasite growth and survival,0.0004970123626195502,0,0,1,0.0005635410371570989
801,HV348,Leishmania parasite growth and survival,0.00036243979295694847,1,0,1,0.0004109549624750696
802,HV348,Potential therapeutics for SARS,0.0004970123626195502,0,0,1,0.0005635410371570989
803,HV348,Potential therapeutics for SARS,0.00036243979295694847,1,0,1,0.0004109549624750696
804,HV348,CD22 mediated BCR regulation,0.0004970123626195502,0,0,1,0.0005635410371570989
805,HV348,CD22 mediated BCR regulation,0.00036243979295694847,1,0,1,0.0004109549624750696
806,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0004970123626195502,0,0,1,0.0005635410371570989
807,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00036243979295694847,1,0,1,0.0004109549624750696
808,HV348,Cell surface interactions at the vascular wall,0.0004970123626195502,0,0,1,0.0005635410371570989
809,HV348,Cell surface interactions at the vascular wall,0.00036243979295694847,1,0,1,0.0004109549624750696
810,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004970123626195502,0,0,1,0.0005635410371570989
811,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00036243979295694847,1,0,1,0.0004109549624750696
812,HV348,Scavenging of heme from plasma,0.0004970123626195502,0,0,1,0.0005635410371570989
813,HV348,Scavenging of heme from plasma,0.00036243979295694847,1,0,1,0.0004109549624750696
814,HV323,Initial triggering of complement,0.006360947950812986,0,0,1,0.007212406521661176
815,HV323,Initial triggering of complement,0.006642677507272517,1,0,1,0.007531847602780812
816,HV323,Regulation of Complement cascade,0.006360947950812986,0,0,1,0.007212406521661176
817,HV323,Regulation of Complement cascade,0.006642677507272517,1,0,1,0.007531847602780812
818,HV323,FCGR activation,0.006360947950812986,0,0,1,0.007212406521661176
819,HV323,FCGR activation,0.006642677507272517,1,0,1,0.007531847602780812
820,HV323,Regulation of actin dynamics for phagocytic cup formation,0.006360947950812986,0,0,1,0.007212406521661176
821,HV323,Regulation of actin dynamics for phagocytic cup formation,0.006642677507272517,1,0,1,0.007531847602780812
822,HV323,Role of phospholipids in phagocytosis,0.006360947950812986,0,0,1,0.007212406521661176
823,HV323,Role of phospholipids in phagocytosis,0.006642677507272517,1,0,1,0.007531847602780812
824,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.006360947950812986,0,0,1,0.007212406521661176
825,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.006642677507272517,1,0,1,0.007531847602780812
826,HV323,FCERI mediated MAPK activation,0.006360947950812986,0,0,1,0.007212406521661176
827,HV323,FCERI mediated MAPK activation,0.006642677507272517,1,0,1,0.007531847602780812
828,HV323,FCERI mediated Ca+2 mobilization,0.006360947950812986,0,0,1,0.007212406521661176
829,HV323,FCERI mediated Ca+2 mobilization,0.006642677507272517,1,0,1,0.007531847602780812
830,HV323,FCERI mediated NF-kB activation,0.006360947950812986,0,0,1,0.007212406521661176
831,HV323,FCERI mediated NF-kB activation,0.006642677507272517,1,0,1,0.007531847602780812
832,HV323,Parasite infection,0.006360947950812986,0,0,1,0.007212406521661176
833,HV323,Parasite infection,0.006642677507272517,1,0,1,0.007531847602780812
834,HV323,Leishmania parasite growth and survival,0.006360947950812986,0,0,1,0.007212406521661176
835,HV323,Leishmania parasite growth and survival,0.006642677507272517,1,0,1,0.007531847602780812
836,HV323,Potential therapeutics for SARS,0.006360947950812986,0,0,1,0.007212406521661176
837,HV323,Potential therapeutics for SARS,0.006642677507272517,1,0,1,0.007531847602780812
838,HV323,CD22 mediated BCR regulation,0.006360947950812986,0,0,1,0.007212406521661176
839,HV323,CD22 mediated BCR regulation,0.006642677507272517,1,0,1,0.007531847602780812
840,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006360947950812986,0,0,1,0.007212406521661176
841,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006642677507272517,1,0,1,0.007531847602780812
842,HV323,Cell surface interactions at the vascular wall,0.006360947950812986,0,0,1,0.007212406521661176
843,HV323,Cell surface interactions at the vascular wall,0.006642677507272517,1,0,1,0.007531847602780812
844,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006360947950812986,0,0,1,0.007212406521661176
845,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006642677507272517,1,0,1,0.007531847602780812
846,HV323,Scavenging of heme from plasma,0.006360947950812986,0,0,1,0.007212406521661176
847,HV323,Scavenging of heme from plasma,0.006642677507272517,1,0,1,0.007531847602780812
848,HV313,Initial triggering of complement,0.0025011622914584146,0,0,1,0.0028359608288167307
849,HV313,Initial triggering of complement,0.002736934731264303,1,0,1,0.0031032931031307527
850,HV313,Regulation of Complement cascade,0.0025011622914584146,0,0,1,0.0028359608288167307
851,HV313,Regulation of Complement cascade,0.002736934731264303,1,0,1,0.0031032931031307527
852,HV313,FCGR activation,0.0025011622914584146,0,0,1,0.0028359608288167307
853,HV313,FCGR activation,0.002736934731264303,1,0,1,0.0031032931031307527
854,HV313,Regulation of actin dynamics for phagocytic cup formation,0.0025011622914584146,0,0,1,0.0028359608288167307
855,HV313,Regulation of actin dynamics for phagocytic cup formation,0.002736934731264303,1,0,1,0.0031032931031307527
856,HV313,Role of phospholipids in phagocytosis,0.0025011622914584146,0,0,1,0.0028359608288167307
857,HV313,Role of phospholipids in phagocytosis,0.002736934731264303,1,0,1,0.0031032931031307527
858,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.0025011622914584146,0,0,1,0.0028359608288167307
859,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.002736934731264303,1,0,1,0.0031032931031307527
860,HV313,FCERI mediated MAPK activation,0.0025011622914584146,0,0,1,0.0028359608288167307
861,HV313,FCERI mediated MAPK activation,0.002736934731264303,1,0,1,0.0031032931031307527
862,HV313,FCERI mediated Ca+2 mobilization,0.0025011622914584146,0,0,1,0.0028359608288167307
863,HV313,FCERI mediated Ca+2 mobilization,0.002736934731264303,1,0,1,0.0031032931031307527
864,HV313,FCERI mediated NF-kB activation,0.0025011622914584146,0,0,1,0.0028359608288167307
865,HV313,FCERI mediated NF-kB activation,0.002736934731264303,1,0,1,0.0031032931031307527
866,HV313,Parasite infection,0.0025011622914584146,0,0,1,0.0028359608288167307
867,HV313,Parasite infection,0.002736934731264303,1,0,1,0.0031032931031307527
868,HV313,Leishmania parasite growth and survival,0.0025011622914584146,0,0,1,0.0028359608288167307
869,HV313,Leishmania parasite growth and survival,0.002736934731264303,1,0,1,0.0031032931031307527
870,HV313,Potential therapeutics for SARS,0.0025011622914584146,0,0,1,0.0028359608288167307
871,HV313,Potential therapeutics for SARS,0.002736934731264303,1,0,1,0.0031032931031307527
872,HV313,CD22 mediated BCR regulation,0.0025011622914584146,0,0,1,0.0028359608288167307
873,HV313,CD22 mediated BCR regulation,0.002736934731264303,1,0,1,0.0031032931031307527
874,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0025011622914584146,0,0,1,0.0028359608288167307
875,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002736934731264303,1,0,1,0.0031032931031307527
876,HV313,Cell surface interactions at the vascular wall,0.0025011622914584146,0,0,1,0.0028359608288167307
877,HV313,Cell surface interactions at the vascular wall,0.002736934731264303,1,0,1,0.0031032931031307527
878,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0025011622914584146,0,0,1,0.0028359608288167307
879,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002736934731264303,1,0,1,0.0031032931031307527
880,HV313,Scavenging of heme from plasma,0.0025011622914584146,0,0,1,0.0028359608288167307
881,HV313,Scavenging of heme from plasma,0.002736934731264303,1,0,1,0.0031032931031307527
882,HV353,Initial triggering of complement,0.00022546740554982303,0,0,1,0.0002556478372066746
883,HV353,Initial triggering of complement,0.0002320227497398661,1,0,1,0.0002630806613004416
884,HV353,Regulation of Complement cascade,0.00022546740554982303,0,0,1,0.0002556478372066746
885,HV353,Regulation of Complement cascade,0.0002320227497398661,1,0,1,0.0002630806613004416
886,HV353,FCGR activation,0.00022546740554982303,0,0,1,0.0002556478372066746
887,HV353,FCGR activation,0.0002320227497398661,1,0,1,0.0002630806613004416
888,HV353,Regulation of actin dynamics for phagocytic cup formation,0.00022546740554982303,0,0,1,0.0002556478372066746
889,HV353,Regulation of actin dynamics for phagocytic cup formation,0.0002320227497398661,1,0,1,0.0002630806613004416
890,HV353,Role of phospholipids in phagocytosis,0.00022546740554982303,0,0,1,0.0002556478372066746
891,HV353,Role of phospholipids in phagocytosis,0.0002320227497398661,1,0,1,0.0002630806613004416
892,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.00022546740554982303,0,0,1,0.0002556478372066746
893,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.0002320227497398661,1,0,1,0.0002630806613004416
894,HV353,FCERI mediated MAPK activation,0.00022546740554982303,0,0,1,0.0002556478372066746
895,HV353,FCERI mediated MAPK activation,0.0002320227497398661,1,0,1,0.0002630806613004416
896,HV353,FCERI mediated Ca+2 mobilization,0.00022546740554982303,0,0,1,0.0002556478372066746
897,HV353,FCERI mediated Ca+2 mobilization,0.0002320227497398661,1,0,1,0.0002630806613004416
898,HV353,FCERI mediated NF-kB activation,0.00022546740554982303,0,0,1,0.0002556478372066746
899,HV353,FCERI mediated NF-kB activation,0.0002320227497398661,1,0,1,0.0002630806613004416
900,HV353,Parasite infection,0.00022546740554982303,0,0,1,0.0002556478372066746
901,HV353,Parasite infection,0.0002320227497398661,1,0,1,0.0002630806613004416
902,HV353,Leishmania parasite growth and survival,0.00022546740554982303,0,0,1,0.0002556478372066746
903,HV353,Leishmania parasite growth and survival,0.0002320227497398661,1,0,1,0.0002630806613004416
904,HV353,Potential therapeutics for SARS,0.00022546740554982303,0,0,1,0.0002556478372066746
905,HV353,Potential therapeutics for SARS,0.0002320227497398661,1,0,1,0.0002630806613004416
906,HV353,CD22 mediated BCR regulation,0.00022546740554982303,0,0,1,0.0002556478372066746
907,HV353,CD22 mediated BCR regulation,0.0002320227497398661,1,0,1,0.0002630806613004416
908,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00022546740554982303,0,0,1,0.0002556478372066746
909,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0002320227497398661,1,0,1,0.0002630806613004416
910,HV353,Cell surface interactions at the vascular wall,0.00022546740554982303,0,0,1,0.0002556478372066746
911,HV353,Cell surface interactions at the vascular wall,0.0002320227497398661,1,0,1,0.0002630806613004416
912,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00022546740554982303,0,0,1,0.0002556478372066746
913,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0002320227497398661,1,0,1,0.0002630806613004416
914,HV353,Scavenging of heme from plasma,0.00022546740554982303,0,0,1,0.0002556478372066746
915,HV353,Scavenging of heme from plasma,0.0002320227497398661,1,0,1,0.0002630806613004416
916,HV307,Initial triggering of complement,0.00806347118668782,0,0,1,0.009142824721063977
917,HV307,Initial triggering of complement,0.007975822380286329,1,0,1,0.009043443492386397
918,HV307,Regulation of Complement cascade,0.00806347118668782,0,0,1,0.009142824721063977
919,HV307,Regulation of Complement cascade,0.007975822380286329,1,0,1,0.009043443492386397
920,HV307,FCGR activation,0.00806347118668782,0,0,1,0.009142824721063977
921,HV307,FCGR activation,0.007975822380286329,1,0,1,0.009043443492386397
922,HV307,Regulation of actin dynamics for phagocytic cup formation,0.00806347118668782,0,0,1,0.009142824721063977
923,HV307,Regulation of actin dynamics for phagocytic cup formation,0.007975822380286329,1,0,1,0.009043443492386397
924,HV307,Role of phospholipids in phagocytosis,0.00806347118668782,0,0,1,0.009142824721063977
925,HV307,Role of phospholipids in phagocytosis,0.007975822380286329,1,0,1,0.009043443492386397
926,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.00806347118668782,0,0,1,0.009142824721063977
927,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.007975822380286329,1,0,1,0.009043443492386397
928,HV307,FCERI mediated MAPK activation,0.00806347118668782,0,0,1,0.009142824721063977
929,HV307,FCERI mediated MAPK activation,0.007975822380286329,1,0,1,0.009043443492386397
930,HV307,FCERI mediated Ca+2 mobilization,0.00806347118668782,0,0,1,0.009142824721063977
931,HV307,FCERI mediated Ca+2 mobilization,0.007975822380286329,1,0,1,0.009043443492386397
932,HV307,FCERI mediated NF-kB activation,0.00806347118668782,0,0,1,0.009142824721063977
933,HV307,FCERI mediated NF-kB activation,0.007975822380286329,1,0,1,0.009043443492386397
934,HV307,Parasite infection,0.00806347118668782,0,0,1,0.009142824721063977
935,HV307,Parasite infection,0.007975822380286329,1,0,1,0.009043443492386397
936,HV307,Leishmania parasite growth and survival,0.00806347118668782,0,0,1,0.009142824721063977
937,HV307,Leishmania parasite growth and survival,0.007975822380286329,1,0,1,0.009043443492386397
938,HV307,Potential therapeutics for SARS,0.00806347118668782,0,0,1,0.009142824721063977
939,HV307,Potential therapeutics for SARS,0.007975822380286329,1,0,1,0.009043443492386397
940,HV307,CD22 mediated BCR regulation,0.00806347118668782,0,0,1,0.009142824721063977
941,HV307,CD22 mediated BCR regulation,0.007975822380286329,1,0,1,0.009043443492386397
942,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00806347118668782,0,0,1,0.009142824721063977
943,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007975822380286329,1,0,1,0.009043443492386397
944,HV307,Cell surface interactions at the vascular wall,0.00806347118668782,0,0,1,0.009142824721063977
945,HV307,Cell surface interactions at the vascular wall,0.007975822380286329,1,0,1,0.009043443492386397
946,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00806347118668782,0,0,1,0.009142824721063977
947,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007975822380286329,1,0,1,0.009043443492386397
948,HV307,Scavenging of heme from plasma,0.00806347118668782,0,0,1,0.009142824721063977
949,HV307,Scavenging of heme from plasma,0.007975822380286329,1,0,1,0.009043443492386397
950,HV205,Initial triggering of complement,0.006527270057734801,0,0,1,0.007400992037206231
951,HV205,Initial triggering of complement,0.006587663186026745,1,0,1,0.007469469219494865
952,HV205,Regulation of Complement cascade,0.006527270057734801,0,0,1,0.007400992037206231
953,HV205,Regulation of Complement cascade,0.006587663186026745,1,0,1,0.007469469219494865
954,HV205,FCGR activation,0.006527270057734801,0,0,1,0.007400992037206231
955,HV205,FCGR activation,0.006587663186026745,1,0,1,0.007469469219494865
956,HV205,Regulation of actin dynamics for phagocytic cup formation,0.006527270057734801,0,0,1,0.007400992037206231
957,HV205,Regulation of actin dynamics for phagocytic cup formation,0.006587663186026745,1,0,1,0.007469469219494865
958,HV205,Role of phospholipids in phagocytosis,0.006527270057734801,0,0,1,0.007400992037206231
959,HV205,Role of phospholipids in phagocytosis,0.006587663186026745,1,0,1,0.007469469219494865
960,HV205,Role of LAT2/NTAL/LAB on calcium mobilization,0.006527270057734801,0,0,1,0.007400992037206231
961,HV205,Role of LAT2/NTAL/LAB on calcium mobilization,0.006587663186026745,1,0,1,0.007469469219494865
962,HV205,FCERI mediated MAPK activation,0.006527270057734801,0,0,1,0.007400992037206231
963,HV205,FCERI mediated MAPK activation,0.006587663186026745,1,0,1,0.007469469219494865
964,HV205,FCERI mediated Ca+2 mobilization,0.006527270057734801,0,0,1,0.007400992037206231
965,HV205,FCERI mediated Ca+2 mobilization,0.006587663186026745,1,0,1,0.007469469219494865
966,HV205,FCERI mediated NF-kB activation,0.006527270057734801,0,0,1,0.007400992037206231
967,HV205,FCERI mediated NF-kB activation,0.006587663186026745,1,0,1,0.007469469219494865
968,HV205,Parasite infection,0.006527270057734801,0,0,1,0.007400992037206231
969,HV205,Parasite infection,0.006587663186026745,1,0,1,0.007469469219494865
970,HV205,Leishmania parasite growth and survival,0.006527270057734801,0,0,1,0.007400992037206231
971,HV205,Leishmania parasite growth and survival,0.006587663186026745,1,0,1,0.007469469219494865
972,HV205,Potential therapeutics for SARS,0.006527270057734801,0,0,1,0.007400992037206231
973,HV205,Potential therapeutics for SARS,0.006587663186026745,1,0,1,0.007469469219494865
974,HV205,CD22 mediated BCR regulation,0.006527270057734801,0,0,1,0.007400992037206231
975,HV205,CD22 mediated BCR regulation,0.006587663186026745,1,0,1,0.007469469219494865
976,HV205,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006527270057734801,0,0,1,0.007400992037206231
977,HV205,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006587663186026745,1,0,1,0.007469469219494865
978,HV205,Cell surface interactions at the vascular wall,0.006527270057734801,0,0,1,0.007400992037206231
979,HV205,Cell surface interactions at the vascular wall,0.006587663186026745,1,0,1,0.007469469219494865
980,HV205,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006527270057734801,0,0,1,0.007400992037206231
981,HV205,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006587663186026745,1,0,1,0.007469469219494865
982,HV205,Scavenging of heme from plasma,0.006527270057734801,0,0,1,0.007400992037206231
983,HV205,Scavenging of heme from plasma,0.006587663186026745,1,0,1,0.007469469219494865
984,PIGR,Neutrophil degranulation,0.0015248577082052595,0,0,1,0.00172897086476856
985,PIGR,Neutrophil degranulation,0.0015382238247445233,1,0,1,0.0017441261320089952
986,IGKC,Initial triggering of complement,0.007395400100138039,0,0,1,0.008385327521145987
987,IGKC,Initial triggering of complement,0.008421935261378506,1,0,1,0.009549271786827171
988,IGKC,Regulation of Complement cascade,0.007395400100138039,0,0,1,0.008385327521145987
989,IGKC,Regulation of Complement cascade,0.008421935261378506,1,0,1,0.009549271786827171
990,IGKC,FCGR activation,0.007395400100138039,0,0,1,0.008385327521145987
991,IGKC,FCGR activation,0.008421935261378506,1,0,1,0.009549271786827171
992,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.007395400100138039,0,0,1,0.008385327521145987
993,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.008421935261378506,1,0,1,0.009549271786827171
994,IGKC,Role of phospholipids in phagocytosis,0.007395400100138039,0,0,1,0.008385327521145987
995,IGKC,Role of phospholipids in phagocytosis,0.008421935261378506,1,0,1,0.009549271786827171
996,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.007395400100138039,0,0,1,0.008385327521145987
997,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.008421935261378506,1,0,1,0.009549271786827171
998,IGKC,FCERI mediated MAPK activation,0.007395400100138039,0,0,1,0.008385327521145987
999,IGKC,FCERI mediated MAPK activation,0.008421935261378506,1,0,1,0.009549271786827171
1000,IGKC,FCERI mediated Ca+2 mobilization,0.007395400100138039,0,0,1,0.008385327521145987
1001,IGKC,FCERI mediated Ca+2 mobilization,0.008421935261378506,1,0,1,0.009549271786827171
1002,IGKC,FCERI mediated NF-kB activation,0.007395400100138039,0,0,1,0.008385327521145987
1003,IGKC,FCERI mediated NF-kB activation,0.008421935261378506,1,0,1,0.009549271786827171
1004,IGKC,Parasite infection,0.007395400100138039,0,0,1,0.008385327521145987
1005,IGKC,Parasite infection,0.008421935261378506,1,0,1,0.009549271786827171
1006,IGKC,Leishmania parasite growth and survival,0.007395400100138039,0,0,1,0.008385327521145987
1007,IGKC,Leishmania parasite growth and survival,0.008421935261378506,1,0,1,0.009549271786827171
1008,IGKC,Potential therapeutics for SARS,0.007395400100138039,0,0,1,0.008385327521145987
1009,IGKC,Potential therapeutics for SARS,0.008421935261378506,1,0,1,0.009549271786827171
1010,IGKC,CD22 mediated BCR regulation,0.007395400100138039,0,0,1,0.008385327521145987
1011,IGKC,CD22 mediated BCR regulation,0.008421935261378506,1,0,1,0.009549271786827171
1012,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007395400100138039,0,0,1,0.008385327521145987
1013,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.008421935261378506,1,0,1,0.009549271786827171
1014,IGKC,Cell surface interactions at the vascular wall,0.007395400100138039,0,0,1,0.008385327521145987
1015,IGKC,Cell surface interactions at the vascular wall,0.008421935261378506,1,0,1,0.009549271786827171
1016,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007395400100138039,0,0,1,0.008385327521145987
1017,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.008421935261378506,1,0,1,0.009549271786827171
1018,IGKC,Scavenging of heme from plasma,0.007395400100138039,0,0,1,0.008385327521145987
1019,IGKC,Scavenging of heme from plasma,0.008421935261378506,1,0,1,0.009549271786827171
1020,IGHM,Potential therapeutics for SARS,0.0007312019773940086,0,0,1,0.0008290786139405631
1021,IGHM,Potential therapeutics for SARS,0.0005664969634584832,1,0,1,0.0006423266508928146
1022,IGHM,CD22 mediated BCR regulation,0.0007312019773940086,0,0,1,0.0008290786139405631
1023,IGHM,CD22 mediated BCR regulation,0.0005664969634584832,1,0,1,0.0006423266508928146
1024,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0007312019773940086,0,0,1,0.0008290786139405631
1025,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0005664969634584832,1,0,1,0.0006423266508928146
1026,IGHM,Cell surface interactions at the vascular wall,0.0007312019773940086,0,0,1,0.0008290786139405631
1027,IGHM,Cell surface interactions at the vascular wall,0.0005664969634584832,1,0,1,0.0006423266508928146
1028,IGHD,Potential therapeutics for SARS,0.0005877930805170133,0,0,1,0.0006664734061794022
1029,IGHD,Potential therapeutics for SARS,0.0005169171790316829,1,0,1,0.000586110256212725
1030,IGHD,CD22 mediated BCR regulation,0.0005877930805170133,0,0,1,0.0006664734061794022
1031,IGHD,CD22 mediated BCR regulation,0.0005169171790316829,1,0,1,0.000586110256212725
1032,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0005877930805170133,0,0,1,0.0006664734061794022
1033,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0005169171790316829,1,0,1,0.000586110256212725
1034,HBD,Factors involved in megakaryocyte development and platelet production,0.0014893962125392152,0,0,1,0.001688762593204736
1035,HBD,Factors involved in megakaryocyte development and platelet production,0.001731399310993359,1,0,1,0.0019631595445789092
1036,APOA1,PPARA activates gene expression,0.023961784708767104,0,0,1,0.027169241698018404
1037,APOA1,PPARA activates gene expression,0.024432045254644572,1,0,1,0.02770244999561705
1038,APOA1,Defective ABCA1 causes TGD,0.023961784708767104,0,0,1,0.027169241698018404
1039,APOA1,Defective ABCA1 causes TGD,0.024432045254644572,1,0,1,0.02770244999561705
1040,APOA1,Platelet degranulation ,0.023961784708767104,0,0,1,0.027169241698018404
1041,APOA1,Platelet degranulation ,0.024432045254644572,1,0,1,0.02770244999561705
1042,APOA1,Chylomicron assembly,0.023961784708767104,0,0,1,0.027169241698018404
1043,APOA1,Chylomicron assembly,0.024432045254644572,1,0,1,0.02770244999561705
1044,APOA1,HDL assembly,0.023961784708767104,0,0,1,0.027169241698018404
1045,APOA1,HDL assembly,0.024432045254644572,1,0,1,0.02770244999561705
1046,APOA1,Chylomicron remodeling,0.023961784708767104,0,0,1,0.027169241698018404
1047,APOA1,Chylomicron remodeling,0.024432045254644572,1,0,1,0.02770244999561705
1048,APOA1,HDL remodeling,0.023961784708767104,0,0,1,0.027169241698018404
1049,APOA1,HDL remodeling,0.024432045254644572,1,0,1,0.02770244999561705
1050,APOA1,HDL clearance,0.023961784708767104,0,0,1,0.027169241698018404
1051,APOA1,HDL clearance,0.024432045254644572,1,0,1,0.02770244999561705
1052,APOA1,Scavenging of heme from plasma,0.023961784708767104,0,0,1,0.027169241698018404
1053,APOA1,Scavenging of heme from plasma,0.024432045254644572,1,0,1,0.02770244999561705
1054,APOA1,Scavenging by Class B Receptors,0.023961784708767104,0,0,1,0.027169241698018404
1055,APOA1,Scavenging by Class B Receptors,0.024432045254644572,1,0,1,0.02770244999561705
1056,APOA1,Scavenging by Class A Receptors,0.023961784708767104,0,0,1,0.027169241698018404
1057,APOA1,Scavenging by Class A Receptors,0.024432045254644572,1,0,1,0.02770244999561705
1058,APOA1,Retinoid metabolism and transport,0.023961784708767104,0,0,1,0.027169241698018404
1059,APOA1,Retinoid metabolism and transport,0.024432045254644572,1,0,1,0.02770244999561705
1060,APOA1,Heme signaling,0.023961784708767104,0,0,1,0.027169241698018404
1061,APOA1,Heme signaling,0.024432045254644572,1,0,1,0.02770244999561705
1062,APOA1,ABC transporters in lipid homeostasis,0.023961784708767104,0,0,1,0.027169241698018404
1063,APOA1,ABC transporters in lipid homeostasis,0.024432045254644572,1,0,1,0.02770244999561705
1064,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.023961784708767104,0,0,1,0.027169241698018404
1065,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.024432045254644572,1,0,1,0.02770244999561705
1066,APOA1,Amyloid fiber formation,0.023961784708767104,0,0,1,0.027169241698018404
1067,APOA1,Amyloid fiber formation,0.024432045254644572,1,0,1,0.02770244999561705
1068,APOA1,Post-translational protein phosphorylation,0.023961784708767104,0,0,1,0.027169241698018404
1069,APOA1,Post-translational protein phosphorylation,0.024432045254644572,1,0,1,0.02770244999561705
1070,APOE,Nuclear signaling by ERBB4,0.04015836448718363,0,0,1,0.04553385001202398
1071,APOE,Nuclear signaling by ERBB4,0.041349565544551777,1,0,1,0.04688450188674552
1072,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.04015836448718363,0,0,1,0.04553385001202398
1073,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.041349565544551777,1,0,1,0.04688450188674552
1074,APOE,Chylomicron assembly,0.04015836448718363,0,0,1,0.04553385001202398
1075,APOE,Chylomicron assembly,0.041349565544551777,1,0,1,0.04688450188674552
1076,APOE,Chylomicron remodeling,0.04015836448718363,0,0,1,0.04553385001202398
1077,APOE,Chylomicron remodeling,0.041349565544551777,1,0,1,0.04688450188674552
1078,APOE,HDL remodeling,0.04015836448718363,0,0,1,0.04553385001202398
1079,APOE,HDL remodeling,0.041349565544551777,1,0,1,0.04688450188674552
1080,APOE,Chylomicron clearance,0.04015836448718363,0,0,1,0.04553385001202398
1081,APOE,Chylomicron clearance,0.041349565544551777,1,0,1,0.04688450188674552
1082,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.04015836448718363,0,0,1,0.04553385001202398
1083,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.041349565544551777,1,0,1,0.04688450188674552
1084,APOE,Scavenging by Class A Receptors,0.04015836448718363,0,0,1,0.04553385001202398
1085,APOE,Scavenging by Class A Receptors,0.041349565544551777,1,0,1,0.04688450188674552
1086,APOE,Retinoid metabolism and transport,0.04015836448718363,0,0,1,0.04553385001202398
1087,APOE,Retinoid metabolism and transport,0.041349565544551777,1,0,1,0.04688450188674552
1088,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.04015836448718363,0,0,1,0.04553385001202398
1089,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.041349565544551777,1,0,1,0.04688450188674552
1090,APOE,Amyloid fiber formation,0.04015836448718363,0,0,1,0.04553385001202398
1091,APOE,Amyloid fiber formation,0.041349565544551777,1,0,1,0.04688450188674552
1092,APOE,Post-translational protein phosphorylation,0.04015836448718363,0,0,1,0.04553385001202398
1093,APOE,Post-translational protein phosphorylation,0.041349565544551777,1,0,1,0.04688450188674552
1094,FIBA,Antigen processing-Cross presentation,0.03223678823416122,0,0,1,0.036551913880659634
1095,FIBA,Antigen processing-Cross presentation,0.03907803370982886,1,0,1,0.04430890920062353
1096,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.03223678823416122,0,0,1,0.036551913880659634
1097,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.03907803370982886,1,0,1,0.04430890920062353
1098,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.03223678823416122,0,0,1,0.036551913880659634
1099,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.03907803370982886,1,0,1,0.04430890920062353
1100,FIBA,Regulation of TLR by endogenous ligand,0.03223678823416122,0,0,1,0.036551913880659634
1101,FIBA,Regulation of TLR by endogenous ligand,0.03907803370982886,1,0,1,0.04430890920062353
1102,FIBA,MyD88 deficiency (TLR2/4),0.03223678823416122,0,0,1,0.036551913880659634
1103,FIBA,MyD88 deficiency (TLR2/4),0.03907803370982886,1,0,1,0.04430890920062353
1104,FIBA,IRAK4 deficiency (TLR2/4),0.03223678823416122,0,0,1,0.036551913880659634
1105,FIBA,IRAK4 deficiency (TLR2/4),0.03907803370982886,1,0,1,0.04430890920062353
1106,FIBA,RAF/MAP kinase cascade,0.03223678823416122,0,0,1,0.036551913880659634
1107,FIBA,RAF/MAP kinase cascade,0.03907803370982886,1,0,1,0.04430890920062353
1108,FIBA,Signaling by RAS mutants,0.03223678823416122,0,0,1,0.036551913880659634
1109,FIBA,Signaling by RAS mutants,0.03907803370982886,1,0,1,0.04430890920062353
1110,FIBA,Signaling by moderate kinase activity BRAF mutants,0.03223678823416122,0,0,1,0.036551913880659634
1111,FIBA,Signaling by moderate kinase activity BRAF mutants,0.03907803370982886,1,0,1,0.04430890920062353
1112,FIBA,Signaling by high-kinase activity BRAF mutants,0.03223678823416122,0,0,1,0.036551913880659634
1113,FIBA,Signaling by high-kinase activity BRAF mutants,0.03907803370982886,1,0,1,0.04430890920062353
1114,FIBA,Signaling by BRAF and RAF1 fusions,0.03223678823416122,0,0,1,0.036551913880659634
1115,FIBA,Signaling by BRAF and RAF1 fusions,0.03907803370982886,1,0,1,0.04430890920062353
1116,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.03223678823416122,0,0,1,0.036551913880659634
1117,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.03907803370982886,1,0,1,0.04430890920062353
1118,FIBA,Signaling by RAF1 mutants,0.03223678823416122,0,0,1,0.036551913880659634
1119,FIBA,Signaling by RAF1 mutants,0.03907803370982886,1,0,1,0.04430890920062353
1120,FIBA,Platelet degranulation ,0.03223678823416122,0,0,1,0.036551913880659634
1121,FIBA,Platelet degranulation ,0.03907803370982886,1,0,1,0.04430890920062353
1122,FIBA,Common Pathway of Fibrin Clot Formation,0.03223678823416122,0,0,1,0.036551913880659634
1123,FIBA,Common Pathway of Fibrin Clot Formation,0.03907803370982886,1,0,1,0.04430890920062353
1124,FIBA,Integrin cell surface interactions,0.03223678823416122,0,0,1,0.036551913880659634
1125,FIBA,Integrin cell surface interactions,0.03907803370982886,1,0,1,0.04430890920062353
1126,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.03223678823416122,0,0,1,0.036551913880659634
1127,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.03907803370982886,1,0,1,0.04430890920062353
1128,FIBA,p130Cas linkage to MAPK signaling for integrins,0.03223678823416122,0,0,1,0.036551913880659634
1129,FIBA,p130Cas linkage to MAPK signaling for integrins,0.03907803370982886,1,0,1,0.04430890920062353
1130,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03223678823416122,0,0,1,0.036551913880659634
1131,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03907803370982886,1,0,1,0.04430890920062353
1132,FIBA,Amyloid fiber formation,0.03223678823416122,0,0,1,0.036551913880659634
1133,FIBA,Amyloid fiber formation,0.03907803370982886,1,0,1,0.04430890920062353
1134,FIBA,Post-translational protein phosphorylation,0.03223678823416122,0,0,1,0.036551913880659634
1135,FIBA,Post-translational protein phosphorylation,0.03907803370982886,1,0,1,0.04430890920062353
1136,FIBB,Antigen processing-Cross presentation,0.017994253201193123,0,0,1,0.020402913236244997
1137,FIBB,Antigen processing-Cross presentation,0.02411497509648994,1,0,1,0.02734293771943087
1138,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.017994253201193123,0,0,1,0.020402913236244997
1139,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.02411497509648994,1,0,1,0.02734293771943087
1140,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.017994253201193123,0,0,1,0.020402913236244997
1141,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.02411497509648994,1,0,1,0.02734293771943087
1142,FIBB,Regulation of TLR by endogenous ligand,0.017994253201193123,0,0,1,0.020402913236244997
1143,FIBB,Regulation of TLR by endogenous ligand,0.02411497509648994,1,0,1,0.02734293771943087
1144,FIBB,MyD88 deficiency (TLR2/4),0.017994253201193123,0,0,1,0.020402913236244997
1145,FIBB,MyD88 deficiency (TLR2/4),0.02411497509648994,1,0,1,0.02734293771943087
1146,FIBB,IRAK4 deficiency (TLR2/4),0.017994253201193123,0,0,1,0.020402913236244997
1147,FIBB,IRAK4 deficiency (TLR2/4),0.02411497509648994,1,0,1,0.02734293771943087
1148,FIBB,RAF/MAP kinase cascade,0.017994253201193123,0,0,1,0.020402913236244997
1149,FIBB,RAF/MAP kinase cascade,0.02411497509648994,1,0,1,0.02734293771943087
1150,FIBB,Signaling by RAS mutants,0.017994253201193123,0,0,1,0.020402913236244997
1151,FIBB,Signaling by RAS mutants,0.02411497509648994,1,0,1,0.02734293771943087
1152,FIBB,Signaling by moderate kinase activity BRAF mutants,0.017994253201193123,0,0,1,0.020402913236244997
1153,FIBB,Signaling by moderate kinase activity BRAF mutants,0.02411497509648994,1,0,1,0.02734293771943087
1154,FIBB,Signaling by high-kinase activity BRAF mutants,0.017994253201193123,0,0,1,0.020402913236244997
1155,FIBB,Signaling by high-kinase activity BRAF mutants,0.02411497509648994,1,0,1,0.02734293771943087
1156,FIBB,Signaling by BRAF and RAF1 fusions,0.017994253201193123,0,0,1,0.020402913236244997
1157,FIBB,Signaling by BRAF and RAF1 fusions,0.02411497509648994,1,0,1,0.02734293771943087
1158,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.017994253201193123,0,0,1,0.020402913236244997
1159,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.02411497509648994,1,0,1,0.02734293771943087
1160,FIBB,Signaling by RAF1 mutants,0.017994253201193123,0,0,1,0.020402913236244997
1161,FIBB,Signaling by RAF1 mutants,0.02411497509648994,1,0,1,0.02734293771943087
1162,FIBB,Platelet degranulation ,0.017994253201193123,0,0,1,0.020402913236244997
1163,FIBB,Platelet degranulation ,0.02411497509648994,1,0,1,0.02734293771943087
1164,FIBB,Common Pathway of Fibrin Clot Formation,0.017994253201193123,0,0,1,0.020402913236244997
1165,FIBB,Common Pathway of Fibrin Clot Formation,0.02411497509648994,1,0,1,0.02734293771943087
1166,FIBB,Integrin cell surface interactions,0.017994253201193123,0,0,1,0.020402913236244997
1167,FIBB,Integrin cell surface interactions,0.02411497509648994,1,0,1,0.02734293771943087
1168,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.017994253201193123,0,0,1,0.020402913236244997
1169,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.02411497509648994,1,0,1,0.02734293771943087
1170,FIBB,p130Cas linkage to MAPK signaling for integrins,0.017994253201193123,0,0,1,0.020402913236244997
1171,FIBB,p130Cas linkage to MAPK signaling for integrins,0.02411497509648994,1,0,1,0.02734293771943087
1172,CRP,Initial triggering of complement,0.0004206502737724738,0,0,1,0.000476957334245659
1173,CRP,Initial triggering of complement,0.00037883826418495223,1,0,1,0.0004295484868592789
1174,SAMP,Amyloid fiber formation,0.004930178138860477,0,0,1,0.005590117893846935
1175,SAMP,Amyloid fiber formation,0.0036355220647100047,1,0,1,0.00412216280527909
1176,C1QA,Initial triggering of complement,0.0008841208194487943,0,0,1,0.001002466741346927
1177,C1QA,Initial triggering of complement,0.0008015656161686261,1,0,1,0.0009088609311533615
1178,C1QA,Regulation of Complement cascade,0.0008841208194487943,0,0,1,0.001002466741346927
1179,C1QA,Regulation of Complement cascade,0.0008015656161686261,1,0,1,0.0009088609311533615
1180,C1QC,Initial triggering of complement,0.001599851410838615,0,0,1,0.001814003013143112
1181,C1QC,Initial triggering of complement,0.001437914442341175,1,0,1,0.0016303896182968765
1182,C1QC,Regulation of Complement cascade,0.001599851410838615,0,0,1,0.001814003013143112
1183,C1QC,Regulation of Complement cascade,0.001437914442341175,1,0,1,0.0016303896182968765
1184,CO9,Terminal pathway of complement,0.005830521282516448,0,0,1,0.006610978434013326
1185,CO9,Terminal pathway of complement,0.00689037222395891,1,0,1,0.007812698036367778
1186,CO9,Regulation of Complement cascade,0.005830521282516448,0,0,1,0.006610978434013326
1187,CO9,Regulation of Complement cascade,0.00689037222395891,1,0,1,0.007812698036367778
1188,APOH,Platelet degranulation ,0.0037843450744091517,0,0,1,0.0042909068437506186
1189,APOH,Platelet degranulation ,0.0034435273391486727,1,0,1,0.0039044682066955386
1190,A2GL,Neutrophil degranulation,0.0004359050693772004,0,0,1,0.0004942540938099432
1191,A2GL,Neutrophil degranulation,0.00043891859817505186,1,0,1,0.000497671005082116
1192,AMBP,Scavenging of heme from plasma,0.002820302249592728,0,0,1,0.003197819962576253
1193,AMBP,Scavenging of heme from plasma,0.003190623561041384,1,0,1,0.0036177114414023045
1194,A1AG1,Platelet degranulation ,0.0020791477168542074,0,0,1,0.0023574565722738936
1195,A1AG1,Platelet degranulation ,0.00214693985363702,1,0,1,0.0024343231734834216
1196,A1AG1,Neutrophil degranulation,0.0020791477168542074,0,0,1,0.0023574565722738936
1197,A1AG1,Neutrophil degranulation,0.00214693985363702,1,0,1,0.0024343231734834216
1198,FETUA,Platelet degranulation ,0.015613880058977748,0,0,1,0.017703910051867895
1199,FETUA,Platelet degranulation ,0.01329487129970208,1,0,1,0.015074485313837843
1200,FETUA,Neutrophil degranulation,0.015613880058977748,0,0,1,0.017703910051867895
1201,FETUA,Neutrophil degranulation,0.01329487129970208,1,0,1,0.015074485313837843
1202,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.015613880058977748,0,0,1,0.017703910051867895
1203,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.01329487129970208,1,0,1,0.015074485313837843
1204,FETUA,Post-translational protein phosphorylation,0.015613880058977748,0,0,1,0.017703910051867895
1205,FETUA,Post-translational protein phosphorylation,0.01329487129970208,1,0,1,0.015074485313837843
1206,CXCL7,Class A/1 (Rhodopsin-like receptors),0.009876566820019347,0,0,1,0.011198616227511437
1207,CXCL7,Class A/1 (Rhodopsin-like receptors),0.013027774087643777,1,0,1,0.014771635221514635
1208,CXCL7,G alpha (i) signalling events,0.009876566820019347,0,0,1,0.011198616227511437
1209,CXCL7,G alpha (i) signalling events,0.013027774087643777,1,0,1,0.014771635221514635
1210,CXCL7,Platelet degranulation ,0.009876566820019347,0,0,1,0.011198616227511437
1211,CXCL7,Platelet degranulation ,0.013027774087643777,1,0,1,0.014771635221514635
1212,CXCL7,Neutrophil degranulation,0.009876566820019347,0,0,1,0.011198616227511437
1213,CXCL7,Neutrophil degranulation,0.013027774087643777,1,0,1,0.014771635221514635
1214,PLF4,Transcriptional regulation by RUNX1,0.026406703877715723,0,0,1,0.029941430858410084
1215,PLF4,Transcriptional regulation by RUNX1,0.03186992655580747,1,0,1,0.036135945131667124
1216,PLF4,Class A/1 (Rhodopsin-like receptors),0.026406703877715723,0,0,1,0.029941430858410084
1217,PLF4,Class A/1 (Rhodopsin-like receptors),0.03186992655580747,1,0,1,0.036135945131667124
1218,PLF4,G alpha (i) signalling events,0.026406703877715723,0,0,1,0.029941430858410084
1219,PLF4,G alpha (i) signalling events,0.03186992655580747,1,0,1,0.036135945131667124
1220,PLF4,Platelet degranulation ,0.026406703877715723,0,0,1,0.029941430858410084
1221,PLF4,Platelet degranulation ,0.03186992655580747,1,0,1,0.036135945131667124
1222,PLF4,Cell surface interactions at the vascular wall,0.026406703877715723,0,0,1,0.029941430858410084
1223,PLF4,Cell surface interactions at the vascular wall,0.03186992655580747,1,0,1,0.036135945131667124
1224,PLF4,Common Pathway of Fibrin Clot Formation,0.026406703877715723,0,0,1,0.029941430858410084
1225,PLF4,Common Pathway of Fibrin Clot Formation,0.03186992655580747,1,0,1,0.036135945131667124
1226,TRFE,Platelet degranulation ,0.003439451843375101,0,0,1,0.0038998471765403476
1227,TRFE,Platelet degranulation ,0.0026526733269034075,1,0,1,0.0030077527045869828
1228,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.003439451843375101,0,0,1,0.0038998471765403476
1229,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.0026526733269034075,1,0,1,0.0030077527045869828
1230,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003439451843375101,0,0,1,0.0038998471765403476
1231,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0026526733269034075,1,0,1,0.0030077527045869828
1232,TRFE,Post-translational protein phosphorylation,0.003439451843375101,0,0,1,0.0038998471765403476
1233,TRFE,Post-translational protein phosphorylation,0.0026526733269034075,1,0,1,0.0030077527045869828
1234,TRFE,Transferrin endocytosis and recycling,0.003439451843375101,0,0,1,0.0038998471765403476
1235,TRFE,Transferrin endocytosis and recycling,0.0026526733269034075,1,0,1,0.0030077527045869828
1236,HEMO,Scavenging of heme from plasma,0.00036720386866644024,0,0,1,0.0004163567439363429
1237,HEMO,Scavenging of heme from plasma,0.0004175487081320197,1,0,1,0.00047344060176717493
1238,ANGI,Adherens junctions interactions,0.00012457301057078416,0,0,1,0.0001412480027837451
1239,ANGI,Adherens junctions interactions,0.0008668579930745287,1,0,1,0.0009828931616718813
1240,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.00012457301057078416,0,0,1,0.0001412480027837451
1241,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0008668579930745287,1,0,1,0.0009828931616718813
1242,C4BPA,Regulation of Complement cascade,0.00234249130482302,0,0,1,0.0026560505909627536
1243,C4BPA,Regulation of Complement cascade,0.002112335023328281,1,0,1,0.0023950862380879936
1244,VTNC,Regulation of Complement cascade,0.007946729962002307,0,0,1,0.0090104568449582
1245,VTNC,Regulation of Complement cascade,0.00831977674616455,1,0,1,0.009433438620596311
1246,VTNC,Integrin cell surface interactions,0.007946729962002307,0,0,1,0.0090104568449582
1247,VTNC,Integrin cell surface interactions,0.00831977674616455,1,0,1,0.009433438620596311
1248,VTNC,ECM proteoglycans,0.007946729962002307,0,0,1,0.0090104568449582
1249,VTNC,ECM proteoglycans,0.00831977674616455,1,0,1,0.009433438620596311
1250,VTNC,Molecules associated with elastic fibres,0.007946729962002307,0,0,1,0.0090104568449582
1251,VTNC,Molecules associated with elastic fibres,0.00831977674616455,1,0,1,0.009433438620596311
1252,VTNC,Syndecan interactions,0.007946729962002307,0,0,1,0.0090104568449582
1253,VTNC,Syndecan interactions,0.00831977674616455,1,0,1,0.009433438620596311
1254,CATA,FOXO-mediated transcription,0.002642284604460489,0,0,1,0.0029959733770278793
1255,CATA,FOXO-mediated transcription,0.0012949680415300037,1,0,1,0.0014683088150218371
1256,CATA,Detoxification of Reactive Oxygen Species,0.002642284604460489,0,0,1,0.0029959733770278793
1257,CATA,Detoxification of Reactive Oxygen Species,0.0012949680415300037,1,0,1,0.0014683088150218371
1258,CATA,Neutrophil degranulation,0.002642284604460489,0,0,1,0.0029959733770278793
1259,CATA,Neutrophil degranulation,0.0012949680415300037,1,0,1,0.0014683088150218371
1260,CATA,Peroxisomal protein import,0.002642284604460489,0,0,1,0.0029959733770278793
1261,CATA,Peroxisomal protein import,0.0012949680415300037,1,0,1,0.0014683088150218371
1262,APOB,Regulation of TLR by endogenous ligand,0.021792955562517716,0,0,1,0.024710099192886182
1263,APOB,Regulation of TLR by endogenous ligand,0.011218689788756753,1,0,1,0.012720391995438564
1264,APOB,Cargo recognition for clathrin-mediated endocytosis,0.021792955562517716,0,0,1,0.024710099192886182
1265,APOB,Cargo recognition for clathrin-mediated endocytosis,0.011218689788756753,1,0,1,0.012720391995438564
1266,APOB,VLDL assembly,0.021792955562517716,0,0,1,0.024710099192886182
1267,APOB,VLDL assembly,0.011218689788756753,1,0,1,0.012720391995438564
1268,APOB,Chylomicron assembly,0.021792955562517716,0,0,1,0.024710099192886182
1269,APOB,Chylomicron assembly,0.011218689788756753,1,0,1,0.012720391995438564
1270,APOB,Chylomicron remodeling,0.021792955562517716,0,0,1,0.024710099192886182
1271,APOB,Chylomicron remodeling,0.011218689788756753,1,0,1,0.012720391995438564
1272,APOB,LDL remodeling,0.021792955562517716,0,0,1,0.024710099192886182
1273,APOB,LDL remodeling,0.011218689788756753,1,0,1,0.012720391995438564
1274,APOB,Chylomicron clearance,0.021792955562517716,0,0,1,0.024710099192886182
1275,APOB,Chylomicron clearance,0.011218689788756753,1,0,1,0.012720391995438564
1276,APOB,LDL clearance,0.021792955562517716,0,0,1,0.024710099192886182
1277,APOB,LDL clearance,0.011218689788756753,1,0,1,0.012720391995438564
1278,APOB,VLDL clearance,0.021792955562517716,0,0,1,0.024710099192886182
1279,APOB,VLDL clearance,0.011218689788756753,1,0,1,0.012720391995438564
1280,APOB,Cell surface interactions at the vascular wall,0.021792955562517716,0,0,1,0.024710099192886182
1281,APOB,Cell surface interactions at the vascular wall,0.011218689788756753,1,0,1,0.012720391995438564
1282,APOB,Scavenging by Class B Receptors,0.021792955562517716,0,0,1,0.024710099192886182
1283,APOB,Scavenging by Class B Receptors,0.011218689788756753,1,0,1,0.012720391995438564
1284,APOB,Scavenging by Class A Receptors,0.021792955562517716,0,0,1,0.024710099192886182
1285,APOB,Scavenging by Class A Receptors,0.011218689788756753,1,0,1,0.012720391995438564
1286,APOB,Scavenging by Class F Receptors,0.021792955562517716,0,0,1,0.024710099192886182
1287,APOB,Scavenging by Class F Receptors,0.011218689788756753,1,0,1,0.012720391995438564
1288,APOB,Scavenging by Class H Receptors,0.021792955562517716,0,0,1,0.024710099192886182
1289,APOB,Scavenging by Class H Receptors,0.011218689788756753,1,0,1,0.012720391995438564
1290,APOB,Retinoid metabolism and transport,0.021792955562517716,0,0,1,0.024710099192886182
1291,APOB,Retinoid metabolism and transport,0.011218689788756753,1,0,1,0.012720391995438564
1292,APOB,Heme signaling,0.021792955562517716,0,0,1,0.024710099192886182
1293,APOB,Heme signaling,0.011218689788756753,1,0,1,0.012720391995438564
1294,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.021792955562517716,0,0,1,0.024710099192886182
1295,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.011218689788756753,1,0,1,0.012720391995438564
1296,APOB,Platelet sensitization by LDL,0.021792955562517716,0,0,1,0.024710099192886182
1297,APOB,Platelet sensitization by LDL,0.011218689788756753,1,0,1,0.012720391995438564
1298,APOB,Post-translational protein phosphorylation,0.021792955562517716,0,0,1,0.024710099192886182
1299,APOB,Post-translational protein phosphorylation,0.011218689788756753,1,0,1,0.012720391995438564
1300,LCAT,HDL remodeling,0.00267746271499408,0,0,1,0.003035860330323852
1301,LCAT,HDL remodeling,0.0022595986215750456,1,0,1,0.0025620621266837346
1302,HRG,Platelet degranulation ,0.0008299560548113125,0,0,1,0.0009410516339232469
1303,HRG,Platelet degranulation ,0.0014785642502486717,1,0,1,0.0016764806949608245
1304,HRG,Dissolution of Fibrin Clot,0.0008299560548113125,0,0,1,0.0009410516339232469
1305,HRG,Dissolution of Fibrin Clot,0.0014785642502486717,1,0,1,0.0016764806949608245
1306,LV743,Initial triggering of complement,0.004847547405750492,0,0,1,0.005496426443613337
1307,LV743,Initial triggering of complement,0.0049930867105939325,1,0,1,0.005661447229748947
1308,LV743,Regulation of Complement cascade,0.004847547405750492,0,0,1,0.005496426443613337
1309,LV743,Regulation of Complement cascade,0.0049930867105939325,1,0,1,0.005661447229748947
1310,LV743,FCGR activation,0.004847547405750492,0,0,1,0.005496426443613337
1311,LV743,FCGR activation,0.0049930867105939325,1,0,1,0.005661447229748947
1312,LV743,Regulation of actin dynamics for phagocytic cup formation,0.004847547405750492,0,0,1,0.005496426443613337
1313,LV743,Regulation of actin dynamics for phagocytic cup formation,0.0049930867105939325,1,0,1,0.005661447229748947
1314,LV743,Role of phospholipids in phagocytosis,0.004847547405750492,0,0,1,0.005496426443613337
1315,LV743,Role of phospholipids in phagocytosis,0.0049930867105939325,1,0,1,0.005661447229748947
1316,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.004847547405750492,0,0,1,0.005496426443613337
1317,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.0049930867105939325,1,0,1,0.005661447229748947
1318,LV743,FCERI mediated MAPK activation,0.004847547405750492,0,0,1,0.005496426443613337
1319,LV743,FCERI mediated MAPK activation,0.0049930867105939325,1,0,1,0.005661447229748947
1320,LV743,FCERI mediated Ca+2 mobilization,0.004847547405750492,0,0,1,0.005496426443613337
1321,LV743,FCERI mediated Ca+2 mobilization,0.0049930867105939325,1,0,1,0.005661447229748947
1322,LV743,FCERI mediated NF-kB activation,0.004847547405750492,0,0,1,0.005496426443613337
1323,LV743,FCERI mediated NF-kB activation,0.0049930867105939325,1,0,1,0.005661447229748947
1324,LV743,Parasite infection,0.004847547405750492,0,0,1,0.005496426443613337
1325,LV743,Parasite infection,0.0049930867105939325,1,0,1,0.005661447229748947
1326,LV743,Leishmania parasite growth and survival,0.004847547405750492,0,0,1,0.005496426443613337
1327,LV743,Leishmania parasite growth and survival,0.0049930867105939325,1,0,1,0.005661447229748947
1328,LV743,Potential therapeutics for SARS,0.004847547405750492,0,0,1,0.005496426443613337
1329,LV743,Potential therapeutics for SARS,0.0049930867105939325,1,0,1,0.005661447229748947
1330,LV743,CD22 mediated BCR regulation,0.004847547405750492,0,0,1,0.005496426443613337
1331,LV743,CD22 mediated BCR regulation,0.0049930867105939325,1,0,1,0.005661447229748947
1332,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004847547405750492,0,0,1,0.005496426443613337
1333,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0049930867105939325,1,0,1,0.005661447229748947
1334,LV743,Cell surface interactions at the vascular wall,0.004847547405750492,0,0,1,0.005496426443613337
1335,LV743,Cell surface interactions at the vascular wall,0.0049930867105939325,1,0,1,0.005661447229748947
1336,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004847547405750492,0,0,1,0.005496426443613337
1337,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0049930867105939325,1,0,1,0.005661447229748947
1338,LV743,Scavenging of heme from plasma,0.004847547405750492,0,0,1,0.005496426443613337
1339,LV743,Scavenging of heme from plasma,0.0049930867105939325,1,0,1,0.005661447229748947
1340,K2C1,Neutrophil degranulation,7.758967850256355e-05,0,0,1,8.797561425950048e-05
1341,K2C1,Neutrophil degranulation,6.954241104288417e-05,1,0,1,7.88511622506886e-05
1342,K2C1,Formation of the cornified envelope,7.758967850256355e-05,0,0,1,8.797561425950048e-05
1343,K2C1,Formation of the cornified envelope,6.954241104288417e-05,1,0,1,7.88511622506886e-05
1344,VWF,RAF/MAP kinase cascade,0.008797122515373302,0,0,1,0.009974680549558891
1345,VWF,RAF/MAP kinase cascade,0.005265031020755766,1,0,1,0.005969793239071219
1346,VWF,Signaling by RAS mutants,0.008797122515373302,0,0,1,0.009974680549558891
1347,VWF,Signaling by RAS mutants,0.005265031020755766,1,0,1,0.005969793239071219
1348,VWF,Signaling by moderate kinase activity BRAF mutants,0.008797122515373302,0,0,1,0.009974680549558891
1349,VWF,Signaling by moderate kinase activity BRAF mutants,0.005265031020755766,1,0,1,0.005969793239071219
1350,VWF,Signaling by high-kinase activity BRAF mutants,0.008797122515373302,0,0,1,0.009974680549558891
1351,VWF,Signaling by high-kinase activity BRAF mutants,0.005265031020755766,1,0,1,0.005969793239071219
1352,VWF,Signaling by BRAF and RAF1 fusions,0.008797122515373302,0,0,1,0.009974680549558891
1353,VWF,Signaling by BRAF and RAF1 fusions,0.005265031020755766,1,0,1,0.005969793239071219
1354,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.008797122515373302,0,0,1,0.009974680549558891
1355,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.005265031020755766,1,0,1,0.005969793239071219
1356,VWF,Signaling by RAF1 mutants,0.008797122515373302,0,0,1,0.009974680549558891
1357,VWF,Signaling by RAF1 mutants,0.005265031020755766,1,0,1,0.005969793239071219
1358,VWF,Platelet degranulation ,0.008797122515373302,0,0,1,0.009974680549558891
1359,VWF,Platelet degranulation ,0.005265031020755766,1,0,1,0.005969793239071219
1360,VWF,Defective factor VIII causes hemophilia A,0.008797122515373302,0,0,1,0.009974680549558891
1361,VWF,Defective factor VIII causes hemophilia A,0.005265031020755766,1,0,1,0.005969793239071219
1362,VWF,Platelet Adhesion to exposed collagen,0.008797122515373302,0,0,1,0.009974680549558891
1363,VWF,Platelet Adhesion to exposed collagen,0.005265031020755766,1,0,1,0.005969793239071219
1364,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.008797122515373302,0,0,1,0.009974680549558891
1365,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.005265031020755766,1,0,1,0.005969793239071219
1366,VWF,Integrin cell surface interactions,0.008797122515373302,0,0,1,0.009974680549558891
1367,VWF,Integrin cell surface interactions,0.005265031020755766,1,0,1,0.005969793239071219
1368,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.008797122515373302,0,0,1,0.009974680549558891
1369,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.005265031020755766,1,0,1,0.005969793239071219
1370,VWF,p130Cas linkage to MAPK signaling for integrins,0.008797122515373302,0,0,1,0.009974680549558891
1371,VWF,p130Cas linkage to MAPK signaling for integrins,0.005265031020755766,1,0,1,0.005969793239071219
1372,VWF,GP1b-IX-V activation signalling,0.008797122515373302,0,0,1,0.009974680549558891
1373,VWF,GP1b-IX-V activation signalling,0.005265031020755766,1,0,1,0.005969793239071219
1374,KV116,Initial triggering of complement,0.005282170805105199,0,0,1,0.005989227306662656
1375,KV116,Initial triggering of complement,0.0059260771996940504,1,0,1,0.006719325197037377
1376,KV116,Regulation of Complement cascade,0.005282170805105199,0,0,1,0.005989227306662656
1377,KV116,Regulation of Complement cascade,0.0059260771996940504,1,0,1,0.006719325197037377
1378,KV116,FCGR activation,0.005282170805105199,0,0,1,0.005989227306662656
1379,KV116,FCGR activation,0.0059260771996940504,1,0,1,0.006719325197037377
1380,KV116,Regulation of actin dynamics for phagocytic cup formation,0.005282170805105199,0,0,1,0.005989227306662656
1381,KV116,Regulation of actin dynamics for phagocytic cup formation,0.0059260771996940504,1,0,1,0.006719325197037377
1382,KV116,Role of phospholipids in phagocytosis,0.005282170805105199,0,0,1,0.005989227306662656
1383,KV116,Role of phospholipids in phagocytosis,0.0059260771996940504,1,0,1,0.006719325197037377
1384,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.005282170805105199,0,0,1,0.005989227306662656
1385,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.0059260771996940504,1,0,1,0.006719325197037377
1386,KV116,FCERI mediated MAPK activation,0.005282170805105199,0,0,1,0.005989227306662656
1387,KV116,FCERI mediated MAPK activation,0.0059260771996940504,1,0,1,0.006719325197037377
1388,KV116,FCERI mediated Ca+2 mobilization,0.005282170805105199,0,0,1,0.005989227306662656
1389,KV116,FCERI mediated Ca+2 mobilization,0.0059260771996940504,1,0,1,0.006719325197037377
1390,KV116,FCERI mediated NF-kB activation,0.005282170805105199,0,0,1,0.005989227306662656
1391,KV116,FCERI mediated NF-kB activation,0.0059260771996940504,1,0,1,0.006719325197037377
1392,KV116,Parasite infection,0.005282170805105199,0,0,1,0.005989227306662656
1393,KV116,Parasite infection,0.0059260771996940504,1,0,1,0.006719325197037377
1394,KV116,Leishmania parasite growth and survival,0.005282170805105199,0,0,1,0.005989227306662656
1395,KV116,Leishmania parasite growth and survival,0.0059260771996940504,1,0,1,0.006719325197037377
1396,KV116,Potential therapeutics for SARS,0.005282170805105199,0,0,1,0.005989227306662656
1397,KV116,Potential therapeutics for SARS,0.0059260771996940504,1,0,1,0.006719325197037377
1398,KV116,CD22 mediated BCR regulation,0.005282170805105199,0,0,1,0.005989227306662656
1399,KV116,CD22 mediated BCR regulation,0.0059260771996940504,1,0,1,0.006719325197037377
1400,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005282170805105199,0,0,1,0.005989227306662656
1401,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0059260771996940504,1,0,1,0.006719325197037377
1402,KV116,Cell surface interactions at the vascular wall,0.005282170805105199,0,0,1,0.005989227306662656
1403,KV116,Cell surface interactions at the vascular wall,0.0059260771996940504,1,0,1,0.006719325197037377
1404,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005282170805105199,0,0,1,0.005989227306662656
1405,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0059260771996940504,1,0,1,0.006719325197037377
1406,KV116,Scavenging of heme from plasma,0.005282170805105199,0,0,1,0.005989227306662656
1407,KV116,Scavenging of heme from plasma,0.0059260771996940504,1,0,1,0.006719325197037377
1408,S10A8,Antigen processing-Cross presentation,0.025940508449621306,0,0,1,0.02941283182380754
1409,S10A8,Antigen processing-Cross presentation,0.021918826375588677,1,0,1,0.024852818718356245
1410,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.025940508449621306,0,0,1,0.02941283182380754
1411,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.021918826375588677,1,0,1,0.024852818718356245
1412,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.025940508449621306,0,0,1,0.02941283182380754
1413,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.021918826375588677,1,0,1,0.024852818718356245
1414,S10A8,Regulation of TLR by endogenous ligand,0.025940508449621306,0,0,1,0.02941283182380754
1415,S10A8,Regulation of TLR by endogenous ligand,0.021918826375588677,1,0,1,0.024852818718356245
1416,S10A8,RHO GTPase Effectors,0.025940508449621306,0,0,1,0.02941283182380754
1417,S10A8,RHO GTPase Effectors,0.021918826375588677,1,0,1,0.024852818718356245
1418,S10A8,MyD88 deficiency (TLR2/4),0.025940508449621306,0,0,1,0.02941283182380754
1419,S10A8,MyD88 deficiency (TLR2/4),0.021918826375588677,1,0,1,0.024852818718356245
1420,S10A8,IRAK4 deficiency (TLR2/4),0.025940508449621306,0,0,1,0.02941283182380754
1421,S10A8,IRAK4 deficiency (TLR2/4),0.021918826375588677,1,0,1,0.024852818718356245
1422,S10A8,Metal sequestration by antimicrobial proteins,0.025940508449621306,0,0,1,0.02941283182380754
1423,S10A8,Metal sequestration by antimicrobial proteins,0.021918826375588677,1,0,1,0.024852818718356245
1424,S10A8,Neutrophil degranulation,0.025940508449621306,0,0,1,0.02941283182380754
1425,S10A8,Neutrophil degranulation,0.021918826375588677,1,0,1,0.024852818718356245
1426,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.0016940288011436065,0,0,1,0.0019207867235713568
1427,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.001952331310631092,1,0,1,0.00221366487921652
1428,IPSP,Common Pathway of Fibrin Clot Formation,0.0016940288011436065,0,0,1,0.0019207867235713568
1429,IPSP,Common Pathway of Fibrin Clot Formation,0.001952331310631092,1,0,1,0.00221366487921652
1430,F13B,Common Pathway of Fibrin Clot Formation,0.0008741089435665969,0,0,1,0.000991114703967405
1431,F13B,Common Pathway of Fibrin Clot Formation,0.0009885557185263343,1,0,1,0.0011208810017716811
1432,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.006275305914621791,0,0,1,0.0071153006838002054
1433,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.00521729199014733,1,0,1,0.005915663996329331
1434,HEP2,Common Pathway of Fibrin Clot Formation,0.006275305914621791,0,0,1,0.0071153006838002054
1435,HEP2,Common Pathway of Fibrin Clot Formation,0.00521729199014733,1,0,1,0.005915663996329331
1436,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006275305914621791,0,0,1,0.0071153006838002054
1437,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00521729199014733,1,0,1,0.005915663996329331
1438,HEP2,Post-translational protein phosphorylation,0.006275305914621791,0,0,1,0.0071153006838002054
1439,HEP2,Post-translational protein phosphorylation,0.00521729199014733,1,0,1,0.005915663996329331
1440,KV230,Initial triggering of complement,0.0054759537298889145,0,0,1,0.006208949467778283
1441,KV230,Initial triggering of complement,0.005615959387873911,1,0,1,0.006367695888677922
1442,KV230,Regulation of Complement cascade,0.0054759537298889145,0,0,1,0.006208949467778283
1443,KV230,Regulation of Complement cascade,0.005615959387873911,1,0,1,0.006367695888677922
1444,KV230,FCGR activation,0.0054759537298889145,0,0,1,0.006208949467778283
1445,KV230,FCGR activation,0.005615959387873911,1,0,1,0.006367695888677922
1446,KV230,Regulation of actin dynamics for phagocytic cup formation,0.0054759537298889145,0,0,1,0.006208949467778283
1447,KV230,Regulation of actin dynamics for phagocytic cup formation,0.005615959387873911,1,0,1,0.006367695888677922
1448,KV230,Role of phospholipids in phagocytosis,0.0054759537298889145,0,0,1,0.006208949467778283
1449,KV230,Role of phospholipids in phagocytosis,0.005615959387873911,1,0,1,0.006367695888677922
1450,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.0054759537298889145,0,0,1,0.006208949467778283
1451,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.005615959387873911,1,0,1,0.006367695888677922
1452,KV230,FCERI mediated MAPK activation,0.0054759537298889145,0,0,1,0.006208949467778283
1453,KV230,FCERI mediated MAPK activation,0.005615959387873911,1,0,1,0.006367695888677922
1454,KV230,FCERI mediated Ca+2 mobilization,0.0054759537298889145,0,0,1,0.006208949467778283
1455,KV230,FCERI mediated Ca+2 mobilization,0.005615959387873911,1,0,1,0.006367695888677922
1456,KV230,FCERI mediated NF-kB activation,0.0054759537298889145,0,0,1,0.006208949467778283
1457,KV230,FCERI mediated NF-kB activation,0.005615959387873911,1,0,1,0.006367695888677922
1458,KV230,Parasite infection,0.0054759537298889145,0,0,1,0.006208949467778283
1459,KV230,Parasite infection,0.005615959387873911,1,0,1,0.006367695888677922
1460,KV230,Leishmania parasite growth and survival,0.0054759537298889145,0,0,1,0.006208949467778283
1461,KV230,Leishmania parasite growth and survival,0.005615959387873911,1,0,1,0.006367695888677922
1462,KV230,Potential therapeutics for SARS,0.0054759537298889145,0,0,1,0.006208949467778283
1463,KV230,Potential therapeutics for SARS,0.005615959387873911,1,0,1,0.006367695888677922
1464,KV230,CD22 mediated BCR regulation,0.0054759537298889145,0,0,1,0.006208949467778283
1465,KV230,CD22 mediated BCR regulation,0.005615959387873911,1,0,1,0.006367695888677922
1466,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0054759537298889145,0,0,1,0.006208949467778283
1467,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005615959387873911,1,0,1,0.006367695888677922
1468,KV230,Cell surface interactions at the vascular wall,0.0054759537298889145,0,0,1,0.006208949467778283
1469,KV230,Cell surface interactions at the vascular wall,0.005615959387873911,1,0,1,0.006367695888677922
1470,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0054759537298889145,0,0,1,0.006208949467778283
1471,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005615959387873911,1,0,1,0.006367695888677922
1472,KV230,Scavenging of heme from plasma,0.0054759537298889145,0,0,1,0.006208949467778283
1473,KV230,Scavenging of heme from plasma,0.005615959387873911,1,0,1,0.006367695888677922
1474,KV401,Initial triggering of complement,0.007683029896028849,0,0,1,0.008711458631123364
1475,KV401,Initial triggering of complement,0.008326674667600929,1,0,1,0.009441259878361407
1476,KV401,Regulation of Complement cascade,0.007683029896028849,0,0,1,0.008711458631123364
1477,KV401,Regulation of Complement cascade,0.008326674667600929,1,0,1,0.009441259878361407
1478,KV401,FCGR activation,0.007683029896028849,0,0,1,0.008711458631123364
1479,KV401,FCGR activation,0.008326674667600929,1,0,1,0.009441259878361407
1480,KV401,Regulation of actin dynamics for phagocytic cup formation,0.007683029896028849,0,0,1,0.008711458631123364
1481,KV401,Regulation of actin dynamics for phagocytic cup formation,0.008326674667600929,1,0,1,0.009441259878361407
1482,KV401,Role of phospholipids in phagocytosis,0.007683029896028849,0,0,1,0.008711458631123364
1483,KV401,Role of phospholipids in phagocytosis,0.008326674667600929,1,0,1,0.009441259878361407
1484,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.007683029896028849,0,0,1,0.008711458631123364
1485,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.008326674667600929,1,0,1,0.009441259878361407
1486,KV401,FCERI mediated MAPK activation,0.007683029896028849,0,0,1,0.008711458631123364
1487,KV401,FCERI mediated MAPK activation,0.008326674667600929,1,0,1,0.009441259878361407
1488,KV401,FCERI mediated Ca+2 mobilization,0.007683029896028849,0,0,1,0.008711458631123364
1489,KV401,FCERI mediated Ca+2 mobilization,0.008326674667600929,1,0,1,0.009441259878361407
1490,KV401,FCERI mediated NF-kB activation,0.007683029896028849,0,0,1,0.008711458631123364
1491,KV401,FCERI mediated NF-kB activation,0.008326674667600929,1,0,1,0.009441259878361407
1492,KV401,Parasite infection,0.007683029896028849,0,0,1,0.008711458631123364
1493,KV401,Parasite infection,0.008326674667600929,1,0,1,0.009441259878361407
1494,KV401,Leishmania parasite growth and survival,0.007683029896028849,0,0,1,0.008711458631123364
1495,KV401,Leishmania parasite growth and survival,0.008326674667600929,1,0,1,0.009441259878361407
1496,KV401,Potential therapeutics for SARS,0.007683029896028849,0,0,1,0.008711458631123364
1497,KV401,Potential therapeutics for SARS,0.008326674667600929,1,0,1,0.009441259878361407
1498,KV401,CD22 mediated BCR regulation,0.007683029896028849,0,0,1,0.008711458631123364
1499,KV401,CD22 mediated BCR regulation,0.008326674667600929,1,0,1,0.009441259878361407
1500,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007683029896028849,0,0,1,0.008711458631123364
1501,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.008326674667600929,1,0,1,0.009441259878361407
1502,KV401,Cell surface interactions at the vascular wall,0.007683029896028849,0,0,1,0.008711458631123364
1503,KV401,Cell surface interactions at the vascular wall,0.008326674667600929,1,0,1,0.009441259878361407
1504,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007683029896028849,0,0,1,0.008711458631123364
1505,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.008326674667600929,1,0,1,0.009441259878361407
1506,KV401,Scavenging of heme from plasma,0.007683029896028849,0,0,1,0.008711458631123364
1507,KV401,Scavenging of heme from plasma,0.008326674667600929,1,0,1,0.009441259878361407
1508,HV434,Initial triggering of complement,0.00790374106378464,0,0,1,0.008961713573945504
1509,HV434,Initial triggering of complement,0.00840621224327997,1,0,1,0.009531444129825263
1510,HV434,Regulation of Complement cascade,0.00790374106378464,0,0,1,0.008961713573945504
1511,HV434,Regulation of Complement cascade,0.00840621224327997,1,0,1,0.009531444129825263
1512,HV434,FCGR activation,0.00790374106378464,0,0,1,0.008961713573945504
1513,HV434,FCGR activation,0.00840621224327997,1,0,1,0.009531444129825263
1514,HV434,Regulation of actin dynamics for phagocytic cup formation,0.00790374106378464,0,0,1,0.008961713573945504
1515,HV434,Regulation of actin dynamics for phagocytic cup formation,0.00840621224327997,1,0,1,0.009531444129825263
1516,HV434,Role of phospholipids in phagocytosis,0.00790374106378464,0,0,1,0.008961713573945504
1517,HV434,Role of phospholipids in phagocytosis,0.00840621224327997,1,0,1,0.009531444129825263
1518,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.00790374106378464,0,0,1,0.008961713573945504
1519,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.00840621224327997,1,0,1,0.009531444129825263
1520,HV434,FCERI mediated MAPK activation,0.00790374106378464,0,0,1,0.008961713573945504
1521,HV434,FCERI mediated MAPK activation,0.00840621224327997,1,0,1,0.009531444129825263
1522,HV434,FCERI mediated Ca+2 mobilization,0.00790374106378464,0,0,1,0.008961713573945504
1523,HV434,FCERI mediated Ca+2 mobilization,0.00840621224327997,1,0,1,0.009531444129825263
1524,HV434,FCERI mediated NF-kB activation,0.00790374106378464,0,0,1,0.008961713573945504
1525,HV434,FCERI mediated NF-kB activation,0.00840621224327997,1,0,1,0.009531444129825263
1526,HV434,Parasite infection,0.00790374106378464,0,0,1,0.008961713573945504
1527,HV434,Parasite infection,0.00840621224327997,1,0,1,0.009531444129825263
1528,HV434,Leishmania parasite growth and survival,0.00790374106378464,0,0,1,0.008961713573945504
1529,HV434,Leishmania parasite growth and survival,0.00840621224327997,1,0,1,0.009531444129825263
1530,HV434,Potential therapeutics for SARS,0.00790374106378464,0,0,1,0.008961713573945504
1531,HV434,Potential therapeutics for SARS,0.00840621224327997,1,0,1,0.009531444129825263
1532,HV434,CD22 mediated BCR regulation,0.00790374106378464,0,0,1,0.008961713573945504
1533,HV434,CD22 mediated BCR regulation,0.00840621224327997,1,0,1,0.009531444129825263
1534,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00790374106378464,0,0,1,0.008961713573945504
1535,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00840621224327997,1,0,1,0.009531444129825263
1536,HV434,Cell surface interactions at the vascular wall,0.00790374106378464,0,0,1,0.008961713573945504
1537,HV434,Cell surface interactions at the vascular wall,0.00840621224327997,1,0,1,0.009531444129825263
1538,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00790374106378464,0,0,1,0.008961713573945504
1539,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00840621224327997,1,0,1,0.009531444129825263
1540,HV434,Scavenging of heme from plasma,0.00790374106378464,0,0,1,0.008961713573945504
1541,HV434,Scavenging of heme from plasma,0.00840621224327997,1,0,1,0.009531444129825263
1542,GELS,Apoptotic cleavage of cellular proteins,0.05479216438309246,0,0,1,0.062126489131551416
1543,GELS,Apoptotic cleavage of cellular proteins,0.03979979743666742,1,0,1,0.045127286186381385
1544,GELS,Neutrophil degranulation,0.05479216438309246,0,0,1,0.062126489131551416
1545,GELS,Neutrophil degranulation,0.03979979743666742,1,0,1,0.045127286186381385
1546,GELS,Amyloid fiber formation,0.05479216438309246,0,0,1,0.062126489131551416
1547,GELS,Amyloid fiber formation,0.03979979743666742,1,0,1,0.045127286186381385
1548,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.05479216438309246,0,0,1,0.062126489131551416
1549,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.03979979743666742,1,0,1,0.045127286186381385
1550,S10A9,Antigen processing-Cross presentation,0.008349150655412602,0,0,1,0.009466744438575888
1551,S10A9,Antigen processing-Cross presentation,0.007045030072845459,1,0,1,0.007988057949160788
1552,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.008349150655412602,0,0,1,0.009466744438575888
1553,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.007045030072845459,1,0,1,0.007988057949160788
1554,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.008349150655412602,0,0,1,0.009466744438575888
1555,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.007045030072845459,1,0,1,0.007988057949160788
1556,S10A9,Regulation of TLR by endogenous ligand,0.008349150655412602,0,0,1,0.009466744438575888
1557,S10A9,Regulation of TLR by endogenous ligand,0.007045030072845459,1,0,1,0.007988057949160788
1558,S10A9,RHO GTPase Effectors,0.008349150655412602,0,0,1,0.009466744438575888
1559,S10A9,RHO GTPase Effectors,0.007045030072845459,1,0,1,0.007988057949160788
1560,S10A9,MyD88 deficiency (TLR2/4),0.008349150655412602,0,0,1,0.009466744438575888
1561,S10A9,MyD88 deficiency (TLR2/4),0.007045030072845459,1,0,1,0.007988057949160788
1562,S10A9,IRAK4 deficiency (TLR2/4),0.008349150655412602,0,0,1,0.009466744438575888
1563,S10A9,IRAK4 deficiency (TLR2/4),0.007045030072845459,1,0,1,0.007988057949160788
1564,S10A9,Metal sequestration by antimicrobial proteins,0.008349150655412602,0,0,1,0.009466744438575888
1565,S10A9,Metal sequestration by antimicrobial proteins,0.007045030072845459,1,0,1,0.007988057949160788
1566,S10A9,Neutrophil degranulation,0.008349150655412602,0,0,1,0.009466744438575888
1567,S10A9,Neutrophil degranulation,0.007045030072845459,1,0,1,0.007988057949160788
1568,APOA4,Chylomicron assembly,0.020963316735431434,0,0,1,0.023769407249897453
1569,APOA4,Chylomicron assembly,0.018234561829731943,1,0,1,0.020675388900735118
1570,APOA4,Assembly of active LPL and LIPC lipase complexes,0.020963316735431434,0,0,1,0.023769407249897453
1571,APOA4,Assembly of active LPL and LIPC lipase complexes,0.018234561829731943,1,0,1,0.020675388900735118
1572,APOA4,Chylomicron remodeling,0.020963316735431434,0,0,1,0.023769407249897453
1573,APOA4,Chylomicron remodeling,0.018234561829731943,1,0,1,0.020675388900735118
1574,APOA4,Retinoid metabolism and transport,0.020963316735431434,0,0,1,0.023769407249897453
1575,APOA4,Retinoid metabolism and transport,0.018234561829731943,1,0,1,0.020675388900735118
1576,APOA4,Amyloid fiber formation,0.020963316735431434,0,0,1,0.023769407249897453
1577,APOA4,Amyloid fiber formation,0.018234561829731943,1,0,1,0.020675388900735118
1578,LDHB,Pyruvate metabolism,0.0003891305489519142,0,0,1,0.00044121846786683344
1579,LDHB,Pyruvate metabolism,0.0004813768793115381,1,0,1,0.0005458126321061477
1580,CO8A,Terminal pathway of complement,0.0002202072331013553,0,0,1,0.00024968355289468896
1581,CO8A,Terminal pathway of complement,0.00011331271635467538,1,0,1,0.00012848043730952883
1582,CO8A,Regulation of Complement cascade,0.0002202072331013553,0,0,1,0.00024968355289468896
1583,CO8A,Regulation of Complement cascade,0.00011331271635467538,1,0,1,0.00012848043730952883
1584,CO8G,Terminal pathway of complement,0.0049975826499936305,0,0,1,0.005666544982929468
1585,CO8G,Terminal pathway of complement,0.005592410752370866,1,0,1,0.006340995099174264
1586,CO8G,Regulation of Complement cascade,0.0049975826499936305,0,0,1,0.005666544982929468
1587,CO8G,Regulation of Complement cascade,0.005592410752370866,1,0,1,0.006340995099174264
1588,TSP1,Transcriptional regulation by RUNX1,0.042466852946006634,0,0,1,0.04815134623182351
1589,TSP1,Transcriptional regulation by RUNX1,0.04544251912074018,1,0,1,0.05152532669682509
1590,TSP1,Diseases associated with O-glycosylation of proteins,0.042466852946006634,0,0,1,0.04815134623182351
1591,TSP1,Diseases associated with O-glycosylation of proteins,0.04544251912074018,1,0,1,0.05152532669682509
1592,TSP1,O-glycosylation of TSR domain-containing proteins,0.042466852946006634,0,0,1,0.04815134623182351
1593,TSP1,O-glycosylation of TSR domain-containing proteins,0.04544251912074018,1,0,1,0.05152532669682509
1594,TSP1,Platelet degranulation ,0.042466852946006634,0,0,1,0.04815134623182351
1595,TSP1,Platelet degranulation ,0.04544251912074018,1,0,1,0.05152532669682509
1596,TSP1,Integrin cell surface interactions,0.042466852946006634,0,0,1,0.04815134623182351
1597,TSP1,Integrin cell surface interactions,0.04544251912074018,1,0,1,0.05152532669682509
1598,TSP1,Syndecan interactions,0.042466852946006634,0,0,1,0.04815134623182351
1599,TSP1,Syndecan interactions,0.04544251912074018,1,0,1,0.05152532669682509
1600,TSP1,Signaling by PDGF,0.042466852946006634,0,0,1,0.04815134623182351
1601,TSP1,Signaling by PDGF,0.04544251912074018,1,0,1,0.05152532669682509
1602,RNAS1,Chaperone Mediated Autophagy,0.01863243378660868,0,0,1,0.021126518876762843
1603,RNAS1,Chaperone Mediated Autophagy,0.018286126097250766,1,0,1,0.020733855415822688
1604,RNAS1,Late endosomal microautophagy,0.01863243378660868,0,0,1,0.021126518876762843
1605,RNAS1,Late endosomal microautophagy,0.018286126097250766,1,0,1,0.020733855415822688
1606,CBG,Metabolism of steroid hormones,7.8810685240762e-05,0,0,1,8.936006151951134e-05
1607,CBG,Metabolism of steroid hormones,0.0001485474515884052,1,0,1,0.0001684315949284617
1608,APOA,LDL remodeling,0.0004450070430492028,0,0,1,0.0005045744320330452
1609,APOA,LDL remodeling,0.00039296585267540354,1,0,1,0.00044556715454085506
1610,CD14,Antigen processing-Cross presentation,0.02179966091500459,0,0,1,0.02471770210496475
1611,CD14,Antigen processing-Cross presentation,0.018099080973468445,1,0,1,0.020521772958766876
1612,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.02179966091500459,0,0,1,0.02471770210496475
1613,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.018099080973468445,1,0,1,0.020521772958766876
1614,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.02179966091500459,0,0,1,0.02471770210496475
1615,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.018099080973468445,1,0,1,0.020521772958766876
1616,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.02179966091500459,0,0,1,0.02471770210496475
1617,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.018099080973468445,1,0,1,0.020521772958766876
1618,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.02179966091500459,0,0,1,0.02471770210496475
1619,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.018099080973468445,1,0,1,0.020521772958766876
1620,CD14,Regulation of TLR by endogenous ligand,0.02179966091500459,0,0,1,0.02471770210496475
1621,CD14,Regulation of TLR by endogenous ligand,0.018099080973468445,1,0,1,0.020521772958766876
1622,CD14,Caspase activation via Death Receptors in the presence of ligand,0.02179966091500459,0,0,1,0.02471770210496475
1623,CD14,Caspase activation via Death Receptors in the presence of ligand,0.018099080973468445,1,0,1,0.020521772958766876
1624,CD14,MyD88 deficiency (TLR2/4),0.02179966091500459,0,0,1,0.02471770210496475
1625,CD14,MyD88 deficiency (TLR2/4),0.018099080973468445,1,0,1,0.020521772958766876
1626,CD14,IRAK4 deficiency (TLR2/4),0.02179966091500459,0,0,1,0.02471770210496475
1627,CD14,IRAK4 deficiency (TLR2/4),0.018099080973468445,1,0,1,0.020521772958766876
1628,CD14,Neutrophil degranulation,0.02179966091500459,0,0,1,0.02471770210496475
1629,CD14,Neutrophil degranulation,0.018099080973468445,1,0,1,0.020521772958766876
1630,CFAH,Regulation of Complement cascade,0.002362039371882532,0,0,1,0.0026782153072025514
1631,CFAH,Regulation of Complement cascade,0.0021342650701718564,1,0,1,0.002419951779214568
1632,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.0010549757531570357,0,0,1,0.0011961918351008876
1633,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.0009044159256505893,1,0,1,0.0010254784932838255
1634,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.0010549757531570357,0,0,1,0.0011961918351008876
1635,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.0009044159256505893,1,0,1,0.0010254784932838255
1636,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.0010549757531570357,0,0,1,0.0011961918351008876
1637,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.0009044159256505893,1,0,1,0.0010254784932838255
1638,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.0010549757531570357,0,0,1,0.0011961918351008876
1639,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.0009044159256505893,1,0,1,0.0010254784932838255
1640,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.0010549757531570357,0,0,1,0.0011961918351008876
1641,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.0009044159256505893,1,0,1,0.0010254784932838255
1642,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0010549757531570357,0,0,1,0.0011961918351008876
1643,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0009044159256505893,1,0,1,0.0010254784932838255
1644,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.0010549757531570357,0,0,1,0.0011961918351008876
1645,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.0009044159256505893,1,0,1,0.0010254784932838255
1646,SAA1,TRAF6 mediated NF-kB activation,0.0010549757531570357,0,0,1,0.0011961918351008876
1647,SAA1,TRAF6 mediated NF-kB activation,0.0009044159256505893,1,0,1,0.0010254784932838255
1648,SAA1,Class A/1 (Rhodopsin-like receptors),0.0010549757531570357,0,0,1,0.0011961918351008876
1649,SAA1,Class A/1 (Rhodopsin-like receptors),0.0009044159256505893,1,0,1,0.0010254784932838255
1650,SAA1,G alpha (q) signalling events,0.0010549757531570357,0,0,1,0.0011961918351008876
1651,SAA1,G alpha (q) signalling events,0.0009044159256505893,1,0,1,0.0010254784932838255
1652,SAA1,G alpha (i) signalling events,0.0010549757531570357,0,0,1,0.0011961918351008876
1653,SAA1,G alpha (i) signalling events,0.0009044159256505893,1,0,1,0.0010254784932838255
1654,SAA1,Interleukin-1 family signaling,0.0010549757531570357,0,0,1,0.0011961918351008876
1655,SAA1,Interleukin-1 family signaling,0.0009044159256505893,1,0,1,0.0010254784932838255
1656,SAA1,Interleukin-4 and Interleukin-13 signaling,0.0010549757531570357,0,0,1,0.0011961918351008876
1657,SAA1,Interleukin-4 and Interleukin-13 signaling,0.0009044159256505893,1,0,1,0.0010254784932838255
1658,SAA1,Advanced glycosylation endproduct receptor signaling,0.0010549757531570357,0,0,1,0.0011961918351008876
1659,SAA1,Advanced glycosylation endproduct receptor signaling,0.0009044159256505893,1,0,1,0.0010254784932838255
1660,SAA1,Scavenging by Class B Receptors,0.0010549757531570357,0,0,1,0.0011961918351008876
1661,SAA1,Scavenging by Class B Receptors,0.0009044159256505893,1,0,1,0.0010254784932838255
1662,SAA1,Amyloid fiber formation,0.0010549757531570357,0,0,1,0.0011961918351008876
1663,SAA1,Amyloid fiber formation,0.0009044159256505893,1,0,1,0.0010254784932838255
1664,CO7,Terminal pathway of complement,0.0034075526234269285,0,0,1,0.003863678016885347
1665,CO7,Terminal pathway of complement,0.0039108936338871515,1,0,1,0.0044343948368522285
1666,CO7,Regulation of Complement cascade,0.0034075526234269285,0,0,1,0.003863678016885347
1667,CO7,Regulation of Complement cascade,0.0039108936338871515,1,0,1,0.0044343948368522285
1668,MBL2,Initial triggering of complement,0.0006934713983143504,0,0,1,0.0007862975258504776
1669,MBL2,Initial triggering of complement,0.0011222059583477694,1,0,1,0.001272421286138652
1670,MBL2,SARS-CoV-2 Infection,0.0006934713983143504,0,0,1,0.0007862975258504776
1671,MBL2,SARS-CoV-2 Infection,0.0011222059583477694,1,0,1,0.001272421286138652
1672,CO6,Terminal pathway of complement,0.0018931249531102881,0,0,1,0.0021465333254907467
1673,CO6,Terminal pathway of complement,0.0020895763808815773,1,0,1,0.002369281187885408
1674,CO6,Regulation of Complement cascade,0.0018931249531102881,0,0,1,0.0021465333254907467
1675,CO6,Regulation of Complement cascade,0.0020895763808815773,1,0,1,0.002369281187885408
1676,CBPN,Regulation of Complement cascade,0.0006019119115068315,0,0,1,0.0006824821441059846
1677,CBPN,Regulation of Complement cascade,0.000543623576083109,1,0,1,0.0006163914963286986
1678,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.009948738778977841,0,0,1,0.011280448921553018
1679,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.008760661698076164,1,0,1,0.009933339189986004
1680,LBP,Regulation of TLR by endogenous ligand,0.009948738778977841,0,0,1,0.011280448921553018
1681,LBP,Regulation of TLR by endogenous ligand,0.008760661698076164,1,0,1,0.009933339189986004
1682,LBP,Interleukin-4 and Interleukin-13 signaling,0.009948738778977841,0,0,1,0.011280448921553018
1683,LBP,Interleukin-4 and Interleukin-13 signaling,0.008760661698076164,1,0,1,0.009933339189986004
1684,A1AG2,Platelet degranulation ,0.002971541865589652,0,0,1,0.003369304087455837
1685,A1AG2,Platelet degranulation ,0.0028535763200651975,1,0,1,0.003235548006373118
1686,A1AG2,Neutrophil degranulation,0.002971541865589652,0,0,1,0.003369304087455837
1687,A1AG2,Neutrophil degranulation,0.0028535763200651975,1,0,1,0.003235548006373118
1688,CPN2,Regulation of Complement cascade,0.00160936152200263,0,0,1,0.001824786120992988
1689,CPN2,Regulation of Complement cascade,0.0014529807693032515,1,0,1,0.0016474726813370123
1690,HV102,Initial triggering of complement,0.01114848856047344,0,0,1,0.012640793828527848
1691,HV102,Initial triggering of complement,0.011696750936981044,1,0,1,0.013262445062036134
1692,HV102,Regulation of Complement cascade,0.01114848856047344,0,0,1,0.012640793828527848
1693,HV102,Regulation of Complement cascade,0.011696750936981044,1,0,1,0.013262445062036134
1694,HV102,FCGR activation,0.01114848856047344,0,0,1,0.012640793828527848
1695,HV102,FCGR activation,0.011696750936981044,1,0,1,0.013262445062036134
1696,HV102,Regulation of actin dynamics for phagocytic cup formation,0.01114848856047344,0,0,1,0.012640793828527848
1697,HV102,Regulation of actin dynamics for phagocytic cup formation,0.011696750936981044,1,0,1,0.013262445062036134
1698,HV102,Role of phospholipids in phagocytosis,0.01114848856047344,0,0,1,0.012640793828527848
1699,HV102,Role of phospholipids in phagocytosis,0.011696750936981044,1,0,1,0.013262445062036134
1700,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.01114848856047344,0,0,1,0.012640793828527848
1701,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.011696750936981044,1,0,1,0.013262445062036134
1702,HV102,FCERI mediated MAPK activation,0.01114848856047344,0,0,1,0.012640793828527848
1703,HV102,FCERI mediated MAPK activation,0.011696750936981044,1,0,1,0.013262445062036134
1704,HV102,FCERI mediated Ca+2 mobilization,0.01114848856047344,0,0,1,0.012640793828527848
1705,HV102,FCERI mediated Ca+2 mobilization,0.011696750936981044,1,0,1,0.013262445062036134
1706,HV102,FCERI mediated NF-kB activation,0.01114848856047344,0,0,1,0.012640793828527848
1707,HV102,FCERI mediated NF-kB activation,0.011696750936981044,1,0,1,0.013262445062036134
1708,HV102,Parasite infection,0.01114848856047344,0,0,1,0.012640793828527848
1709,HV102,Parasite infection,0.011696750936981044,1,0,1,0.013262445062036134
1710,HV102,Leishmania parasite growth and survival,0.01114848856047344,0,0,1,0.012640793828527848
1711,HV102,Leishmania parasite growth and survival,0.011696750936981044,1,0,1,0.013262445062036134
1712,HV102,Potential therapeutics for SARS,0.01114848856047344,0,0,1,0.012640793828527848
1713,HV102,Potential therapeutics for SARS,0.011696750936981044,1,0,1,0.013262445062036134
1714,HV102,CD22 mediated BCR regulation,0.01114848856047344,0,0,1,0.012640793828527848
1715,HV102,CD22 mediated BCR regulation,0.011696750936981044,1,0,1,0.013262445062036134
1716,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01114848856047344,0,0,1,0.012640793828527848
1717,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.011696750936981044,1,0,1,0.013262445062036134
1718,HV102,Cell surface interactions at the vascular wall,0.01114848856047344,0,0,1,0.012640793828527848
1719,HV102,Cell surface interactions at the vascular wall,0.011696750936981044,1,0,1,0.013262445062036134
1720,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01114848856047344,0,0,1,0.012640793828527848
1721,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.011696750936981044,1,0,1,0.013262445062036134
1722,HV102,Scavenging of heme from plasma,0.01114848856047344,0,0,1,0.012640793828527848
1723,HV102,Scavenging of heme from plasma,0.011696750936981044,1,0,1,0.013262445062036134
1724,FBLN1,Molecules associated with elastic fibres,0.00041667306018670886,0,0,1,0.00047244774205502574
1725,FBLN1,Molecules associated with elastic fibres,0.00043097413333939946,1,0,1,0.000488663116566939
1726,ZA2G,Miscellaneous transport and binding events,0.020696005181221867,0,0,1,0.02346631412418652
1727,ZA2G,Miscellaneous transport and binding events,0.02770717875788658,1,0,1,0.031415983641977833
1728,PON1,Arachidonic acid metabolism,0.004259542651080165,0,0,1,0.004829713029174847
1729,PON1,Arachidonic acid metabolism,0.006416636189833417,1,0,1,0.007275549031456347
1730,PON1,Atorvastatin ADME,0.004259542651080165,0,0,1,0.004829713029174847
1731,PON1,Atorvastatin ADME,0.006416636189833417,1,0,1,0.007275549031456347
1732,PROP,Initial triggering of complement,0.005640140675176735,0,0,1,0.006395114014968792
1733,PROP,Initial triggering of complement,0.007101050805698862,1,0,1,0.008051577459476617
1734,PROP,Activation of C3 and C5,0.005640140675176735,0,0,1,0.006395114014968792
1735,PROP,Activation of C3 and C5,0.007101050805698862,1,0,1,0.008051577459476617
1736,PROP,Regulation of Complement cascade,0.005640140675176735,0,0,1,0.006395114014968792
1737,PROP,Regulation of Complement cascade,0.007101050805698862,1,0,1,0.008051577459476617
1738,PROP,Diseases associated with O-glycosylation of proteins,0.005640140675176735,0,0,1,0.006395114014968792
1739,PROP,Diseases associated with O-glycosylation of proteins,0.007101050805698862,1,0,1,0.008051577459476617
1740,PROP,O-glycosylation of TSR domain-containing proteins,0.005640140675176735,0,0,1,0.006395114014968792
1741,PROP,O-glycosylation of TSR domain-containing proteins,0.007101050805698862,1,0,1,0.008051577459476617
1742,PROP,Neutrophil degranulation,0.005640140675176735,0,0,1,0.006395114014968792
1743,PROP,Neutrophil degranulation,0.007101050805698862,1,0,1,0.008051577459476617
1744,KAIN,Platelet degranulation ,0.001324917050415865,0,0,1,0.0015022667138564075
1745,KAIN,Platelet degranulation ,0.0012072897488730752,1,0,1,0.0013688941531417435
1746,BLVRB,Cytoprotection by HMOX1,0.0003906513528470147,0,0,1,0.00044294284228649656
1747,BLVRB,Cytoprotection by HMOX1,0.00023438953077957765,1,0,1,0.00026576425298176914
1748,BLVRB,Heme degradation,0.0003906513528470147,0,0,1,0.00044294284228649656
1749,BLVRB,Heme degradation,0.00023438953077957765,1,0,1,0.00026576425298176914
1750,PRDX2,Transcriptional Regulation by TP53,0.0038510762545479436,0,0,1,0.004366570471648981
1751,PRDX2,Transcriptional Regulation by TP53,0.0034689403744346666,1,0,1,0.003933282959284181
1752,PRDX2,Neurodegenerative Diseases,0.0038510762545479436,0,0,1,0.004366570471648981
1753,PRDX2,Neurodegenerative Diseases,0.0034689403744346666,1,0,1,0.003933282959284181
1754,PRDX2,Detoxification of Reactive Oxygen Species,0.0038510762545479436,0,0,1,0.004366570471648981
1755,PRDX2,Detoxification of Reactive Oxygen Species,0.0034689403744346666,1,0,1,0.003933282959284181
1756,MASP1,Initial triggering of complement,0.010681426290184086,0,0,1,0.01211121191867646
1757,MASP1,Initial triggering of complement,0.011498591990726614,1,0,1,0.01303776111754508
1758,MASP1,SARS-CoV-2 Infection,0.010681426290184086,0,0,1,0.01211121191867646
1759,MASP1,SARS-CoV-2 Infection,0.011498591990726614,1,0,1,0.01303776111754508
1760,MASP1,Scavenging by Class A Receptors,0.010681426290184086,0,0,1,0.01211121191867646
1761,MASP1,Scavenging by Class A Receptors,0.011498591990726614,1,0,1,0.01303776111754508
1762,LUM,Keratan sulfate/keratin metabolism,0.0028878536350673027,0,0,1,0.0032744135861857344
1763,LUM,Keratan sulfate/keratin metabolism,0.004660839415759139,1,0,1,0.005284726248127886
1764,LUM,Diseases associated with glycosaminoglycan metabolism,0.0028878536350673027,0,0,1,0.0032744135861857344
1765,LUM,Diseases associated with glycosaminoglycan metabolism,0.004660839415759139,1,0,1,0.005284726248127886
1766,LUM,Integrin cell surface interactions,0.0028878536350673027,0,0,1,0.0032744135861857344
1767,LUM,Integrin cell surface interactions,0.004660839415759139,1,0,1,0.005284726248127886
1768,LUM,ECM proteoglycans,0.0028878536350673027,0,0,1,0.0032744135861857344
1769,LUM,ECM proteoglycans,0.004660839415759139,1,0,1,0.005284726248127886
1770,APOC4,VLDL assembly,0.001622243656628382,0,0,1,0.0018393926218645785
1771,APOC4,VLDL assembly,0.002397052864407047,1,0,1,0.002717915607186561
1772,APOC4,VLDL clearance,0.001622243656628382,0,0,1,0.0018393926218645785
1773,APOC4,VLDL clearance,0.002397052864407047,1,0,1,0.002717915607186561
1774,APOC4,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.001622243656628382,0,0,1,0.0018393926218645785
1775,APOC4,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.002397052864407047,1,0,1,0.002717915607186561
1776,TYB4,Platelet degranulation ,0.0008193187101070873,0,0,1,0.0009289904042274269
1777,TYB4,Platelet degranulation ,0.0007507455978420389,1,0,1,0.0008512382883579947
1778,HBB,Cytoprotection by HMOX1,0.007841647615763713,0,0,1,0.008891308471919582
1779,HBB,Cytoprotection by HMOX1,0.010321673045778837,1,0,1,0.011703303118572922
1780,HBB,Factors involved in megakaryocyte development and platelet production,0.007841647615763713,0,0,1,0.008891308471919582
1781,HBB,Factors involved in megakaryocyte development and platelet production,0.010321673045778837,1,0,1,0.011703303118572922
1782,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.007841647615763713,0,0,1,0.008891308471919582
1783,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.010321673045778837,1,0,1,0.011703303118572922
1784,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.007841647615763713,0,0,1,0.008891308471919582
1785,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.010321673045778837,1,0,1,0.011703303118572922
1786,HBB,Neutrophil degranulation,0.007841647615763713,0,0,1,0.008891308471919582
1787,HBB,Neutrophil degranulation,0.010321673045778837,1,0,1,0.011703303118572922
1788,HBB,Scavenging of heme from plasma,0.007841647615763713,0,0,1,0.008891308471919582
1789,HBB,Scavenging of heme from plasma,0.010321673045778837,1,0,1,0.011703303118572922
1790,HBB,Heme signaling,0.007841647615763713,0,0,1,0.008891308471919582
1791,HBB,Heme signaling,0.010321673045778837,1,0,1,0.011703303118572922
1792,HBB,Chaperone Mediated Autophagy,0.007841647615763713,0,0,1,0.008891308471919582
1793,HBB,Chaperone Mediated Autophagy,0.010321673045778837,1,0,1,0.011703303118572922
1794,HBB,Late endosomal microautophagy,0.007841647615763713,0,0,1,0.008891308471919582
1795,HBB,Late endosomal microautophagy,0.010321673045778837,1,0,1,0.011703303118572922
1796,HBA,Cytoprotection by HMOX1,0.012661829482837788,0,0,1,0.014356706302951152
1797,HBA,Cytoprotection by HMOX1,0.006133594046319053,1,0,1,0.006954619664076907
1798,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.012661829482837788,0,0,1,0.014356706302951152
1799,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.006133594046319053,1,0,1,0.006954619664076907
1800,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.012661829482837788,0,0,1,0.014356706302951152
1801,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.006133594046319053,1,0,1,0.006954619664076907
1802,HBA,Scavenging of heme from plasma,0.012661829482837788,0,0,1,0.014356706302951152
1803,HBA,Scavenging of heme from plasma,0.006133594046319053,1,0,1,0.006954619664076907
1804,HBA,Heme signaling,0.012661829482837788,0,0,1,0.014356706302951152
1805,HBA,Heme signaling,0.006133594046319053,1,0,1,0.006954619664076907
1806,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.00027801946355110804,0,0,1,0.00031523436562760616
1807,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.0014949122117129728,1,0,1,0.0016950169484866722
1808,LV321,Initial triggering of complement,0.0031682077437143966,0,0,1,0.003592295105924058
1809,LV321,Initial triggering of complement,0.0030594873044354474,1,0,1,0.0034690216549609597
1810,LV321,Regulation of Complement cascade,0.0031682077437143966,0,0,1,0.003592295105924058
1811,LV321,Regulation of Complement cascade,0.0030594873044354474,1,0,1,0.0034690216549609597
1812,LV321,FCGR activation,0.0031682077437143966,0,0,1,0.003592295105924058
1813,LV321,FCGR activation,0.0030594873044354474,1,0,1,0.0034690216549609597
1814,LV321,Regulation of actin dynamics for phagocytic cup formation,0.0031682077437143966,0,0,1,0.003592295105924058
1815,LV321,Regulation of actin dynamics for phagocytic cup formation,0.0030594873044354474,1,0,1,0.0034690216549609597
1816,LV321,Role of phospholipids in phagocytosis,0.0031682077437143966,0,0,1,0.003592295105924058
1817,LV321,Role of phospholipids in phagocytosis,0.0030594873044354474,1,0,1,0.0034690216549609597
1818,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.0031682077437143966,0,0,1,0.003592295105924058
1819,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.0030594873044354474,1,0,1,0.0034690216549609597
1820,LV321,FCERI mediated MAPK activation,0.0031682077437143966,0,0,1,0.003592295105924058
1821,LV321,FCERI mediated MAPK activation,0.0030594873044354474,1,0,1,0.0034690216549609597
1822,LV321,FCERI mediated Ca+2 mobilization,0.0031682077437143966,0,0,1,0.003592295105924058
1823,LV321,FCERI mediated Ca+2 mobilization,0.0030594873044354474,1,0,1,0.0034690216549609597
1824,LV321,FCERI mediated NF-kB activation,0.0031682077437143966,0,0,1,0.003592295105924058
1825,LV321,FCERI mediated NF-kB activation,0.0030594873044354474,1,0,1,0.0034690216549609597
1826,LV321,Parasite infection,0.0031682077437143966,0,0,1,0.003592295105924058
1827,LV321,Parasite infection,0.0030594873044354474,1,0,1,0.0034690216549609597
1828,LV321,Leishmania parasite growth and survival,0.0031682077437143966,0,0,1,0.003592295105924058
1829,LV321,Leishmania parasite growth and survival,0.0030594873044354474,1,0,1,0.0034690216549609597
1830,LV321,Potential therapeutics for SARS,0.0031682077437143966,0,0,1,0.003592295105924058
1831,LV321,Potential therapeutics for SARS,0.0030594873044354474,1,0,1,0.0034690216549609597
1832,LV321,CD22 mediated BCR regulation,0.0031682077437143966,0,0,1,0.003592295105924058
1833,LV321,CD22 mediated BCR regulation,0.0030594873044354474,1,0,1,0.0034690216549609597
1834,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0031682077437143966,0,0,1,0.003592295105924058
1835,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0030594873044354474,1,0,1,0.0034690216549609597
1836,LV321,Cell surface interactions at the vascular wall,0.0031682077437143966,0,0,1,0.003592295105924058
1837,LV321,Cell surface interactions at the vascular wall,0.0030594873044354474,1,0,1,0.0034690216549609597
1838,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0031682077437143966,0,0,1,0.003592295105924058
1839,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0030594873044354474,1,0,1,0.0034690216549609597
1840,LV321,Scavenging of heme from plasma,0.0031682077437143966,0,0,1,0.003592295105924058
1841,LV321,Scavenging of heme from plasma,0.0030594873044354474,1,0,1,0.0034690216549609597
1842,FHR1,Regulation of Complement cascade,0.00033187028852933763,0,0,1,0.00037629351031376535
1843,FHR1,Regulation of Complement cascade,0.00029971827532147084,1,0,1,0.0003398377192055679
1844,LG3BP,Platelet degranulation ,0.0013231238792685087,0,0,1,0.001500233513871491
1845,LG3BP,Platelet degranulation ,0.0012064482301266809,1,0,1,0.0013679399910669196
1846,APOF,LDL remodeling,0.00042150311959938063,0,0,1,0.00047792433961207903
1847,APOF,LDL remodeling,0.0003727080730269644,1,0,1,0.00042259772558457764
1848,ITIH4,Platelet degranulation ,0.0007772491150533525,0,0,1,0.0008812894917100683
1849,ITIH4,Platelet degranulation ,0.0007106127873614408,1,0,1,0.0008057334129398798
1850,PCOC1,Crosslinking of collagen fibrils,0.00025061038277099916,0,0,1,0.0002841563825188261
1851,PCOC1,Crosslinking of collagen fibrils,0.0004298702384519941,1,0,1,0.000487411457420108
1852,PCOC1,Collagen biosynthesis and modifying enzymes,0.00025061038277099916,0,0,1,0.0002841563825188261
1853,PCOC1,Collagen biosynthesis and modifying enzymes,0.0004298702384519941,1,0,1,0.000487411457420108
1854,PON3,Arachidonic acid metabolism,0.0033414722349104273,0,0,1,0.003788752293742241
1855,PON3,Arachidonic acid metabolism,0.004579173141647824,1,0,1,0.005192128356657176
1856,PON3,Atorvastatin ADME,0.0033414722349104273,0,0,1,0.003788752293742241
1857,PON3,Atorvastatin ADME,0.004579173141647824,1,0,1,0.005192128356657176
1858,FCN2,Initial triggering of complement,0.0018412749994047301,0,0,1,0.0020877428830684028
1859,FCN2,Initial triggering of complement,0.0016557895532691258,1,0,1,0.0018774288777147381
1860,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.012439991381721574,0,0,1,0.014105173578644074
1861,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.016905666334050256,1,0,1,0.0191686111981388
1862,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.012439991381721574,0,0,1,0.014105173578644074
1863,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.016905666334050256,1,0,1,0.0191686111981388
1864,FHR5,Regulation of Complement cascade,0.0005236532149185721,0,0,1,0.0005937479588847826
1865,FHR5,Regulation of Complement cascade,0.00047223892140638596,1,0,1,0.0005354514929018313
1866,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.017189000425255334,0,1,2,0.3254130433284373
1867,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.005264736139808779,1,1,2,0.09966919350698282
1868,Nuclear signaling by ERBB4,Signaling by ERBB4,0.000683536497610894,0,1,2,0.012940350596932283
1869,Nuclear signaling by ERBB4,Signaling by ERBB4,0.0056781655490880335,1,1,2,0.10749601990448358
1870,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.002852900691120771,0,1,2,0.05400960342332539
1871,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.0026983043704442403,1,1,2,0.05108286783928217
1872,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.00573278421919765,0,1,2,0.10853003161099375
1873,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.006447731179643459,1,1,2,0.12206502843810742
1874,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.0013541862570079781,0,1,2,0.02563673629788543
1875,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.002650284744306543,1,1,2,0.05017378573477523
1876,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.0003307346951232086,0,1,2,0.006261293909575749
1877,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.00045389520531504085,1,1,2,0.008592903395169896
1878,Initial triggering of complement,Complement cascade,0.0048955574835904975,0,1,2,0.0926800989069628
1879,Initial triggering of complement,Complement cascade,0.004372763936035594,1,1,2,0.08278284862285944
1880,Terminal pathway of complement,Complement cascade,0.003980845853141239,0,1,2,0.07536326325228054
1881,Terminal pathway of complement,Complement cascade,0.0035312785288190355,1,1,2,0.0668522930056475
1882,Activation of C3 and C5,Complement cascade,0.0015766020143189517,0,1,2,0.029847393501920488
1883,Activation of C3 and C5,Complement cascade,0.0014013964660689068,1,1,2,0.026530494947406225
1884,Regulation of Complement cascade,Complement cascade,0.004529997589277682,0,1,2,0.08575951278885593
1885,Regulation of Complement cascade,Complement cascade,0.0040308379426189705,1,1,2,0.07630968698704257
1886,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.0006241019263791275,0,1,2,0.011815166803520245
1887,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.0008584035324067737,1,1,2,0.016250840594194686
1888,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,0.0005574778037784572,0,1,2,0.010553874235121871
1889,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,0.0007757448914373018,1,1,2,0.014685991024713746
1890,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.00047425772171570663,0,1,2,0.008978395760510122
1891,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.0006600322585390021,1,1,2,0.01249538080355991
1892,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.0008586018634963656,0,1,2,0.01625459529323791
1893,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.0011948397484204624,1,1,2,0.02262007267461635
1894,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.001584143491387027,0,1,2,0.029990164747670665
1895,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.0021758268221202743,1,1,2,0.041191599885092404
1896,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.001842760486029276,0,1,2,0.034886164584830376
1897,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.0025256254587831387,1,1,2,0.047813802229177235
1898,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.0013235482573676388,0,1,2,0.02505671393138355
1899,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.001823231507715047,1,1,2,0.03451645232064361
1900,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.0017629173838744983,0,1,2,0.033374617303535595
1901,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.0007151113362788357,1,1,2,0.01353810870324094
1902,RHO GTPase Effectors,Signaling by Rho GTPases,0.0036248133441070924,0,1,2,0.06862304454134058
1903,RHO GTPase Effectors,Signaling by Rho GTPases,0.003102557382572149,1,1,2,0.05873597155076668
1904,Metabolism of steroid hormones,Metabolism of steroids,0.00013801556747078029,0,1,2,0.0026128375546131117
1905,Metabolism of steroid hormones,Metabolism of steroids,0.000746366844395445,1,1,2,0.01412982141284438
1906,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,0.0001310044010793397,0,1,2,0.0024801058694495838
1907,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,3.6653850862703146e-05,1,1,2,0.0006939112725492714
1908,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0008947227970594978,0,1,2,0.016938417657997005
1909,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0009288979834741672,1,1,2,0.017585404169276297
1910,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.005108067780571851,0,1,2,0.09670323118740225
1911,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.005304651384493593,1,1,2,0.10042484775834931
1912,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.0005874069913781244,0,1,2,0.011120477747845373
1913,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.0006090768023299927,1,1,2,0.011530719120568743
1914,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.0033059122503140003,0,1,2,0.0625857780985808
1915,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.0030855158234782396,1,1,2,0.05841334978855749
1916,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.005828373881761365,0,1,2,0.11033968442593542
1917,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.005378079182439378,1,1,2,0.10181494390142323
1918,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.013952154651908827,0,1,2,0.2641347951563171
1919,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.012696783615596825,1,1,2,0.24036877622990857
1920,FOXO-mediated transcription,Generic Transcription Pathway,0.0003460601258850446,0,1,2,0.006551426840004961
1921,FOXO-mediated transcription,Generic Transcription Pathway,0.0003233008331373833,1,1,2,0.0061205599755107575
1922,Arachidonic acid metabolism,Fatty acid metabolism,0.001640298547218872,0,1,2,0.0310532624941615
1923,Arachidonic acid metabolism,Fatty acid metabolism,0.002117135895662771,1,1,2,0.04008049438030457
1924,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.00029765001633885426,0,1,2,0.005634952310622615
1925,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.0005104812333003794,1,1,2,0.009664160077991438
1926,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.0010865514687788491,0,1,2,0.020570016373308492
1927,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.0018525377085115257,1,1,2,0.03507126177748466
1928,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.0011065332518085825,0,1,2,0.020948300896315445
1929,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.001898015907150439,1,1,2,0.03593223092391856
1930,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.0003474284880215156,0,1,2,0.00657733194653752
1931,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.0006001722962324835,1,1,2,0.011362143731841096
1932,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.0019714089454068193,0,1,2,0.03732166901498047
1933,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.002211588121436263,1,1,2,0.04186861384494412
1934,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.003329394391496384,0,1,2,0.06303032954642417
1935,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.009806966317504905,1,1,2,0.18566028717468855
1936,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.00625383831408648,0,1,2,0.1183943514993912
1937,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.007086978541761522,1,1,2,0.13416692060170743
1938,G alpha (q) signalling events,GPCR downstream signalling,0.0012722324249643743,0,1,2,0.02408522979733564
1939,G alpha (q) signalling events,GPCR downstream signalling,0.0033192592020044893,1,1,2,0.06283845551211895
1940,G alpha (i) signalling events,GPCR downstream signalling,0.003538188704372987,0,1,2,0.06698311278581581
1941,G alpha (i) signalling events,GPCR downstream signalling,0.009393996819085095,1,1,2,0.17784216756575774
1942,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.007529642797181375,0,1,2,0.14254720560753267
1943,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.006698263972698621,1,1,2,0.12680798245664762
1944,Adherens junctions interactions,Cell-cell junction organization,0.00027624716430416486,0,1,2,0.005229764862591409
1945,Adherens junctions interactions,Cell-cell junction organization,0.0006157295117563103,1,1,2,0.011656664688503978
1946,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.0022597653364675955,0,1,2,0.042780679338839854
1947,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.0039603483316066855,1,1,2,0.07497521504131832
1948,Interleukin-1 family signaling,Signaling by Interleukins,0.0016497188348343357,0,1,2,0.031231602385146273
1949,Interleukin-1 family signaling,Signaling by Interleukins,0.0013498578840221952,1,1,2,0.025554793835198958
1950,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.008209523111970807,0,1,2,0.15541833928960883
1951,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.006714698285172367,1,1,2,0.12711910814777477
1952,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.0016049951883172348,0,1,2,0.030384918019457866
1953,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.002992831884623475,1,1,2,0.056658706594408643
1954,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.007627992882990882,0,1,2,0.14440911729192948
1955,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.002796456223589487,1,1,2,0.05294102668797195
1956,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.008387919038054735,0,1,2,0.1587956363859002
1957,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.005832447461679714,1,1,2,0.11041680328134738
1958,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0025092440077969513,0,1,2,0.04750367728370812
1959,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.001740338632452403,1,1,2,0.032947168351703304
1960,Defective ABCA1 causes TGD,ABC transporter disorders,0.002481315805996682,0,1,2,0.046974955373319235
1961,Defective ABCA1 causes TGD,ABC transporter disorders,0.003772271867633519,1,1,2,0.07141465113383036
1962,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.002383188159602989,0,1,2,0.04511725479401669
1963,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.0043323099394769315,1,1,2,0.08201699500663573
1964,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.0021123991247367748,0,1,2,0.03999082034432552
1965,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.0038408996947734936,1,1,2,0.07271387677430592
1966,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.0013420305564873166,0,1,2,0.025406611019954454
1967,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.004611463285281291,1,1,2,0.08730177815668112
1968,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0008251684493292397,0,1,2,0.015621651620899681
1969,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0006103353305361978,1,1,2,0.011554544909361801
1970,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.00036068997959655543,0,1,2,0.006828391474476535
1971,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.00026485976344683406,1,1,2,0.00501418462657371
1972,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,8.84094726599548e-05,0,1,2,0.0016737212662504663
1973,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,6.520289475324441e-05,1,1,2,0.001234386636252694
1974,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.00018903691978101428,0,1,2,0.0035787467476579428
1975,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.00013809543283118523,1,1,2,0.0026143495232757987
1976,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.00018350969787214792,0,1,2,0.0034741083127275943
1977,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.000134742799430475,1,1,2,0.002550879245127063
1978,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.0011547751856062884,0,1,2,0.021861591611585598
1979,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.0008505252248965358,1,1,2,0.016101692653083633
1980,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.004890158844039313,0,1,2,0.09257789472506034
1981,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.003942454658726008,1,1,2,0.07463646151264487
1982,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.000164054198446404,0,1,2,0.003105787111902913
1983,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,1.4337602817588627e-05,1,1,2,0.00027143189548420684
1984,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.00840638651880661,0,1,2,0.1591452529409878
1985,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.008926583104533906,1,1,2,0.16899333892054624
1986,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.0076300352796244714,0,1,2,0.14444778286222312
1987,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.004227706216941341,1,1,2,0.08003669278709674
1988,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.0020222464500786806,0,1,2,0.038284097702002175
1989,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.0012601416452880678,1,1,2,0.023856333566412306
1990,VLDL assembly,Plasma lipoprotein assembly,0.0007378984225228166,0,1,2,0.013969501739472787
1991,VLDL assembly,Plasma lipoprotein assembly,0.0005398805510664394,1,1,2,0.010220732375934776
1992,Chylomicron assembly,Plasma lipoprotein assembly,0.002530035406547,0,1,2,0.047897289022315534
1993,Chylomicron assembly,Plasma lipoprotein assembly,0.0018608386717883871,1,1,2,0.035228411213499115
1994,HDL assembly,Plasma lipoprotein assembly,0.001009562906482162,0,1,2,0.019112509727277103
1995,HDL assembly,Plasma lipoprotein assembly,0.0007381435471485732,1,1,2,0.01397414230893516
1996,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.004184408655821702,0,1,2,0.07921700631411607
1997,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.003832767920430395,1,1,2,0.0725599303334902
1998,Chylomicron remodeling,Plasma lipoprotein remodeling,0.001138585137936305,0,1,2,0.021555090212226687
1999,Chylomicron remodeling,Plasma lipoprotein remodeling,0.001035027059814194,1,1,2,0.01959458357837688
2000,LDL remodeling,Plasma lipoprotein remodeling,0.003543014507904657,0,1,2,0.06707447233988498
2001,LDL remodeling,Plasma lipoprotein remodeling,0.0032294662381181847,1,1,2,0.06113854272342701
2002,HDL remodeling,Plasma lipoprotein remodeling,0.004077251704821684,0,1,2,0.07718836772687873
2003,HDL remodeling,Plasma lipoprotein remodeling,0.003681542239674885,1,1,2,0.0696970059174921
2004,HDL clearance,Plasma lipoprotein clearance,0.0013233824363380157,0,1,2,0.025053574695560493
2005,HDL clearance,Plasma lipoprotein clearance,0.0014068627162055005,1,1,2,0.026633979097068
2006,Chylomicron clearance,Plasma lipoprotein clearance,0.0006395335465632585,0,1,2,0.012107310055796185
2007,Chylomicron clearance,Plasma lipoprotein clearance,0.0006812216711905038,1,1,2,0.012896527530343168
2008,LDL clearance,Plasma lipoprotein clearance,0.0007747281206764116,0,1,2,0.014666742059708048
2009,LDL clearance,Plasma lipoprotein clearance,0.0008263706389449314,1,1,2,0.015644410837364953
2010,VLDL clearance,Plasma lipoprotein clearance,0.0002713538825561294,0,1,2,0.005137127846703497
2011,VLDL clearance,Plasma lipoprotein clearance,0.0002895549863027689,1,1,2,0.005481701493547339
2012,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.001663671782761461,0,1,2,0.031495752198168435
2013,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.0033434564750309268,1,1,2,0.06329654545690788
2014,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.003040462331782599,0,1,2,0.05756042096881589
2015,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0029451485954236946,1,1,2,0.05575599184250183
2016,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.00046281328274156943,0,1,2,0.008761735709103716
2017,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.00044836740832023025,1,1,2,0.00848825407301733
2018,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.00033670355811261265,0,1,2,0.006374293259307488
2019,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.00032777455205572695,1,1,2,0.006205254050337542
2020,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.001478452062358005,0,1,2,0.027989270645443962
2021,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0014356289738712553,1,1,2,0.02717856663680821
2022,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0027461690890388706,0,1,2,0.05198901731630777
2023,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0026719948955194967,1,1,2,0.05058479080793514
2024,Parasite infection,Leishmania infection,0.0003483896887619331,0,1,2,0.00659552888937599
2025,Parasite infection,Leishmania infection,0.0004348751574685627,1,1,2,0.00823282593278988
2026,Cell recruitment (pro-inflammatory response),Leishmania infection,0.0040982695385222145,0,1,2,0.07758626621192452
2027,Cell recruitment (pro-inflammatory response),Leishmania infection,0.005132104073782155,1,1,2,0.09715827354765535
2028,Leishmania parasite growth and survival,Leishmania infection,0.001375057456633276,0,1,2,0.02603185878435675
2029,Leishmania parasite growth and survival,Leishmania infection,0.0017149414961713748,1,1,2,0.03246636323188414
2030,Potential therapeutics for SARS,SARS-CoV Infections,0.0035817441817790974,0,1,2,0.06780768199319805
2031,Potential therapeutics for SARS,SARS-CoV Infections,0.004338587367611373,1,1,2,0.08213583594810799
2032,SARS-CoV-2 Infection,SARS-CoV Infections,0.002385451777837662,0,1,2,0.04516010841438175
2033,SARS-CoV-2 Infection,SARS-CoV Infections,0.0028808653176018426,1,1,2,0.054539014906460744
2034,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.00016707930404171307,0,1,2,0.003163056807278163
2035,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,2.6396382617014507e-05,1,1,2,0.0004997223217031222
2036,Cytoprotection by HMOX1,Cellular response to chemical stress,0.0010704408119186902,0,1,2,0.020265017958672252
2037,Cytoprotection by HMOX1,Cellular response to chemical stress,0.00016839470014990844,1,1,2,0.003187959189043267
2038,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.00045630721875856875,0,1,2,0.008638566354957498
2039,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.00035151528016575664,1,1,2,0.006654700928805635
2040,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.000235513678709837,0,1,2,0.004458620108115182
2041,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.0001767363497429679,1,1,2,0.003345878876826192
2042,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.016160920820827377,0,1,2,0.3059499852922497
2043,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.014589662948375303,1,1,2,0.27620376425096427
2044,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.001159996902951772,0,1,2,0.021960446396084767
2045,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.001969039392577998,1,1,2,0.03727680989704007
2046,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0029753579282001084,0,1,2,0.056327898915192964
2047,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.002166836373502787,1,1,2,0.04102139747813882
2048,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.001398855045472089,0,1,2,0.026482382119997542
2049,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.00253533143260226,1,1,2,0.047997550579913534
2050,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.006229064226343013,0,1,2,0.11792534160417693
2051,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.009201153195049652,1,1,2,0.17419135431127342
2052,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005268350704106022,0,1,2,0.09973762252200245
2053,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006248338129040121,1,1,2,0.11829022491200829
2054,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.0006751073724644958,0,1,2,0.012780774868348579
2055,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.0014688127911387599,1,1,2,0.027806785072966227
2056,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.005000753154613786,0,1,2,0.09467160758145031
2057,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.005911741146004506,1,1,2,0.11191794927555791
2058,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.010028332762164664,0,1,2,0.1898510793479023
2059,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.010569442151882356,1,1,2,0.20009507544571567
2060,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.00521528651819902,0,1,2,0.09873303948630872
2061,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0040910985548553505,1,1,2,0.07745050895082956
2062,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.001391082066930659,0,1,2,0.026335228211083972
2063,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.00027886611203362333,1,1,2,0.005279345392574352
2064,Integrin cell surface interactions,Integrin cell surface interactions,0.009738300131595157,0,1,2,0.1843603353463195
2065,Integrin cell surface interactions,Integrin cell surface interactions,0.009537331885431983,1,1,2,0.18055571105296905
2066,ECM proteoglycans,ECM proteoglycans,0.0023505302244512414,0,1,2,0.04449899207927858
2067,ECM proteoglycans,ECM proteoglycans,0.0031423534514340374,1,1,2,0.05948936962863442
2068,Collagen biosynthesis and modifying enzymes,Collagen biosynthesis and modifying enzymes,0.00016008548159181924,0,1,2,0.003030653468421134
2069,Collagen biosynthesis and modifying enzymes,Collagen biosynthesis and modifying enzymes,4.8876901838149824e-05,1,1,2,0.0009253115935844979
2070,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.0019524472077451453,0,1,2,0.036962695450106116
2071,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.0015504824139675338,1,1,2,0.029352911075333943
2072,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.0002553499675873864,0,1,2,0.004834150212966494
2073,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.0015793776783909897,1,1,2,0.029899940902618213
2074,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.0028134980190944302,0,1,2,0.0532636529257895
2075,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.0027978189927512207,1,1,2,0.05296682591127189
2076,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.004729256206910564,0,1,2,0.08953177130122782
2077,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.004871254999006203,1,1,2,0.09222001715273825
2078,Neutrophil degranulation,Neutrophil degranulation,0.01733150764294677,0,1,2,0.3281109144237863
2079,Neutrophil degranulation,Neutrophil degranulation,0.01858909956352064,1,1,2,0.35191897795364213
2080,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.0009082363996006066,0,1,2,0.01719425001708939
2081,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.0008348652614563666,1,1,2,0.015805226527340212
2082,Heme degradation,Heme degradation,9.032103349756542e-05,0,1,2,0.0017099099226170328
2083,Heme degradation,Heme degradation,9.846663270092911e-05,1,1,2,0.001864118088358055
2084,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.00019494946533547182,0,1,2,0.0036906799255678776
2085,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",8.060279656046127e-05,1,1,2,0.001525929413032345
2086,Scavenging of heme from plasma,Scavenging of heme from plasma,0.004414693462198559,0,1,2,0.083576636183302
2087,Scavenging of heme from plasma,Scavenging of heme from plasma,0.0046625838641842915,1,1,2,0.08826956585497538
2088,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.001995547717923737,0,1,2,0.03777865145913713
2089,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.0013724660442124674,1,1,2,0.025982799538239367
2090,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.007881456971178855,0,1,2,0.14920756503590235
2091,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.0075046077413092,1,1,2,0.14207325520205752
2092,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.004486820834485291,0,1,2,0.08494211335721742
2093,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.0037931580249386896,1,1,2,0.07181005679116724
2094,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.0024677004546434455,0,1,2,0.046717196759657624
2095,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.0016120196578638072,1,1,2,0.0305179015529017
2096,Retinoid metabolism and transport,Retinoid metabolism and transport,0.01762014674406185,0,1,2,0.3335752768645155
2097,Retinoid metabolism and transport,Retinoid metabolism and transport,0.016188839534144454,1,1,2,0.30647852757170513
2098,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.01762014674406185,0,1,2,0.3335752768645155
2099,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.016188839534144454,1,1,2,0.30647852757170513
2100,Heme signaling,Heme signaling,0.009570204964176354,0,1,2,0.1811780467521447
2101,Heme signaling,Heme signaling,0.000989246517650591,1,1,2,0.01872789062462052
2102,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.004525541056363892,0,1,2,0.08567514407035622
2103,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.003684893288052545,1,1,2,0.06976044618882477
2104,Syndecan interactions,Syndecan interactions,0.0110057278146165,0,1,2,0.20835460431641634
2105,Syndecan interactions,Syndecan interactions,0.006065009086749307,1,1,2,0.11481953667497223
2106,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.002816248214587105,0,1,2,0.05331571816884485
2107,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00455145025422016,1,1,2,0.08616564326844915
2108,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.002720003972851123,0,1,2,0.05149367320803798
2109,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.0022949955865803878,1,1,2,0.04344763975671159
2110,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.018897250813788402,0,1,2,0.35775273405779356
2111,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.02512765780443624,1,1,2,0.475703496163925
2112,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.0039017469554105785,0,1,2,0.0738658048546043
2113,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.00481085285147258,1,1,2,0.09107651571773859
2114,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008920683778263107,0,1,2,0.16888165600310634
2115,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004839154753008215,1,1,2,0.09161231231340107
2116,Amyloid fiber formation,Amyloid fiber formation,0.011941740232364606,0,1,2,0.22607469518366027
2117,Amyloid fiber formation,Amyloid fiber formation,0.009403171430822218,1,1,2,0.17801585645125848
2118,Platelet sensitization by LDL,Platelet sensitization by LDL,0.0018357008479621918,0,1,2,0.03475251525960075
2119,Platelet sensitization by LDL,Platelet sensitization by LDL,0.002289861896511016,1,1,2,0.04335045145793624
2120,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,6.693746354941442e-05,0,1,2,0.001267224573122769
2121,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.0012216884967113347,1,1,2,0.023128358943435973
2122,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.007012551293014552,0,1,2,0.1327579033859228
2123,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.0062399367148030915,1,1,2,0.11813117379166987
2124,Formation of the cornified envelope,Formation of the cornified envelope,1.31092115543056e-06,0,1,2,2.481766433174971e-05
2125,Formation of the cornified envelope,Formation of the cornified envelope,8.148109948256622e-06,1,1,2,0.00015425569783226743
2126,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,0.0010255672800290223,0,1,2,0.01941549604257191
2127,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,0.000953537094170021,1,1,2,0.018051858750583048
2128,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.002046945709349765,0,1,2,0.03875169098424751
2129,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.0013568389560570254,1,1,2,0.025686955789957618
2130,Signaling by PDGF,Signaling by PDGF,0.0003585308047630549,0,1,2,0.006787515121211964
2131,Signaling by PDGF,Signaling by PDGF,0.006337321862844398,1,1,2,0.1199748177857994
2132,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.00013618315582878063,0,1,2,0.002578147308857026
2133,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.0005596249175795223,1,1,2,0.010594522255314513
2134,Peroxisomal protein import,Peroxisomal protein import,0.00180809106508316,0,1,2,0.034229821487419425
2135,Peroxisomal protein import,Peroxisomal protein import,0.00029712898196529507,1,1,2,0.0056250883640879745
2136,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.007556667021250572,0,1,2,0.1430588138907593
2137,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.006844522136567635,1,1,2,0.12957686447647213
2138,Late endosomal microautophagy,Late endosomal microautophagy,0.009348820543462703,0,1,2,0.1769869142658086
2139,Late endosomal microautophagy,Late endosomal microautophagy,0.010572783675254391,1,1,2,0.20015833539469147
2140,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.01471187955390564,0,1,2,0.27851750423391664
2141,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.013442644237839347,1,1,2,0.2544890141133267
2142,Atorvastatin ADME,Atorvastatin ADME,0.0038326255415766517,0,1,2,0.07255723489251308
2143,Atorvastatin ADME,Atorvastatin ADME,0.0048444021113729354,1,1,2,0.09171165252008288
2144,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0011355313488256719,0,2,3,0.0323097563116542
2145,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.001164549495927212,1,2,3,0.03313542199004881
2146,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.014398905234226336,0,2,3,0.40969817324160646
2147,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.020852150566089835,1,2,3,0.5933151066776196
2148,SARS-CoV Infections,Infectious disease,0.001716039666284106,0,2,3,0.04882720630840445
2149,SARS-CoV Infections,Infectious disease,0.002427321740551031,1,2,3,0.06906561761442327
2150,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.005667198412555258,0,2,3,0.1612512062029954
2151,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.006639131312059406,1,2,3,0.18890602627179787
2152,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,0,2,3,0.0
2153,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,1,2,3,0.0
2154,Cell-cell junction organization,Cell junction organization,0.00023150762424336915,0,2,3,0.0065871848728163976
2155,Cell-cell junction organization,Cell junction organization,0.0006384465472460582,1,2,3,0.018165991085028164
2156,Integrin cell surface interactions,Integrin cell surface interactions,0.008821549275235898,0,2,3,0.25100329257213533
2157,Integrin cell surface interactions,Integrin cell surface interactions,0.008473542621616483,1,2,3,0.2411013112794958
2158,Signaling by Interleukins,Cytokine Signaling in Immune system,0.00614874263015839,0,2,3,0.17495278858566898
2159,Signaling by Interleukins,Cytokine Signaling in Immune system,0.005439059346694594,1,2,3,0.1547598683541994
2160,O-linked glycosylation,Post-translational protein modification,0.0014849619336499036,0,2,3,0.042252253324339496
2161,O-linked glycosylation,Post-translational protein modification,0.0013780237111990668,1,2,3,0.03920949460934567
2162,Late endosomal microautophagy,Late endosomal microautophagy,0.007689377271522903,0,2,3,0.2187891211354118
2163,Late endosomal microautophagy,Late endosomal microautophagy,0.008099854399873421,1,2,3,0.23046860140887881
2164,Platelet sensitization by LDL,Platelet homeostasis,0.00028109720116942287,0,2,3,0.007998178191262247
2165,Platelet sensitization by LDL,Platelet homeostasis,0.002575881040951601,1,2,3,0.07329263855817454
2166,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.00989684681657682,0,2,3,0.2815991907471842
2167,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.006683874481409826,1,2,3,0.19017912269473516
2168,ECM proteoglycans,ECM proteoglycans,0.0023340489993236707,0,2,3,0.06641168864743123
2169,ECM proteoglycans,ECM proteoglycans,0.00295203718798228,1,2,3,0.08399556935639581
2170,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.0005983436472600464,0,2,3,0.01702492621942259
2171,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.0008626546668555257,1,2,3,0.024545480048646588
2172,Toll-like Receptor Cascades,Innate Immune System,0.00340043060645538,0,2,3,0.09675389795524772
2173,Toll-like Receptor Cascades,Innate Immune System,0.003531338130529797,1,2,3,0.10047866540141333
2174,Heme degradation,Metabolism of porphyrins,0.00011869446023588399,0,2,3,0.00337726394760546
2175,Heme degradation,Metabolism of porphyrins,9.163645594780497e-05,1,2,3,0.0026073710461618897
2176,Diseases of glycosylation,Diseases of metabolism,0.0038849899455943152,0,2,3,0.11054127087305055
2177,Diseases of glycosylation,Diseases of metabolism,0.005418244907344582,1,2,3,0.15416762626078817
2178,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.0002689493590036909,0,2,3,0.007652530472691429
2179,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.00024961513964202224,1,2,3,0.0071024057080183904
2180,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0027440911881417224,0,2,3,0.07807879340143874
2181,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.001749357585510904,1,2,3,0.04977521523140116
2182,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.011778001671909793,0,2,3,0.335124489738841
2183,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.01136805662009482,1,2,3,0.3234601488652861
2184,Neutrophil degranulation,Innate Immune System,0.012314570512979838,0,2,3,0.3503917111302439
2185,Neutrophil degranulation,Innate Immune System,0.012766554251317149,1,2,3,0.3632521966268455
2186,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0033537750372497786,0,2,3,0.09542638720605225
2187,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0021369559853413296,1,2,3,0.06080371731393657
2188,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,0.00011507844136767917,0,2,3,0.0032743758251675675
2189,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,2.1284178962833507e-05,1,2,3,0.0006056077943545722
2190,Metabolism of steroids,Metabolism of lipids,0.000511121924541009,0,2,3,0.014543169455023996
2191,Metabolism of steroids,Metabolism of lipids,0.00038355056242622584,1,2,3,0.010913327243677683
2192,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.005444982358916713,0,2,3,0.15492839833950145
2193,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.006334222778957329,1,2,3,0.1802303341281506
2194,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.0001331684118918119,0,2,3,0.00378909744859451
2195,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,3.2881556909983085e-06,1,2,3,9.355929204491236e-05
2196,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.0063239448679085096,0,2,3,0.1799378923547697
2197,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.001863531822608366,1,2,3,0.05302386334798818
2198,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.005154474782438886,0,2,3,0.14666246273816844
2199,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.008262161409829404,1,2,3,0.2350867917783251
2200,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.0009484632988801918,0,2,3,0.026987029542652672
2201,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.000993236212041181,1,2,3,0.02826097227887959
2202,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.004322196731870531,0,2,3,0.12298130146929492
2203,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.003734172584849587,1,2,3,0.10625000037816869
2204,Retinoid metabolism and transport,Visual phototransduction,0.006177003643563388,0,2,3,0.17575691121705223
2205,Retinoid metabolism and transport,Visual phototransduction,0.007096098364628317,1,2,3,0.20190830412720479
2206,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.000596448645728891,0,2,3,0.01697100693507596
2207,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.000559892837934218,1,2,3,0.015930868991862843
2208,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.005150937470180434,0,2,3,0.14656181408836494
2209,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.0056882809754795725,1,2,3,0.1618510773304761
2210,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.0024219653213974094,0,2,3,0.06891320914262232
2211,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.004391972242195177,1,2,3,0.12496665373406692
2212,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.00035808302460764625,0,2,3,0.010188688560978954
2213,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.0046197701548774785,1,2,3,0.13144828460641597
2214,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0010971146240027051,0,2,3,0.031216668904947575
2215,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.000705603034184559,1,2,3,0.020076823163749456
2216,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.000829726077445243,0,2,3,0.023608548892467572
2217,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.0009583778125761323,1,2,3,0.02726913141663059
2218,Fatty acid metabolism,Metabolism of lipids,0.0016327262203992782,0,2,3,0.04645665340662258
2219,Fatty acid metabolism,Metabolism of lipids,0.0012274982887062306,1,2,3,0.03492653075768104
2220,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.0003269951828793489,0,2,3,0.009304132981306652
2221,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.0044931672711047855,1,2,3,0.12784599892114742
2222,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.0031054284297356606,0,2,3,0.08836007558206639
2223,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.003770412288349226,1,2,3,0.1072811440714633
2224,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.004386501283502906,0,2,3,0.124810986220069
2225,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.004072724064052486,1,2,3,0.11588294957266514
2226,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.0012809975608998516,0,2,3,0.03644876829803108
2227,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.002956091892865006,1,2,3,0.08411093959854019
2228,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.002022107279805745,0,2,3,0.05753587826008642
2229,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.0021080286591356142,1,2,3,0.05998063580110915
2230,Post-translational protein phosphorylation,Post-translational protein modification,0.00482184697906754,0,2,3,0.1371980624109354
2231,Post-translational protein phosphorylation,Post-translational protein modification,0.00448387101927546,1,2,3,0.12758148871495376
2232,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.0013333433826039859,0,2,3,0.03793818622114077
2233,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.0016515149189328686,1,2,3,0.04699125623521137
2234,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.0013789885281851784,0,2,3,0.039236946957304925
2235,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.0016052373622416616,1,2,3,0.04567450123682409
2236,Collagen biosynthesis and modifying enzymes,Collagen formation,0.00010747366659852877,0,2,3,0.003057993935006306
2237,Collagen biosynthesis and modifying enzymes,Collagen formation,0.00010627267180452783,1,2,3,0.0030238215194531245
2238,Peroxisomal protein import,Peroxisomal protein import,0.001399376441479228,0,2,3,0.03981705292348113
2239,Peroxisomal protein import,Peroxisomal protein import,7.801959076378677e-05,1,2,3,0.0022199245910030202
2240,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.0013799850027457071,0,2,3,0.03926530007169031
2241,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.0019670064377557603,1,2,3,0.05596807057160378
2242,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006787999335220302,0,2,3,0.19314183143552185
2243,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002910753622883899,1,2,3,0.08282091052431297
2244,Molecules associated with elastic fibres,Elastic fibre formation,0.0015151602261444348,0,2,3,0.0431114981814149
2245,Molecules associated with elastic fibres,Elastic fibre formation,0.002850604409312409,1,2,3,0.08110945937429208
2246,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.001838567151563416,0,2,3,0.052313532947425384
2247,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.0017222176886532979,1,2,3,0.04900299220585499
2248,Apoptotic execution phase,Apoptosis,0.014850852211090967,0,2,3,0.4225576127483943
2249,Apoptotic execution phase,Apoptosis,0.004386500829809351,1,2,3,0.12481097331093335
2250,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0009693915465198875,0,2,3,0.027582509871723122
2251,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0012469099555494747,1,2,3,0.03547885916847908
2252,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.004333362534397442,0,2,3,0.12329900679644566
2253,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.0027383614399138596,1,2,3,0.07791576243874375
2254,Transferrin endocytosis and recycling,Iron uptake and transport,9.013120488666877e-05,0,2,3,0.0025645414976659675
2255,Transferrin endocytosis and recycling,Iron uptake and transport,0.00059691280491843,1,2,3,0.016984213853862774
2256,Clathrin-mediated endocytosis,Membrane Trafficking,0.007637330775303031,0,2,3,0.21730822004758316
2257,Clathrin-mediated endocytosis,Membrane Trafficking,0.003168671601505877,1,2,3,0.09015956044030915
2258,Atorvastatin ADME,Atorvastatin ADME,0.004100080500836727,0,2,3,0.1166613339008196
2259,Atorvastatin ADME,Atorvastatin ADME,0.004988869640202863,1,2,3,0.14195042920854706
2260,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.002786431816410615,0,2,3,0.0792835293013899
2261,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.002615620522152614,1,2,3,0.07442336291455989
2262,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.0003081987649236741,0,2,3,0.008769310508718898
2263,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.0008461351511954283,1,2,3,0.024075443245245007
2264,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.00016880830884285456,0,2,3,0.004803174591115952
2265,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.0014353200080331008,1,2,3,0.04083977050633638
2266,Cellular response to chemical stress,Cellular responses to stress,5.822486940089106e-05,0,2,3,0.0016566969670772959
2267,Cellular response to chemical stress,Cellular responses to stress,3.560544451821547e-06,1,2,3,0.00010130968528005625
2268,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.0014434775383563069,0,2,3,0.041071880185316434
2269,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.001439799822906078,1,2,3,0.040967236583795974
2270,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.003049174806869417,0,2,3,0.0867594673308405
2271,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.004344055942141391,1,2,3,0.12360327087396798
2272,SLC transporter disorders,Disorders of transmembrane transporters,0.0002580411504692566,0,2,3,0.00734215457694116
2273,SLC transporter disorders,Disorders of transmembrane transporters,0.00040503949664775926,1,2,3,0.011524761026472789
2274,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.00040741919760542596,0,2,3,0.011592471669702793
2275,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.0011186342901295088,1,2,3,0.03182897711571096
2276,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.007861765820574426,0,2,3,0.22369416582355228
2277,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0080603456250727,1,2,3,0.22934444143980054
2278,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.0009402915979281945,0,2,3,0.026754516660746075
2279,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.0038717429794922196,1,2,3,0.1101643493137558
2280,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.004395527705608751,0,2,3,0.12506781884640517
2281,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.004582701976159309,1,2,3,0.13039356795544946
2282,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.0010315578554170595,0,2,3,0.029351354292742275
2283,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.00010604039542657345,1,2,3,0.0030172124609040836
2284,GPCR ligand binding,Signaling by GPCR,0.0022546963329151412,0,2,3,0.06415383348826628
2285,GPCR ligand binding,Signaling by GPCR,0.006264191843713993,1,2,3,0.17823771414955697
2286,ABC transporter disorders,Disorders of transmembrane transporters,0.0020135213506104073,0,2,3,0.05729157916583652
2287,ABC transporter disorders,Disorders of transmembrane transporters,0.003157053684614516,1,2,3,0.08982899091090152
2288,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0036338335274226606,0,2,3,0.10339501051165573
2289,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0036469472147215272,1,2,3,0.10376813983249025
2290,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",0.00029551402840853695,0,2,3,0.008408386306929605
2291,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",0.0003485172451470595,1,2,3,0.00991650937048614
2292,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.00622553797244596,0,2,3,0.17713787911421097
2293,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.004663475166861932,1,2,3,0.13269184189638067
2294,Amyloid fiber formation,Amyloid fiber formation,0.009491599175547032,0,2,3,0.2700685073001037
2295,Amyloid fiber formation,Amyloid fiber formation,0.007807047762692199,1,2,3,0.22213724965575993
2296,Antimicrobial peptides,Innate Immune System,0.002408148644767415,0,2,3,0.06852007736742852
2297,Antimicrobial peptides,Innate Immune System,0.0024989542193927113,1,2,3,0.07110380699401893
2298,Heme signaling,Cellular responses to stress,0.007752207752542649,0,2,3,0.22057686352824968
2299,Heme signaling,Cellular responses to stress,0.0004779657150236723,1,2,3,0.013599761727151782
2300,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.007583716405906208,0,2,3,0.21578270759756948
2301,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.004735524402543202,1,2,3,0.1347418894355439
2302,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.002353215616203582,0,2,3,0.06695704454742396
2303,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.001607596768610239,1,2,3,0.0457416344294812
2304,Formation of the cornified envelope,Keratinization,2.1086236002691287e-06,0,2,3,5.9997563914158176e-05
2305,Formation of the cornified envelope,Keratinization,2.4808586798783723e-06,1,2,3,7.058892691374564e-05
2306,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.004096898178895578,0,2,3,0.11657078594146113
2307,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.003496890073812267,1,2,3,0.09949850019584287
2308,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.006660012138411689,0,2,3,0.1895001573028134
2309,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.0048862426030219595,1,2,3,0.1390303384812138
2310,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.010719740826227234,0,2,3,0.3050133439095965
2311,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.010376828755508787,1,2,3,0.29525632095052473
2312,Assembly of collagen fibrils and other multimeric structures,Collagen formation,6.66732551573045e-05,0,2,3,0.0018970824793741253
2313,Assembly of collagen fibrils and other multimeric structures,Collagen formation,6.592819184187127e-05,1,2,3,0.0018758828760489538
2314,GPCR downstream signalling,Signaling by GPCR,0.0033396724571692314,0,2,3,0.0950251204984098
2315,GPCR downstream signalling,Signaling by GPCR,0.009208041004657743,1,2,3,0.262000306090964
2316,Generic Transcription Pathway,RNA Polymerase II Transcription,0.015467379658489409,0,2,3,0.4400999303651561
2317,Generic Transcription Pathway,RNA Polymerase II Transcription,0.012569950204963655,1,2,3,0.3576581380972102
2318,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.0009856750638427276,0,2,3,0.028045831714084986
2319,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.0011636535541273444,1,2,3,0.03310992937705043
2320,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.004718287607183506,0,2,3,0.13425144356785249
2321,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.004848369313488586,1,2,3,0.1379527136698781
2322,Complement cascade,Innate Immune System,0.005645064368384048,0,2,3,0.16062141683249254
2323,Complement cascade,Innate Immune System,0.005891403632199829,1,2,3,0.16763061265267953
2324,Leishmania infection,Infectious disease,0.0027555978267889696,0,2,3,0.07840619668364956
2325,Leishmania infection,Infectious disease,0.00388250089531241,1,2,3,0.11047044886700115
2326,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.0012720382281476048,0,2,3,0.03619384459360013
2327,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.0004066388609749977,1,2,3,0.011570268419747372
2328,Syndecan interactions,Non-integrin membrane-ECM interactions,0.007854032153998061,0,2,3,0.22347411651999377
2329,Syndecan interactions,Non-integrin membrane-ECM interactions,0.0052205728037498286,1,2,3,0.14854317784431467
2330,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.0008688867355277054,0,2,3,0.02472280374853726
2331,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.002315413173687011,1,2,3,0.06588143557638247
2332,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.0005663674781441684,0,2,3,0.016115094682862454
2333,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.0005928177455785543,1,2,3,0.016867695389189846
2334,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.0001022515120027937,0,3,4,0.004780254073248019
2335,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.0003807564971985455,1,3,4,0.01780035092878887
2336,Cell surface interactions at the vascular wall,Hemostasis,0.005134129735100282,0,3,4,0.24002035860483267
2337,Cell surface interactions at the vascular wall,Hemostasis,0.005497478280521304,1,3,4,0.2570068884882258
2338,MAPK family signaling cascades,Signal Transduction,0.0003089027644088349,0,3,4,0.01444119181105666
2339,MAPK family signaling cascades,Signal Transduction,0.0011500198080142809,1,3,4,0.05376337976719574
2340,Innate Immune System,Immune System,0.017221641169709805,0,3,4,0.8051110319744889
2341,Innate Immune System,Immune System,0.01678165934040798,1,3,4,0.7845418991521038
2342,Amyloid fiber formation,Metabolism of proteins,0.003262034505488615,0,3,4,0.15249998192214018
2343,Amyloid fiber formation,Metabolism of proteins,0.002668244125288104,1,3,4,0.124740305531913
2344,"Platelet activation, signaling and aggregation",Hemostasis,0.003530149014781461,0,3,4,0.16503432444715832
2345,"Platelet activation, signaling and aggregation",Hemostasis,0.003759478250738412,1,3,4,0.17575545700379103
2346,Diseases of programmed cell death,Disease,0.00011462414759914309,0,3,4,0.005358674289710409
2347,Diseases of programmed cell death,Disease,0.00013099187530119316,1,3,4,0.006123864901418934
2348,Cell junction organization,Cell-Cell communication,0.0004440640502055535,0,3,4,0.020759976485434394
2349,Cell junction organization,Cell-Cell communication,0.0005043588742309452,1,3,4,0.023578757083370944
2350,ECM proteoglycans,Extracellular matrix organization,0.0019290613894994077,0,3,4,0.09018354236608336
2351,ECM proteoglycans,Extracellular matrix organization,0.0015049258743514593,1,3,4,0.07035522409300263
2352,Integrin signaling,Signal Transduction,4.364691950361344e-05,0,3,4,0.00204049173117534
2353,Integrin signaling,Signal Transduction,0.00016302168579211739,1,3,4,0.007621257253528303
2354,Cytokine Signaling in Immune system,Immune System,0.002699567765406281,0,3,4,0.12620468444750085
2355,Cytokine Signaling in Immune system,Immune System,0.0026315145707056565,1,3,4,0.12302320033256366
2356,Miscellaneous transport and binding events,Transport of small molecules,0.010466458266710688,0,3,4,0.4893065029743246
2357,Miscellaneous transport and binding events,Transport of small molecules,0.014466144718541398,1,3,4,0.676291683717239
2358,Disorders of transmembrane transporters,Disease,0.0017872618687679053,0,3,4,0.0835544204755155
2359,Disorders of transmembrane transporters,Disease,0.0020188386865315033,1,3,4,0.09438062739120404
2360,Membrane Trafficking,Vesicle-mediated transport,0.005810190793836836,0,3,4,0.27162618590743026
2361,Membrane Trafficking,Vesicle-mediated transport,0.002795611014034492,1,3,4,0.13069470245770334
2362,Cellular responses to stress,Cellular responses to stimuli,0.007530449591995606,0,3,4,0.35204821552704624
2363,Cellular responses to stress,Cellular responses to stimuli,0.0018486555707367455,1,3,4,0.08642457357310789
2364,Metabolism of lipids,Metabolism,0.0017722932106665503,0,3,4,0.08285463631136443
2365,Metabolism of lipids,Metabolism,0.0016112485071477804,1,3,4,0.07532580289959458
2366,Post-translational protein modification,Metabolism of proteins,0.00503367244597808,0,3,4,0.23532398437908295
2367,Post-translational protein modification,Metabolism of proteins,0.004168802421912613,1,3,4,0.19489134554185863
2368,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.0002159486846560419,0,3,4,0.010095592321523737
2369,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.0002476226519910116,1,3,4,0.01157634902040538
2370,SLC-mediated transmembrane transport,Transport of small molecules,0.0011872325024129883,0,3,4,0.055503071733521814
2371,SLC-mediated transmembrane transport,Transport of small molecules,0.001611604722052868,1,3,4,0.07534245593207932
2372,Signaling by Nuclear Receptors,Signal Transduction,0.0005315036181679175,0,3,4,0.024847772770576048
2373,Signaling by Nuclear Receptors,Signal Transduction,0.0019715776717210386,1,3,4,0.09217117684980386
2374,Keratinization,Developmental Biology,1.5647045142597974e-07,0,3,4,7.314987310422951e-06
2375,Keratinization,Developmental Biology,2.314253870395781e-07,1,3,4,1.0819127535431623e-05
2376,Infectious disease,Disease,0.0026144321096604655,0,3,4,0.12222459596581214
2377,Infectious disease,Disease,0.0030091374946039115,1,3,4,0.14067705683560627
2378,Atorvastatin ADME,Drug ADME,0.00404503954757911,0,3,4,0.18910543614490571
2379,Atorvastatin ADME,Drug ADME,0.004246738791800262,1,3,4,0.19853486769925638
2380,Platelet homeostasis,Hemostasis,0.0009716743208381131,0,3,4,0.04542573541533534
2381,Platelet homeostasis,Hemostasis,0.0010350019932486732,1,3,4,0.04838630155328766
2382,Elastic fibre formation,Extracellular matrix organization,0.0018429268102260862,0,3,4,0.08615675424966363
2383,Elastic fibre formation,Extracellular matrix organization,0.0014378616192001696,1,3,4,0.06721997286221851
2384,Degradation of the extracellular matrix,Extracellular matrix organization,0.0006744182929469918,0,3,4,0.03152902806801283
2385,Degradation of the extracellular matrix,Extracellular matrix organization,0.0005257152337876578,1,3,4,0.024577166033626224
2386,Diseases of Immune System,Disease,0.003710301490955555,0,3,4,0.1734564454619889
2387,Diseases of Immune System,Disease,0.004309954175916475,1,3,4,0.2014901843639646
2388,Signaling by GPCR,Signal Transduction,0.0019764099536096155,0,3,4,0.092397085833725
2389,Signaling by GPCR,Signal Transduction,0.007444201264801717,1,3,4,0.34801610969991537
2390,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.0009716486820283227,0,3,4,0.04542453680200891
2391,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.003613234116396088,1,3,4,0.1689185496056938
2392,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.00701881698902677,0,3,4,0.3281294119177516
2393,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.007491461000184813,1,3,4,0.3502255004281375
2394,ABC-family proteins mediated transport,Transport of small molecules,0.0025919163382946715,0,3,4,0.12117198456011756
2395,ABC-family proteins mediated transport,Transport of small molecules,0.00350316278851557,1,3,4,0.16377271945470018
2396,Diseases of metabolism,Disease,0.0031339519964722973,0,3,4,0.14651212977751515
2397,Diseases of metabolism,Disease,0.0035467008412640925,1,3,4,0.165808121669454
2398,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.006157398413083623,0,3,4,0.2878581281414175
2399,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.0049323861752533366,1,3,4,0.23058885529675868
2400,Platelet Adhesion to exposed collagen,Hemostasis,0.001335943410353459,0,3,4,0.06245530069811085
2401,Platelet Adhesion to exposed collagen,Hemostasis,0.001429224224867914,1,3,4,0.06681617502460917
2402,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.008841940334120635,0,3,4,0.4133603549690425
2403,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.004218342407103708,1,3,4,0.19720733785688582
2404,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,3.5833038984341384e-05,0,3,4,0.001675193131198617
2405,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,3.242216480642034e-05,1,3,4,0.001515734900577068
2406,Integrin cell surface interactions,Extracellular matrix organization,0.006609311861578319,0,3,4,0.3089850636811414
2407,Integrin cell surface interactions,Extracellular matrix organization,0.0053121789493277985,1,3,4,0.24834415220826067
2408,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.005574119407238369,0,3,4,0.26058985807949747
2409,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.00759057220743823,1,3,4,0.3548589453806652
2410,Peptide hormone metabolism,Metabolism of proteins,0.001916788841981708,0,3,4,0.08960980126327199
2411,Peptide hormone metabolism,Metabolism of proteins,0.0015516953123274814,1,3,4,0.0725416934371654
2412,Factors involved in megakaryocyte development and platelet production,Hemostasis,8.923954793939171e-05,0,3,4,0.0041719452766667536
2413,Factors involved in megakaryocyte development and platelet production,Hemostasis,9.545409647824218e-05,1,3,4,0.004462475170889011
2414,Peroxisomal protein import,Protein localization,0.0008714425080070161,0,3,4,0.04073990219712538
2415,Peroxisomal protein import,Protein localization,0.00035415936235022924,1,3,4,0.01655693594445185
2416,Apoptosis,Programmed Cell Death,0.015673260218015947,0,3,4,0.7327242847636312
2417,Apoptosis,Programmed Cell Death,0.004132266875995177,1,3,4,0.19318331023979496
2418,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.0036923175535574725,0,3,4,0.17261569711199998
2419,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.0030441013773343053,1,3,4,0.14231161694689307
2420,Sensory processing of sound,Sensory Perception,0.008935999405398375,0,3,4,0.4177576127679204
2421,Sensory processing of sound,Sensory Perception,0.008159703680520455,1,3,4,0.38146581885497255
2422,Adaptive Immune System,Immune System,0.002186720014090866,0,3,4,0.10222907270188072
2423,Adaptive Immune System,Immune System,0.0021438498522811074,1,3,4,0.10022489436164943
2424,Gene Silencing by RNA,Gene expression (Transcription),9.570773716198278e-05,0,3,4,0.004474332862651645
2425,Gene Silencing by RNA,Gene expression (Transcription),7.780546047598963e-05,1,3,4,0.0036374021476682453
2426,Chaperone Mediated Autophagy,Autophagy,0.003503586277169011,0,3,4,0.1637925175322145
2427,Chaperone Mediated Autophagy,Autophagy,0.003359114400258056,1,3,4,0.15703846309774794
2428,Metabolism of porphyrins,Metabolism,8.126332003189782e-05,0,3,4,0.003799056942820791
2429,Metabolism of porphyrins,Metabolism,7.455661016852924e-05,1,3,4,0.003485518526473614
2430,Iron uptake and transport,Transport of small molecules,0.00022086763025198715,0,3,4,0.010325552830278464
2431,Iron uptake and transport,Transport of small molecules,0.00029887992813269824,1,3,4,0.013972624618297777
2432,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.001479398742984915,0,3,4,0.06916183172839949
2433,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.002012710385905781,1,3,4,0.09409412958345134
2434,Integration of energy metabolism,Metabolism,0.0019860950348088097,0,3,4,0.09284986299022242
2435,Integration of energy metabolism,Metabolism,0.001837829251058896,1,3,4,0.0859184435636376
2436,Reversible hydration of carbon dioxide,Metabolism,0.002537508354674119,0,3,4,0.1186284135143197
2437,Reversible hydration of carbon dioxide,Metabolism,0.0023433038688826023,1,3,4,0.10954936161509135
2438,Dissolution of Fibrin Clot,Hemostasis,0.001100221489964477,0,3,4,0.0514353104014149
2439,Dissolution of Fibrin Clot,Hemostasis,0.001176874859516813,1,3,4,0.05501885234474312
2440,Visual phototransduction,Sensory Perception,0.004132562347251099,0,3,4,0.19319712350912446
2441,Visual phototransduction,Sensory Perception,0.0038428493862814957,1,3,4,0.1796530542369767
2442,Diseases of hemostasis,Disease,0.002451973565077127,0,3,4,0.11462966554114291
2443,Diseases of hemostasis,Disease,0.002809572429553222,1,3,4,0.13134739807163123
2444,Metabolism of carbohydrates,Metabolism,0.00048563735058391555,0,3,4,0.02270352660591182
2445,Metabolism of carbohydrates,Metabolism,0.0004429745406839692,1,3,4,0.020709041959123882
2446,Late endosomal microautophagy,Autophagy,0.005623444758736869,0,3,4,0.2628958162780291
2447,Late endosomal microautophagy,Autophagy,0.005376130100698259,1,3,4,0.25133386596251
2448,RNA Polymerase II Transcription,Gene expression (Transcription),0.013622657442684656,0,3,4,0.6368586874986902
2449,RNA Polymerase II Transcription,Gene expression (Transcription),0.01080680893193283,1,3,4,0.5052178828834684
2450,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.00552971399808777,0,3,4,0.2585139069878345
2451,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.007631309108816771,1,3,4,0.35676339388154366
2452,Collagen formation,Extracellular matrix organization,6.381595278013223e-05,0,3,4,0.0029833932255896186
2453,Collagen formation,Extracellular matrix organization,5.106117350408857e-05,1,3,4,0.0023871078074725618
2454,Metabolism of vitamins and cofactors,Metabolism,0.006236326130757496,0,3,4,0.291547995767946
2455,Metabolism of vitamins and cofactors,Metabolism,0.005662317255497709,1,3,4,0.26471310393802233
2456,Protein localization,root,0.001423558821958277,0,4,5,0.1636826744340937
2457,Protein localization,root,1.2604793335140262e-05,1,4,5,0.0014493157936014446
2458,Hemostasis,root,0.0037803190004889755,0,4,5,0.4346660739756851
2459,Hemostasis,root,0.005413614743287686,1,4,5,0.6224645767135987
2460,Developmental Biology,root,9.596196248098968e-05,0,4,5,0.011033833249844392
2461,Developmental Biology,root,0.0036542272960138136,1,4,5,0.42016788317802184
2462,Autophagy,root,0.007103576487651873,0,4,5,0.8167786111897544
2463,Autophagy,root,0.0018828055448680797,1,4,5,0.21648746948117384
2464,Gene expression (Transcription),root,0.003776776071996816,0,4,5,0.43425870337604405
2465,Gene expression (Transcription),root,0.00017097705728588567,1,4,5,0.019659167975178516
2466,Extracellular matrix organization,root,0.006553975748691862,0,4,5,0.7535847919837607
2467,Extracellular matrix organization,root,0.00918510696861026,1,4,5,1.056115736416983
2468,Programmed Cell Death,root,0.009834931153601501,0,4,5,1.1308333798825363
2469,Programmed Cell Death,root,0.004597026015490119,1,4,5,0.5285721257541276
2470,Signal Transduction,root,0.0015074436040865772,0,4,5,0.17332785752824467
2471,Signal Transduction,root,0.006875952381823133,1,4,5,0.7906060907199194
2472,Sensory Perception,root,0.0031085859396226085,0,4,5,0.3574293190117028
2473,Sensory Perception,root,0.001570943744841256,1,4,5,0.1806291876210674
2474,Disease,root,0.0036559084150172205,0,4,5,0.4203611804624579
2475,Disease,root,0.00935137456932297,1,4,5,1.0752334048523193
2476,Vesicle-mediated transport,root,0.008651806401858836,0,4,5,0.9947961325505196
2477,Vesicle-mediated transport,root,0.0004060522284997171,1,4,5,0.046688421788801504
2478,Cell-Cell communication,root,4.691980857162477e-05,0,4,5,0.005394901589225899
2479,Cell-Cell communication,root,0.00029330711782846555,1,4,5,0.03372483998285123
2480,Drug ADME,root,0.001417459061896775,0,4,5,0.16298131596202195
2481,Drug ADME,root,0.0004612346885699837,1,4,5,0.05303337396557818
2482,Immune System,root,0.01725391520632416,0,4,5,1.9838779696825126
2483,Immune System,root,0.015891062619132475,1,4,5,1.8271753783388747
2484,Metabolism,root,0.006705306567216266,0,4,5,0.7709850094656774
2485,Metabolism,root,0.0068657398690221355,1,4,5,0.7894318425032842
2486,Transport of small molecules,root,0.0027003130780410864,0,4,5,0.31048556589681897
2487,Transport of small molecules,root,0.005527862587228914,1,4,5,0.635600944776637
2488,Metabolism of proteins,root,0.003975415114780307,0,4,5,0.45709848299618194
2489,Metabolism of proteins,root,0.006861507798699012,1,4,5,0.7889452334652894
2490,Cellular responses to stimuli,root,0.004653652204268238,0,4,5,0.5350830797654709
2491,Cellular responses to stimuli,root,6.109642362268837e-05,1,4,5,0.007024947520723576
